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Abstract  
 
Contemporary research has confirmed the presence of cognitive deficits as a 
core feature of schizophrenia that has a definite and adverse impact on 
functional outcome. 
 
Cognitive functioning can be improved by psychopharmacological 
intervention, with evidence supporting the superiority of second generation 
antipsychotics over their first generation predecessors. Despite evidence 
that cognitive impairment contributes to medication non-adherence and that 
depot antipsychotics are able to enhance treatment compliance whilst 
decreasing relapse rates, depot preparations remain less frequently 
prescribed than their oral counterparts, especially in patients with first 
episode psychosis (FEP). The aims of this study were primarily to investigate 
cognitive deficits in patients with FEP, and to then describe the response of 
these impairments to treatment with a very low dose flupenthixol decanoate. 
 
This was a prospective, non-randomized, single arm, open-label, longitudinal 
study of 58 participants with FEP treated according to a fixed protocol over a 
period of 12 months. There was a wash-out phase of up to seven days 
during which all psychotropic medications were discontinued. There was an 
initial treatment period of one week with oral flupenthixol 1mg/day, after 
which flupenthixol decanoate was initiated at 10mg intramuscular depot 
injection every fortnight. Dose increases, in cases of poor or inadequate 
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response, were allowed at 6-weekly intervals and in increments of 10mg per 
injection, up to a maximum of 30mg per fortnight.  
 
The principal findings of the study were as follows: The majority of 
participants were markedly ill, with significant cognitive impairment at 
baseline. There was a discrepancy between subjectively reported, and 
objectively measured, cognitive impairment. The majority of the participants 
responded to, and achieved remission, on a very low dose of flupenthixol 
decanoate (22.48 ± 0.47mg/month). The majority of symptomatic and 
cognitive improvement occurred between baseline and three months, with 
response leveling out at six months. Social cognition did not improve 
significantly over time, whereas functional outcome and quality of life did 
improve with treatment. Flupenthixol decanoate was well tolerated and side-
effects were of a mild and transient nature.  
 
This study reconfirms that the majority of individuals with FEP experience 
significant cognitive impairment at baseline. It also suggests that these 
impairments can be successfully treated with a very low dose of flupenthixol 
decanoate. The use of depot flupenthixol decanoate ensures sustained 
treatment delivery, thereby decreasing the risk for relapse. This holds the 
promise of improved long-term functional outcome for those suffering with 
psychotic illness. 
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Abstrak 
 
Onlangse navorsing het kognitiewe inkorting identifiseer as een van die kern 
simptoomkomplekse van skisofrenie, met toenemende bewyse vir die 
duidelike en ongunstige impak hiervan op funksionele uitkoms.  
 
Kognitiewe funksionering kan deur psigofarmakologiese ingrepe verbeter 
word. Onlangse literatuur toon dat die tweede generasie antipsigotika relatief 
meer effektief is as hulle eerste generasie voorgangers. Ondanks bewyse vir 
die negatiewe impak van kognitiewe inkorting op behandelingsinskiklikheid, 
én data wat daarop wys dat die gebruik van langwerkende intramuskulere 
(depot) antipsigotika inskiklikheid verbeter en periodes van simptoom-
terugval voorkom, word dié preparate steeds minder gereeld as hulle orale 
eweknieë voorgeskryf, veral by pasiënte met 'n eerste episode psigose 
(FEP). Die doel van hierdie studie was om kognitiewe probleme by pasiënte 
met FEP te beskryf, en ook om die respons hiervan op behandeling met 'n 
baie lae dosis flupentiksol dekanoaat, te ondersoek. 
 
Die studie was 'n prospektiewe, nie-ewekansige, enkel middel, oop studie 
van 58 deelnemers met FEP, wat oor „n tydperk van 12 maande volgens 'n 
spesifieke protokol behandel is. Daar was 'n uitwas periode van 7 dae, 
waartydens alle psigotrope medikasie gestaak is. Hierna is behandeling met 
orale flupentiksol 1mg/dag begin vir een week, waarna flupentiksol 
dekanoaat geinisieer is teen 10mg intramuskulêr elke 2de week. 
Dosisverhogings, in geval van onvoldoende respons, was toelaatbaar met  
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6-weeklikse tussenposes, in inkremente van 10mg per inspuiting, tot 'n 
maksimum van 30mg elke 2de week.  
 
Die vernaamste bevindinge van die studie was soos volg:  
Die meerderheid van die deelnemers was ernstig siek, met beduidende 
kognitiewe inkorting tydens basislyn evaluasie. Daar was 'n verskil tussen 
subjektief-gerapporteerde en objektief-meetbare kognitiewe inkorting. Die 
meerderheid van die deelnemers het goed reageer op behandeling en het 
ook remissie op 'n baie lae dosis flupentiksol dekanoaat (22.48 ± 
0.47mg/maand), bereik. Die meerderheid van simptomatiese en kognitiewe 
verbetering het plaasgevind binne die eerste 3 maande, met afplatting in die 
tempo en hoeveelheid van verbetering vanaf 6 maande. Sosiale kognisie het 
nie beduidend gedurende die studieperiode verbeter nie. Funksionele 
uitkoms en lewenskwailiteit van deelnemers het ook met behandeling 
verbeter. Flupentiksol dekanoaat is goed verdra en die newe-effekte, indien 
dit teenwoordig was, was van ligte graad en verbygaande aard.  
 
Hierdie studie herbevestig dat  individue met FEP beduidende kognitiewe 
inkorting by basislyn ervaar, maar dat hierdie inkortings effektief met 'n baie 
lae dosis van flupentiksol dekanoaat behandel kan word. Die gebruik van 
depot flupentiksol is 'n suksesvolle manier om volgehoue behandeling te 
verseker en sodoende die risiko vir terugvalle te verminder. Dit verstewig 
dus die hoop op beter langtermyn funksionering vir persone met psigotiese 
siektes.   
 
 
 
 6 
CONTENTS 
 
 
Chapter 1           Introduction ........................................................................................... 7 
Chapter 2          Schizophrenia ...................................................................................... 18 
Chapter 3          Cognition .............................................................................................. 43 
Chapter 4          Treatment of schizophrenia .................................................................. 92 
Chapter 5          Treatment of cognition in schizophrenia ............................................ 128 
Chapter 6          Flupenthixol ........................................................................................ 187 
Chapter 7          The use of depot antipsychotics ......................................................... 216 
Chapter 8          Purpose of this study ......................................................................... 227 
Chapter 9          Methodology ...................................................................................... 236 
Chapter 10        Results:  Demographic data ............................................................... 257 
Chapter 11        Results:  Psychopathology and treatment effects .............................. 283 
Chapter 12        Results:  Cognitive data ..................................................................... 300 
Chapter 13        Discussion .......................................................................................... 333 
Chapter 14        Conclusion ......................................................................................... 412 
Index of acronyms and abbreviations .......................................................................... 416 
 
 
7 
 
CHAPTER 1 
INTRODUCTION 
 
Mental health refers to “a state of well-being in which the individual realizes 
his or her own abilities, can cope with the normal stresses of life, can work 
productively and fruitfully, and is able to make a contribution to his or her 
community” 1. 
  
Throughout human history, mental illness has been surrounded by stigmas 
founded in ignorance. The general public frequently considers mental 
illnesses as character flaws, or a lack of willpower2. Patients are often 
viewed as “crazy”, or “psycho”3, and their illnesses are not considered as 
real, treatable, biologically-based brain disorders4.  The stigmas, myths, and 
misconceptions surrounding mental illness frequently prevent individuals 
from seeking timely help, intervention, support and treatment; thus adversely 
affecting potential recovery, productivity and social functioning5.  
 
Furthermore, discrimination of such a nature has impacted harshly on the 
health care delivery system.  Psychiatry remains the most poorly funded 
medical speciality6 within the South African medical aid funds structure, with 
exclusion criteria, or restricted benefits, available for treatment7 – a situation 
exacerbated by an ineffectual portion (2.5%)8 of the country‟s health budget 
being spent on mental health6. Historically regarded as „low priority‟ by policy 
makers, mental health is now one of the four priority programs in the 
Reconstruction and Development Program‟s health section9-11. 
Introduction 
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Recent decades have seen rapid development in technology (including brain 
imaging techniques, and psychopharmacological developments) which has 
helped to shift the opinion from mental illnesses being „all in the mind‟, to „all 
in the brain‟. Contemporary treatments for serious mental illnesses are highly 
effective; with 70% to 90% of patients having a significant reduction in 
symptoms, and improved quality of life, with combined pharmacological and 
psychosocial interventions. 
  
One in 4 people worldwide will suffer from a mental or behavioral disorder 
during his or her lifetime12. According to the South African Stress and Health 
study, the first large population-based mental health epidemiological survey 
in South Africa, the lifetime prevalence for any mental disorder is currently 
30.3%, with a 47.5% projected lifetime risk of any such disorder13.   
 
Disabling in nature, often lasting for many years, and with a characteristic 
onset in early adulthood, mental illnesses greatly diminish an individual‟s role 
and productivity in the community. These disorders greatly affect the 
emotional and socio-economic capabilities of relatives who care for the 
affected individual, particularly when health systems are unable to offer the 
necessary treatment and support. Yet, without treatment, the direct and 
indirect costs to the individual, and society as a whole, are staggering.  
 
The North American mental health sector experienced the largest increase in 
expenditure of all the health conditions, between 1996 and 2006. Figures 
rose from $35.2 billion (1996 dollars) to $57.5 billion (2006 dollars); with a 
Introduction 
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near doubling in number of individuals with mental disorders (19.3 million to 
36.2 million) 14. Neuropsychiatric conditions currently account for 14% of the 
global burden of disease. Within the category of non-communicable 
diseases mental disorders account for 28% of the disability adjusted life 
years, this figure surpasses both cardiovascular disease, and cancer15. 
When taking the direct, indirect and indeterminate costs into account, 
schizophrenia is the most costly illness that psychiatrists treat; ranking as the 
world‟s 9th most important cause of disability16.  
 
It is quite possible that patients suffering from schizophrenia have been 
stigmatised and discriminated against more so than any other „group‟, with or 
without illness17. Throughout history, prevailing misconceptions have led to 
the ostracism and institutionalization of those afflicted with this disorder. 
Sadly, these ignorant concepts remain prevalent in modern society. 
Schizophrenia is, invariably, synonymous with a „split-personality‟, and 
patients who are considered dangerous18. These individuals are seen as 
having factitious disorders, or psychological „hang-ups‟ from childhood 
parental abuse. This lack of public awareness, combined with inadequate 
treatment and care facilities, has resulted in the marginalization of these 
patients. Evidence suggests that this “de-humanization” of individuals with 
schizophrenia has led to the abuse of basic human rights, particularly in 
developing countries19. 
 
With its early onset, devastating effects, and typically lifelong course, 
schizophrenia has been referred to as “youth‟s greatest disabler” 20. 
Introduction 
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Schizophrenia will affect almost 1% of the population at some point in life, 
with the course of the illness being marked by frequent relapses, re-
hospitalizations, suicidality, and prominent impairment in social and 
occupational functioning15.  
 
Extrapolated figures for the prevalence of schizophrenia in South Africa 
estimate that 1 in every 124 South Africans (0.81%) are affected with 
schizophrenia21. Further estimates indicate that 80% percent of these 
individuals are unemployed; and 50% will attempt suicide - 10% of the latter 
will be successful. It is not unrealistic to propose that the direct costs (e.g. 
medication, hospitalization), indirect costs (e.g. loss of earnings, financial 
and social burdens on informal caregivers), and indeterminate costs in South 
Africa likely amount to billions of Rand annually.  
 
The assessment and management of schizophrenia has, however, 
undergone important new developments, with the emergence of improved 
diagnostic precision and more effective treatment options. These recent 
developments provide the potential for improved outcome vis-á-vis reduced 
functional impairment, better quality of life, and reduced emotional distress 
for patients and their families. 
 
Cognitive impairment is well documented in schizophrenia, and has been 
significantly correlated with poor functional outcome17. Cognitive impairment 
is possibly the more common of the symptoms of schizophrenia and a major 
barrier to functional recovery, with up to 79% of the variance in improvement 
Introduction 
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in work habits ascribable to neurocognitive functioning22. A comprehensive 
neuropsychological assessment by Palmer et al. indicated that 85% of the 
patient group was cognitively impaired by comparison to 5% of healthy 
volunteers23. A review by Green indicates that the relationship between 
cognitive symptoms and social and vocational impairments is particularly 
strong, suggesting that improving cognition may be the most direct pathway 
to improvement in functional outcome24.  
 
Neuropsychological domains affected in schizophrenia include attention, 
memory, executive function, motor function and language25. The National 
Institute of Mental Health‟s Measurement and Treatment Research to 
Improve Cognition in Schizophrenia (NIMH-MATRICS) initiative identified 7 
domains that were included in their consensus cognitive battery, namely: 
working memory; attention and vigilance; verbal learning and memory; visual 
learning and memory; reasoning and problem solving; speed of processing 
and social cognition26. 
 
Given the heterogeneity of schizophrenia, it has been proposed that 
cognitive approaches hold the most promise for understanding variability in 
the neurobiological substrates of the disorder27. There is evidence for 
cognitive symptoms being a core feature of schizophrenia, as these 
impairments have been observed in patients before the onset of other 
clinical features28,29. First degree relatives without any psychotic features 
demonstrate similar deficits, suggesting that there might be a genetic 
vulnerability to schizophrenia30. Byrne et al. linked enhanced genetic risk for 
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schizophrenia to neuropsychological impairment and symptoms, thereby 
indicating that what is inherited by the patient due to genetic liability is not 
the disease itself, but a state of susceptibility due to a spectrum of 
neuropsychological impairments31. Supporting this work are findings that 
patients with velocardiofacial syndrome with neuropsychological impairment, 
are significantly more likely to develop schizophrenia than those without 
neuropsychological impairment32. 
 
Subjective experiences of cognitive dysfunction, as measured by cognitive 
complaints, are increasingly acknowledged as important in assessment of 
quality of life33; while cognitive dysfunction has also been reported to be a 
strong predictor of long-term symptomatic deterioration34.  
 
“First Episode Psychosis” (FEP) refers to the developmental stage at which 
full threshold psychotic symptoms are reached35 in one of the schizophrenia 
spectrum disorders. These disorders include schizophrenia, schizo-affective 
disorder, and schizophreniform disorder36. The relationship of the 
neuropsychological deficits to negative symptoms, disorganization, and lack 
of insight, has important implications for treatment, prevention of relapse and 
rehabilitative strategies in FEP. The correlations between subjective 
complaints of cognitive dysfunction, objective impairment in neurocognitive 
function, and clinical outcome still remain largely unexplored. 
 
Psychopharmacological treatment can improve cognitive functioning, with 
evidence supporting second generation antipsychotics (SGAs) superiority 
Introduction 
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over first generation antipsychotics (FGAs). It is not clear if this is due to true 
pro-cognitive effects or reduced cognitive liability of the SGAs37, and should 
therefore be further explored. 
 
Patients with schizophrenia are generally severely impaired; frequently 
requiring lifelong supervision and support; and they remain vulnerable to 
exploitation by others in society. In many cases the outcome can be 
substantially improved by better identification of these cognitive deficits, and 
adjustment to treatment. 
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CHAPTER 2 
SCHIZOPHRENIA 
 
The first known treatment of mental illness has been dated to the Neolithic 
era. Archaeological evidence indicates that a medical intervention known as 
trepanning (making a burr hole), has been used in the treatment of 
migraines, epileptic seizures and mental disorders since 9500 BCE1. This 
theory was supported by the renowned French physical anthropologist, Paul 
Broca2. 
 
Schizophrenia has travelled through the millennia under a number of 
different guises. Early historical accounts that make strong arguments for 
incidents of psychosis, if not schizophrenia, are the 7 years of madness 
suffered by King Nebuchadnezzar (634 BCE - 562 BCE)3; and the 
contemporary reports of the insanity of the Roman Emperor Caligula (12 CE 
- 41 CE)4.   
 
During the Graeco-Roman period Hippocrates ascribed mental illness to an 
internal imbalance of the four bodily humors5. Galen of Pergamum (129-199 
CE), the prominent Roman physician, mentioned spirits and temperature 
imbalances as the causes6; while the Greek physician, Aretaeus of 
Cappadocia (circa. 1st century CE) was the first to use the expression 
“insanity”7. It was not until the 18th century that the French physician, Phillipe 
Pinel, arrived at the understanding that mental illness is a disease of the 
central nervous system8. 
Schizophrenia 
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The first fully documented case of schizophrenia is the intriguing instance of 
James Tilly Matthews, a London tea broker, who was admitted to the 
Bethlem psychiatric hospital (notoriously known as „Bedlam‟) in 1797, and 
was kept there at the whim of the apothecary, John Haslam, until 18149. 
 
Benedict Morel first used the term “demence precoce” in 1860 to refer to 
patients with a cognitive disorder, with onset during early adulthood10; this 
term was subsequently translated into Latin “dementia praecox” by Arnold 
Pick in 189111. In 1911 Paul Eugen Bleuler introduced the term 
“schizophrenia” into medical vernacular to describe his view of the condition 
as a schism between emotion, behavior and thinking, thus earning himself 
the title: “the father of schizophrenia”12. 
 
The diagnosis and concept of schizophrenia varied over the years until the 
introduction of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM), in 1952. This publication had as its goal the establishment of reliable, 
standardized criteria, or prototypes, with which to diagnose the presence of 
mental disorders. This helped to establish diagnostic accuracy for the clinical 
management of patients, as well as research. The current edition of the 
DSM, the DSM-IV-TR, does, however, state that: “…there is no assumption 
each category of mental disorder is a completely discrete entity with absolute 
boundaries...” (pg xxxi)13.  See table 2.1 for the DSM-IV-TR Manual criteria 
for schizophrenia. 
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Table 2.1: DSM-IV-TR Diagnostic criteria for schizophrenia 
A. Characteristic        
symptoms 
Two (or more) of the following, each present for a significant portion of time 
during a 1-month period (or less if successfully treated): 
 delusions 
 hallucinations 
 disorganized speech (e.g. frequent derailment or incoherence) 
 grossly disorganized or catatonic behavior 
 negative symptoms, i.e. affective flattening, alogia, or avolition 
Note: Only one Criterion A symptom is required if delusions are bizarre or 
hallucinations consist of a voice keeping up a running commentary on the 
person's behavior or thoughts, or two or more voices conversing with each other. 
B. Social/occupational 
dysfunction 
For a significant portion of the time since the onset of the disturbance, one or 
more major areas of functioning such as work, interpersonal relations, or self-care 
are markedly below the level achieved prior to the onset (or when the onset is in 
childhood or adolescence, failure to achieve expected level of interpersonal, 
academic, or occupational achievement). 
C. Duration 
Continuous signs of the disturbance persist for at least 6 months. This 6 month 
period must include at least 1 month of symptoms (or less if successfully treated) 
that meet Criterion A (i.e. active-phase symptoms) and may include periods of 
prodromal or residual symptoms. During these prodromal or residual periods, the 
signs of the disturbance may be manifested by only negative symptoms or two or 
more symptoms listed in Criterion A present in an attenuated form (e.g. odd 
beliefs, unusual perceptual experiences). 
D. Schizoaffective and 
Mood disorder 
exclusion 
Schizoaffective disorder and Mood disorder with psychotic features have been 
ruled out because either (1) no major depressive episode, manic episode, or 
mixed episode have occurred concurrently with the active-phase symptoms; or 
(2) if mood episodes have occurred during active-phase symptoms, their total 
duration has been brief relative to the duration of the active and residual periods. 
E. Substance/general 
medical condition 
exclusion: 
The disturbance is not due to the direct physiological effects of a substance (e.g. 
a drug of abuse, a medication) or a general medical condition. 
F. Relationship to a 
Pervasive 
Developmental 
disorder 
If there is a history of Autistic disorder or another Pervasive Developmental 
disorder, the additional diagnosis of Schizophrenia is made only if prominent 
delusions or hallucinations are also present for at least a month (or less if 
successfully treated). 
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Epidemiology 
A meta-analysis of 55 studies across 33 countries, spanning the period 
1965-2001, concluded that schizophrenia affects roughly 1% of any given 
population, with a prevalence rate of 15.2 in every 100 000 individuals per 
year14.  Schizophrenia has a similar prevalence in all areas of the world, and 
in all population groups15. However, the incidence of schizophrenia has an 
association with social factors, being increased in urbanicity16, migration17, 
and the male gender18. Schizophrenia generally presents in late 
adolescence and early adulthood, with the onset in men occurring one 
decade earlier than in women19. As schizophrenia has its onset in early 
adulthood and follows a lifelong, debilitating course, it consumes a far larger 
portion of health expenditure, as discussed in Chapter 1, than its prevalence 
would suggest. 
 
Etiology 
 
Schizophrenia is a heterogeneous, polygenic, multi-factorial disease20. 
Whereas the neurobiological basis of schizophrenia has been suspected for 
more than a century, the precise understanding of the pathogenesis of the 
disorder remains elusive, thus leading to the existence of multiple theories of 
the pathophysiology of schizophrenia. 
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 Non-Biological theories 
 
Psychological theories: Psychoanalytic thinking predominated psychiatry 
during the 18th and 19th centuries. These disciplines theorized that serious 
inadequacies in the „caretaking person‟ during the child‟s preverbal period 
can result in impairments of: early object relations; the development of 
psychic structure; and basic ego functions21. Yet this ego defect and ego 
disintegration hypotheses, with regression in response to conflict and 
frustration in the absence of underlying biological abnormalities, did not 
stand the test of time22. Technological advances in brain imaging, 
psychopharmacology, and neuropathology, have confirmed the biological 
underpinnings of schizophrenia.   
 
Social causation hypothesis:  A review by Elizabeth Cantor-Graae reported 
on the strong evidence for the role of social factors in the development of 
schizophrenia23. This review reminded us of the markedly increased 
incidence of schizophrenia in second generation migrants, those of urban 
birth and/or upbringing, and people exposed to social adversity during 
childhood. Whether the social environment influenced the development of 
schizophrenia (causation), or the individuals at risk aggregated in adverse 
social environments (selection), is an ongoing debate24; as is the mechanism 
by which these social factors contribute to the development of schizophrenia. 
There is an established relationship between stress, cortisol, and psychosis, 
as documented by stress-induced, psychotic episodes25. Patients with 
psychosis have an elevated measurement of urinary cortisol26; and non-
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suppression on the dexametasone suppression test. These conditions are 
suggestive of hypothalamus-hypohysis-adrenal (HPA) axis overactivity27; 
and anatomical changes, such as enlarged ventricles, and structural 
changes in the hippocampus that are associated with greater severity and 
cognitive impairment28,29. Animal experiments also support dopamine 
dysregulation or sensitization due to social defeat30, or social exclusion31.  
 
 Biological Theories 
 
Evidence for the biological underpinnings of schizophrenia was noted by the 
French physician and neurosurgeon, Henri Laborit (1914-1995), who used 
chlorpromazine, an antihistamine, to calm patients prior to surgery. His 
observation of the calming effect of the drug led him to use it as treatment for 
patients with schizophrenia. Subsequent studies have proven the efficacy of 
antipsychotic medication in the treatment of the disorder32.  
 
The current concept of the etiological pathways of schizophrenia, known as 
the “double-hit” or stress-diathesis model, is as follows: an individual has a 
genetic predisposition to develop schizophrenia with early environmental 
insults leading to neurodevelopmental abnormalities (the “first hit” or 
diathesis). Later environmental insults, such as stressors, can cause further 
brain dysfunction (the “second hit”) with the onset of psychosis and the 
clinical picture of schizophrenia, followed by neurodegeneration33.  
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Genetic Factors: Early evidence, suggestive of a genetic underpinning of 
mental illnesses resembling schizophrenia, is reports of familial aggregation 
of the disease. Examples of this genetic connection are found in historical 
documentation of the French Duke of Bourbon, Peter I; Joan of Bourbon; 
Charles VI of France; and Henry VI of England; this being the lineage of 
father, daughter, grandson, and great grandson. The risk of developing 
schizophrenia increases as the degree of genetic affinity with the proband 
increases34; this means that the risk in the general population is 1%; in 
siblings 9%; in fraternal twins 17%; and in monozygotic twins 48%35.  
Adoption studies have shown that an „adopted-away‟ offspring's risk of 
developing schizophrenia is due to the presence of the illness in the 
biological parents, not the adoptive parents36. Studies of twins confirmed the 
heritability of the disease as 80%37.  Subsequently, various chromosomal 
abnormalities were implied, such as: chromosome 22q11 deletion 
(velocardiofacial syndrome), a balanced reciprocal translocation of 
chromosomes 1q42/11q14; and loci on the X chromosome38.  
 
In a meta-analysis of 20 genome scans, Lewis et al. found that linkage 
analysis implied more than 4000 genes, with clusters on chromosomes 8p, 
22q, 2p, and 5q, amongst others39. Tandon et al. summarized association 
studies that examined the relationship between specific gene variants and 
the risk of developing schizophrenia, and documented the following: 
Neuroregulin 1 (NRG1); Dysbindin (DTNBP1); dopamine receptors (DRD1-4); 
“Disrupted in schizophrenia 1” (DISC1); Catecholamine-O-methyl-
transferase (COMT); and the metabotropic glutamate receptor (GRM3). The 
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results of this analysis concluded that none of the genes appeared to be a 
prerequisite for the development of schizophrenia40. 
 
Current approaches include the study of intermediate phenotypes, and 
endophenotypes41, which seek to identify very specific aspects, or 
syndromes, of a disorder; with a view to linking these aspects to candidate 
genes, and the breaking down of the complex phenomenon into smaller, 
salient units, to enable more rigorous scientific investigation. 
 
Neurodevelopmental Hypothesis: Advocates for the neurodevelopmental 
hypothesis of schizophrenia find support in evidence of early environmental 
insults that increase the risk for the development of schizophrenia with an 
odds ratio of 2.0 (95% CI 1.6-2.4)42. These risk factors include being born 
both during the winter and in urban areas; maternal infections such as 
influenza and rubella; prenatal stressors such as famine, bereavement, and 
maternal deprivation; and obstetric complications such as Rh incompatibility, 
hypoxia, central nervous system damage, low birth weight and pre-
eclampsia43. The common underlying mechanisms for increasing the risk for 
the development of schizophrenia appear to be hypoxia-ischemia44, 
inflammation and infection45, malnutrition46, and the stress response47. Later 
developmental insults include any emotional stressors, physical stressors 
and abuse of substances such as cannabis. According to Andreasson et al., 
regular cannabis use increases the incidence of schizophrenia as much as 6 
times48. 
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Further support for the neurodevelopmental hypothesis has been 
summarized by Murray and Lewis, who documented the presence of 
developmental abnormalities in a significant number of patients. These 
anomalies include corpus callosum agenesis, aqueduct stenosis, cavum 
septum pellucidum, cerebral hamartomas, and arteriovenous 
malformations49. Abnormal cytoarchitecture, such as neuronal displacement 
indicative of failure of neuronal migration in the second trimester50, and a 
reduction in neuropil and dendritic spines in the prefrontal cortex51, were also 
found. These non-progressive abnormalities are present at first onset of 
psychosis, and markers of neurodegeneration, such as glial response, are 
absent52. A number of patients also have dermatoglyphic abnormalities, 
some minor physical abnormalities, and neurological soft signs displaying 
problems with sensory integration, motor coordination, motor sequencing, 
and primitive reflexes53,54. 
 
Neurodegenerative Hypothesis: Supporters of the neurodegenerative 
hypothesis, such as DeLisi et al.55 and Lieberman et al.56 mention the 
progressive nature of structural changes in a subgroup of patients, cognitive 
deterioration, and the influence of the duration of untreated psychosis (DUP), 
as evidence in support of the neurodegenerative hypothesis. On a 
neuropathological level synaptic integrity was disturbed, and proposed to be 
related to excessive apoptosis57. 
 
Integrative Hypothesis: Current evidence seems to favor the integrative 
hypothesis. This represents a combination of neurodevelopmental and 
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neurodegenerative mechanisms. In a meta-analysis of the time course of 
brain volume reduction, Woods et al. found significant whole brain volume 
loss both prior to, and after, attainment of maximal brain volume58.  Reduced 
brain weight and volume, ventricular enlargement and loss of asymmetry59 
and structural loss in the hippocampus60 was confirmed in post mortem 
studies. 
 
Pathophysiology 
 
Neurochemistry: Neurotransmitter abnormalities led to the proposal of the 
dopamine excess theory61,62, and the glutamate hypothesis63. Three factors 
that support the dopamine excess hypothesis are: an increased striatal 
dopamine release in response to an amphetamine challenge associated with 
acute psychosis64; post mortem studies, and positron emission tomography 
(PET) studies that demonstrated increased dopamine receptor type 2 (D2) 
binding in the brains of patients with schizophrenia65; and hypofrontality , 
with a resultant hyperactive mesocortical dopamine system66.  
Evidence has been documented for glutamatergic dysregulation in 
phencyclidine (PCP)63 and ketamine induced psychosis67, and postmortem 
studies have shown reduced expression of N-methyl-D-aspartic-acid 
(NMDA) receptors in the prefrontal cortex and hippocampus68. These data 
lend credence to the glutamate hypothesis of Kim et al. which states that 
schizophrenia patients have a deficiency in glutamatergic function and/or an 
increase in dopaminergic function63.   
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Further evidence of neurotransmitter dysfunction suggests reduced gamma-
amino-butyric acid (GABA) expression in the prefrontal cortex69, deficits in 
muscarinic activity70, and serotonergic deficits71. 
 
Changes suggestive of a reduction in neuronal, and membrane integrity (e.g. 
reduced N-acetyl aspartate (NAA) in the prefrontal cortex and hippocampus), 
were the result of in vivo metabolic studies with magnetic resonance 
spectroscopy72; as were the observations of decreased phosphomonoesters 
(PME) in the prefrontal region73. 
 
Structural Imaging: In a review of fifteen voxel-based morphometric studies 
of patients with schizophrenia, significant volume deficits and reduced grey 
matter were present in the left medial temporal lobe, correlating with memory 
deficits. Significant volume deficits and decreased density of grey matter 
were also present in the left superior temporal gyrus correlating with the 
presence of positive symptoms 74.  In a meta-analysis of 58 studies, the 
absolute regional brain volumes, and volume of ventricular structures, of 
1588 patients with schizophrenia were compared to those of healthy 
comparison subjects. The mean cerebral volume of the group with 
schizophrenia was 98% of the healthy group (effect size 0.25), while the 
mean total ventricular volume were 126% of the comparator group (mean 
effect size 0.49). Other important differences were noted for the hippocampi-
amygdalae structures, and the superior temporal gyri75. 
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Fractional anisotropy is a measure used in diffusion tensor imaging studies 
to reflect fibre density, axonal diameter, and myelination in white matter. A 
lower value (approaching zero) reflects isotropic diffusion, i.e. diffusion which 
is unrestricted in all directions, while a higher value (approaching one) is 
indicative of diffusion occurring along one axis only, such as occurring along 
axons76,77. Reduced fractional anisotropy in various white matter tracts, 
including the corpus callosum, the cingulum, arcuate fasciculus, and the 
uncinate fasciculus reflecting reduced white matter integrity78. A meta-
analysis of fractional anisotropy studies by Ellison-Wright and Bullmore 
identified two consistent locations of reduction in fractional anisotropy in 
schizophrenia: in the deep white matter of the left frontal lobe, and in the 
deep white matter of the temporal lobe79. These white matter changes are 
thought to be related to glial integrity80 influenced by neuregulin81; thereby 
lending support for the glutamatergic developmental model of schizophrenia.  
 
Functional Imaging: Functional imaging studies report conflicting results with 
regard to prefrontal activation in response to cognitive tasks. Berman & 
Meyer-Lindenberg demonstrated hypofrontality with a lack of activation of 
the dorso-lateral prefrontal cortex (DLPFC)82, while a meta-analysis by Hill et 
al. showed moderated effect sizes for both activated (0.42), and resting 
(0.55), hypofrontality83. When controlling for performance differences, it was 
demonstrated that patients show more prefrontal activity than normal 
controls84. It would therefore appear that inefficient information processing is 
present, and it is assumed that the increase in subcortical dopamine is 
secondary to this hypofrontality85. This supports the dopamine theory‟s 
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connection to the etiology of schizophrenia whereby an excess of dopamine 
causes psychosis86.  
 
Neurophysiology: Neurophysiological studies have centered on event-related 
potentials including mismatch negativity (MMN), P300 event-related 
potentials, P50 gating deficits, and changes in pre-pulse inhibition. MMN 
refers to the brain's response to standard and anomalous sounds; this is the 
pre-attentive stage of auditory information processing. Patients with 
schizophrenia were observed to have a reduction in the amplitude of MMN87; 
particularly in the primary and secondary auditory cortices, as well as the 
DLPFC, which relates to prolonged illness duration and impairments in 
sensory memory. 
 
 Additionally, an increased latency for and amplitude reduction of the P300 
wave was demonstrated in the superior temporal gyrus, the inferior parietal 
lobe, frontal lobe, hippocampus, and thalamus88. The P300 wave is linked 
with higher cognitive functions, and these changes were also present in „at 
risk‟ individuals.  
 
The P50 gating deficit noted in patients is symptomatic of frontal-
hippocampal mismatch communication89, and has been linked to 
chromosome 15q14 - the alpha7-nicotinergic receptor gene
90. Abnormal pre-
pulse inhibition serves to further confirm the presence of sensori-motor 
gating deficits, most noticeably in the striatum, hippocampus, thalamus, 
frontal, and parietal regions91.  
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Further evidence of neurophysiological changes in schizophrenia includes 
abnormal eye movements, changes in sleep patterns and architecture, and 
electroencephalogram (EEG) abnormalities. Abnormal anti-saccade and 
tracking eye movement92 has been linked to failure of the frontal-striatal 
saccade suppression mechanism93 with a 91% incidence of inheritability94. 
Decreases in total and non-rapid eye movement (NREM) sleep and 
sustained waking time have been documented95. Evidence for 
thalamocortical integration dysfunction96 are indicators of perceptual 
anomalies that include the presence of gamma-band abnormalities and 
variations in synchronicity on EEG97. 
 
Clinical Presentation 
 
In the 20th century schizophrenia became synonymous with the presence of 
positive symptoms such as hallucinations and delusions. However, when we 
carefully consider the diagnostic criteria, it becomes clear that these are 
neither necessary, nor sufficient for the diagnosis. Bleuler was the first to talk 
about the “abnormal A‟s” of schizophrenia, later be known as the negative 
symptoms of schizophrenia: abnormal affect, abnormal thoughts and 
speech, alogia, avolition and anhedonia. Other symptoms include apathy, 
asociality and poor attention98. Factor analysis also revealed the presence of 
separate mood symptoms and aggression/hostility clusters99. 
 
Although the earliest researchers of schizophrenia recognized cognitive 
impairment in schizophrenia and named it “dementia praecox” (dementia 
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with early onset), the focus has only recently shifted to cognitive symptoms 
as a separate symptom cluster. The importance of cognitive impairment, the 
affected domains, the course, relationship to outcome, and treatment 
thereof, will be discussed in the following chapter. 
 
Prognosis 
 
The course of life and outcome of patients with schizophrenia has been the 
subject of numerous longitudinal studies conducted by a host of medical 
professionals, beginning with Bleuler in 1911100, through to present day 
studies. The findings of these studies show that approximately 10% of 
patients succumbed to suicide; 50% had a chronic, unremitting and 
debilitating course; 10% recovered after a single psychotic episode; and 
25% significantly improved, and functioned well between episodes. 
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CHAPTER 3 
COGNITION 
 
Defining cognition 
 
Cognition (L: cognoscere, “the action or faculty of knowing including 
perceiving, and conceiving”) is a general term embracing the mental 
activities associated with thinking, learning, and memory; or any process by 
which one attain knowledge1.  
 
Cognition can be conscious or unconscious, and is in close relation to 
abstract concepts describing capabilities of the mind, such as reasoning, 
perception, intelligence, and learning. Cognition is considered an abstract 
property of advanced living organisms, and is studied as a direct property of 
a brain at the factual and symbolic levels, particularly mental processes such 
as perception; memory and learning; thinking, and expressive functions2. 
 
Thomas Aquinas (1225 – 1274), the medieval empiricist, divided the study of 
behavior into two broad categories, namely: cognition (how we know the 
world), and affect (feelings and emotions). Subsequently, mental processes 
described as “cognitive” have been largely influenced by research which has 
successfully used this “time-tested” paradigm3. 
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The history of cognition in schizophrenia 
 
Although impaired cognition is not categorically listed as part of the DSM-IV-
TR4 diagnostic criteria of schizophrenia, the manual does make several 
references to cognitive processes in the description of this disorder, for 
example the presence of delusions, and disorganized speech with 
derailment and incoherence (which is the “visible” manifestation of 
underlying disorganized thought processes). 
 
Cognitive deficits have been noted as a consistent feature of schizophrenia 
since early descriptions of the disorder by Benedict Morel5, Emile Kraepelin6 
and Eugene Bleuler 7.  Morel used the term “demence precoce” to describe 
cognitive dysfunction with onset during early adulthood. Kraepelin followed 
by describing “a rapid yielding of will-tension” and attentional problems on 
calculation tasks in patients with “dementia praecox”.  
 
The importance of cognitive deficits: evidence for effects on functional 
outcome 
 
Cognitive impairment has been noted as a feature of schizophrenia, and has 
important clinical and economic implications. Long-term deficits in the 
domains of employment8,9, independent living10, and social functioning11,12 
are major causes of disability in schizophrenia. There is also a negative 
impact on quality of life13, with increasing acknowledgement of self-
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perception of cognitive dysfunction (as measured by cognitive complaints) 
attributing to a major role in quality of life14,15.  
 
The bulk of the literature supports the negative impact of cognitive 
impairment on functional outcome and recovery16, with up to 79% of the 
variance in improvement in work habits ascribable to neurocognitive 
functioning17.  A review and meta-analysis of 37 studies, which included both 
recently and chronically ill patients, demonstrated that immediate and 
secondary verbal memory, executive functions, and vigilance, are all 
significantly related to functional outcome, both in terms of social skills 
acquisition, problem-solving, community outcome and activities of daily 
living18. However, Stirling et al. followed 49 FEP patients over a period of 10 
years and concluded that baseline cognitive scores bear no significant 
relationship to outcome variables (work performance, social competence, 
and Global Assessment of Functioning scores) 10 years later19. In a cross-
sectional study of 78 schizophrenia patients, in the 50-85 year old age 
bracket, Bowie et al. found that neuropsychological performance contributed 
little to real life performance (interpersonal skills, work skills, and community 
activities - as rated by case managers) after accounting for functional 
capacity (as measured by performance) 20. The discrepancies in findings 
reported in the above studies can be ascribed to the methodological 
differences between these studies, with regard to test measures used, 
patients included (recently versus chronically ill), and duration of the studies. 
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Cognitive impairment is associated with both poor premorbid, and current 
social functioning, with neuropsychological deficits accounting for 5-25% of 
the variance in social and vocational outcome after a FEP21,22. In a review of 
studies with a minimum follow-up period of 6 months, cognitive deficits 
correlated well with present functioning, and predicted future outcomes, with 
regard to job performance, job tenure, and social relations23. Although 
Addington and Addington found no relationship between neurocognitive test 
performance of 80 FEP patients at baseline and community functioning 2.5 
years later, poor performance on cognitive flexibility tests at baseline did 
predict lower quality of life scores24. Furthermore, the attrition rate (18.75%) 
in their study can be seen as support of the negative impact of cognitive 
impairment on compliance with treatment25, on response to health promoting 
interventions26, and on the ability to acquire skills in psychosocial 
rehabilitation18; all of which have the potential to negatively impact on 
relapse prevention.  
 
Fujij and Wylie evaluated the predictive validity of neuropsychological 
measures at baseline to functional outcome 19.7 years later in 26 patients. 
Verbal memory significantly predicted community functioning, while 
executive functioning predicted the duration of hospital inpatient stay13. The 
relationship between cognitive symptoms, specifically working memory, and 
functional outcome27,28, seems stronger than the relationship between 
positive and negative symptoms with functional outcome29. 
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Cognition: is it an independent domain? 
 
For many years, cognitive symptoms were seen as a product of other 
symptom clusters of schizophrenia, namely; positive, negative, and 
disorganized symptoms. It has been demonstrated that there is a connection 
between changes in the superior temporal gyri and negative symptoms in 
patients with schizophrenia30; however, the relationships between cognitive 
deficits and structural differences of the brain are less well-documented.  
 
Differences in cognitive deficits associated with clinical symptoms have been 
reported. Cross-sectional correlation of negative symptoms and 
neurocognitive impairment has been reported31-33. On the other hand, Bell 
and Mishara failed to demonstrate a relationship between negative 
symptoms and neurocognition34, which might be due to measurements not 
distinguishing between verbal fluency, poverty of speech, and motor 
retardation35. Green and Walker found that negative symptoms were 
associated with more impairment in visuomotor and visuospatial skills, 
whereas verbal memory deficits and distractibility were more strongly 
associated with the presence of positive symptoms36. Further studies have 
linked deficit symptoms to frontal, and parietal lobe functions37,38, with 
positive symptoms correlating to frontal lobe and encoding memory tasks39.  
 
Using Liddle's three-factor model, psychomotor paucity was correlated with 
reduced verbal fluency40, disorganization with errors on continuous 
performance tasks, difficulties with set-shifting41, and reality distortion with 
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widespread cognitive dysfunction42. Although negative symptoms have been 
associated with slower information processing, the relationship accounts for 
a meager portion of the variance in performance41,43. Another area of 
uncertainty is the relationship between poor motivation and negative 
symptoms44,45. The presence of depressive symptoms may also adversely 
affect cognitive functioning with impaired verbal memory, even when 
controlling for psychomotor retardation and speed of processing46. 
 
Isolated reports of a significant correlation between positive symptoms and 
working memory exist47,48. However, across different patient samples (FEP, 
chronic and elderly), the correlation between positive symptoms and 
cognitive ability is low, and the severity of psychotic symptoms not strongly 
correlated with the cognitive problems32,49,50. If neurocognitive deficits were 
the results of these positive symptoms of the disease, then, logically, the 
cognitive problems should disappear as the patient improves clinically. 
However, long term studies reported no significant improvement in cognitive 
deficits by patients recovering from an acute psychotic episode, despite 
clinical improvement in psychopathology51-53. Though SGAs do seem to lead 
to substantial clinical improvements, with mild improvements in cognition, the 
correlation between these improvements is not statistically significant54.  
 
Cross-sectional correlations between neurocognitive impairment and 
psychopathological symptoms are undoubtedly weak and support the 
proposal that cognition is a separable domain, and not caused by psychosis. 
Only in recent years has there been an increase in evidence for, with a 
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movement toward, recognizing cognitive symptoms as a separate symptoms 
complex viewed as a potential target for therapeutic intervention55. 
 
With cognition being a central concept in schizophrenia, various studies 
have attempted to specify the neuropsychological association of the 
cognitive factor. Concerns regarding the validity of the Positive and Negative 
Syndrome Scale (PANSS) cognitive factor have been raised by Harvey et 
al.56 and Good et al.57. With this in mind, Ehmann et al. examined the 
relationship between four versions of the PANSS cognitive factor; those of 
Bell et al.58, Fredrikson et al.59, White et al.60, and Peuskens et al.61. The 
authors examined neuropsychological and intellectual functioning of 37 
patients with a mean PANSS score of 88.35 (SD 19.02). Correlations among 
the four versions of the cognitive factor ranged from 0.84 (Bell with 
Peuskens‟ factors) to 0.92 (Fredrikson with Peusken‟s factors). The factor 
described by Bell et al. failed to show any significant correlations with any 
cognitive and intellectual variables. PANSS positive subscale scores were 
associated with performance IQ (r=0.33, p<0.05) and vocabulary (r=-0.33, 
p<0.05), while verbal IQ showed an inverse correlation with PANSS negative 
subscale (r=-0.26, ns). It appeared that the cognitive factor is likely to be 
more closely associated with verbal intellectual and memory scores, than 
with measures of attention, executive function, nonverbal memory and 
nonverbal intelligence62.   
 
Heinrichs and Zakzanis‟ review and meta-analysis of 204 studies (7420 
patients with schizophrenia and 5865 controls) reported that individuals with 
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schizophrenia score 0.5 to1.5 standard deviations below the control mean in 
various neuropsychological domains, the most consistent of which are: 
attention, memory, verbal fluency, intelligence, motor speed, spatial ability, 
and executive functioning. Various studies have shown abnormal cognitive 
functioning to be present in patients with schizophrenia, even in the early 
phases of the disease. At group level, patients‟ cognitive function operates 
on comparable levels to age- and gender matched healthy controls63.  
 
In summary: Cognitive deficits in patients are characterized by generalized 
intellectual deficits, with an average of 19 IQ points below controls, 
representing specific abnormalities in definitive neuropsychological domains 
such as working memory, attention and executive functioning. With  
this evidence indicating the significance of cognitive disorders in 
schizophrenia, Keefe proposed that the diagnostic criteria for schizophrenia 
be revised to include “a level of cognitive functioning suggesting a consistent 
severe impairment, and/or a significant decline from premorbid levels 
considering the patient's educational, familial, and socioeconomic 
background” (pg 912)64. Furthermore, Mortimer contended that cognitive 
approaches hold the most promise for understanding variability in the 
neurobiological substrates of the disorder65.  
 
Cognitive deficits: a state, or trait marker of schizophrenia? 
 
These early observations were the first among many descriptions of 
cognitive deficits in schizophrenia, leading to the inception of behavioral and 
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biological „markers‟ (namely state markers, and trait markers), that serve as 
indicators for detection, treatment, and prevention of the disorder66. State 
markers typically encompass the information processing difficulties 
intrinsically characteristic of psychosis, and reflect the status of clinical 
manifestations in patients; these being the influence of positive symptoms 
such as hallucinations, delusions, and thought disorder, on cognitive 
processes.  
 
Trait markers are considered to be present independent of the clinical state 
of the patient; therefore, the proviso for a cognitive deficit as a trait marker of 
schizophrenia, while contributing to the vulnerability for the development of 
the disorder, is that it should be present at all stages during the course of, 
and also be specific to, the illness. In addition to an association in the 
presence of the illness, a further requirement of a trait marker is that it 
correlates to illness liability; requiring the demonstration of the marker in 
individuals at risk for development of the illness, as well as unaffected family 
members.  
 
Trait markers are primarily linked to information-processing, with an early 
perceptual processing deficit that leads to impairment in perceptual 
organization and higher cognitive skills. This means that reduced perceptual 
sensitivity causes erroneous early information processing, and interference 
between relevant and irrelevant perceptual information. As a result, 
excessive use of attentional resources leads to a decreased attentional 
capacity for task-relevant, cognitive processes. Abnormal attention level, and 
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increased distractibility are typical, primary problems of these trait markers. 
These problems present with deficits in reaction time crossover; backward 
masking; selective attention tasks, such as dichotic listening; serial recall 
tasks; sustained attention tasks; language; and span of apprehension.  
 
The term „endophenotype‟ is frequently used to describe a trait marker, or an 
enduring phenotype associated with schizophrenia, that is not immediately 
visible within the clinical domain67. 
 
Cognition as an endophenotype of schizophrenia 
 
Nearly four decades ago the endophenotype concept was borrowed from the 
entomological writings of John and Lewis68 and introduced to psychiatry by 
Gottesman and Shields69. An endophenotype is “not the obvious and 
external, but the microscopic and internal” (pg 720)70, and therefore a 
distinctive type of biomarker that stands to play a pivotal role in the 
understanding of complex illnesses. The endophenotypic approach seeks to 
identify very specific sets of symptoms of a disorder, link them to candidate 
genes, and break down the more complex phenomenon into salient units 
that are amenable to rigorous scientific investigation67,69. In other words, the 
endophenotype concept seeks to separate behavioral symptoms into more 
stable phenotypes with an obvious genetic connection. 
 
The criteria for a biomarker to be called an endophenotype are that it must 
be associated with illness in the population; be heritable; be state-
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independent (manifests in an individual whether or not illness is active); and 
within families, endophenotype and illness co-segregate71,72. An additional 
suggestion to these requirements is that when present in afflicted family 
members the endophenotype is found in unaffected family members at a 
higher rate than in the general population73.  
 
Studies involving families, twins, and adoption scenarios have consistently 
supported schizophrenia as a highly heritable disorder consisting of diverse 
constituents. If cognitive impairments are present in both the patient, and 
first degree relatives who do not have schizophrenia, and if they are stable in 
and out of psychotic episode, then they are not closely linked to the clinical 
symptoms. Instead, they appear to reflect a predisposition to illness and, as 
such, may be valuable endophenotypes for the genetics of schizophrenia.  
 
There is currently a growing interest in the use of different cognitive deficits 
as potential endophenotypes of schizophrenia liability74. Generalized 
impairments are supported by Blanchard and Neale75, and Dickinson and 
Harvey76; while Saykin et al.77 support the viewpoint of multiple specific 
selective deficits of differential magnitude.   
 
In a study by Keefe et al., 147 out of 150 patients (98.1%) with schizophrenia 
performed significantly worse on cognitive tests than would be predicted by 
their parents‟ educational level78. In a monozygotic twin study, affected twins 
performed significantly worse than their unaffected siblings79, demonstrating 
the presence of a general cognitive deficit in schizophrenia. Although 63.6% 
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of the variance in cognitive performance was approximated to be due to the 
general cognitive factor, verbal memory and processing speed also 
demonstrated direct effects, of 13.8% and 9.1% respectively80. 
 
Genome-wide searches have revealed possible susceptibility genes for the 
disorder in relatively broad regions of multiple chromosomes81, with meta-
analysis of the data providing some support for chromosomes 6p, 8p, 10p, 
13q, 15q, 18q and 22q82. A number of studies have successfully linked 
genes with neuropsychological performance, for example; it has been 
established that individuals with velocardiofacial syndrome (VCFS) and 
schizophrenia perform significantly worse in terms of spatial working 
memory, visual recognition, and attentional tasks, in comparison to 
individuals with VCFS, but without schizophrenia83. 
 
An indication of cognition as a cognitive endophenotype is the cognitive 
deficits present in „at risk‟ individuals; that is to say, individuals with a family 
history of schizophrenia, and/or manifestations of mild symptoms, and signs 
of the early onset of the illness 84. Neuropsychological deficits are detectable 
in genetically at risk, but otherwise healthy, first degree relatives of probands 
with schizophrenia85. Studies have identified the following cognitive 
impairments as valid endophenotypes for schizophrenia: IQ86, verbal 
memory87, visual memory88, attention89, executive function90, language91, 
and psychomotor speed92.   
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In a meta-analysis by Sitskoorn et al.93, of 37 studies encompassing 1639 
relatives of schizophrenia patients and 1380 healthy controls, differences in 
cognitive performance between the groups were documented. Patients were 
more impaired than their relatives; while their relatives showed attenuated 
cognitive deficits when compared to healthy controls. Yet, despite a 65% 
overlap between relatives and controls, no test adequately discriminated 
between the two groups. The cognitive performance of first degree relatives 
was more than half of a standard deviation below that of healthy controls; 
with these deficiencies being more pronounced in the domains of memory, 
executive functioning and attention. These functions are deemed to be 
related to frontal and temporal lobe dysfunction94,95. 
 
The course of cognitive impairment in schizophrenia 
 
Even though several decades of research have been invested in the 
temporal trajectory of cognitive impairment, the net yield of results is laced 
with incongruities; and both the timing and course of this disorder remain 
tantalizingly elusive. Relative and successful comparison of studies such as 
these has proven to be a problematic issue due to the methodological 
differences of the tests, and dissimilar categories of the test subjects 
themselves (e.g. chronic patients, and first episode patients). A 
representative sample of such discrepancies are the conflicting reports by 
Yung & McGorry84, who noted cognitive dysfunction during the prodromal 
period; and Moritz, who observed it to be a strong predictor of long term 
symptomatic deterioration96.   
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The trajectory of cognitive impairment in relation to the lifespan of 
schizophrenia is not clear. As next discussed, there is evidence for three 
distinct groups of patients: a small group, who remain cognitively preserved; 
those who are premorbidly compromised; and those with cognitive 
deterioration, specifically during the first 3 to 5 years after onset of illness. 
 
 Cognitive preservation  
 
The group of patients in which the integrity of cognitive functions remain 
preserved are high functioning individuals (IQ 120-140) demonstrating no 
cognitive impairment, nor decline, and account for between 25% and 31% of 
all patients97-101. This „cognitively preserved‟ group demonstrates executive 
dysfunction suggestive of prefrontal cortex involvement102. 
 
 Cognitive aberration  
 
Long-term studies, as well as retrospective reviews of academic records, 
provide more than enough evidence for cognitive impairment to be a 
neurodevelopmental abnormality that is present before the onset of the first 
psychotic episode103-106. IQ deficits with scores below 84, predating the 
onset of psychosis, were reported107. A higher incidence of consequent 
development of schizophrenia was found in a group of individuals with pre-
morbid IQs below 96108. These observations correlated with similar findings 
of an earlier meta-analysis109. A small group of individuals with 
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schizophrenia displayed severe cognitive impairment, prior to the first 
psychotic episode110-112. 
 
A meta-analysis of 18 studies determined premorbid IQ in subjects who were 
subsequently diagnosed with schizophrenia, schizo-affective disorder or 
schizophreniform disorder. A mean effect size (MES) of -0.54 was 
calculated; being suggestive of a medium sized deficit in global cognition 
prior to the onset of schizophrenia113. This equates to a mean premorbid IQ 
estimate of 94.7 (0.35 of a SD below the mean and at the lower end of the 
average range).  
 
A 1994 birth cohort study by the UK National Survey of Health and 
Development, based on the examination of childhood data from 5362 adult 
patients who developed schizophrenia, reported a wide range of cognitive 
and behavioral differences from those of the general population. This 
included differences in educational achievement, and slower attainment of 
neurodevelopmental and motor developmental milestones. Lower verbal, 
non-verbal, and mathematics educational test scores, at all ages, were 
documented for the afflicted group114.  
 
The data of 61 schizophrenia patients, drawn from the 1966 North Finland 
Birth Cohort, compared to 104 healthy individuals, demonstrated 
associations between delayed motor developmental milestones at 12 
months with impaired neurocognitive measures at ages 33 to 55. This is 
seen as evidence that infant motor developmental delays and adult cognitive 
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deficits are age dependent manifestations of the same underlying neural 
process115.  
 
 A study of 44 FEP patients (all of who underwent premorbid cognitive 
assessments at age 16 to 17 years, as part of the compulsory Israeli Draft 
Board aptitude evaluations) found that the majority of cognitive impairment 
occurred prior to, and was exhibited at, the first psychotic episode116. 
It would therefore appear that up to approximately 50% of patients can be 
considered "premorbidly impaired". These patients are impaired in all 
domains, including attention, memory, executive functioning, language, 
oculomotor speed and visuospatial perception, and display a high frequency 
of hallucinations. There is evidence for increased parietal and temporal 
cortical dysfunction (thus explaining the semantic memory and visuospatial 
deficits), though frontal lobe dysfunction is also present117. 
 
 Cognitive deterioration  
 
The first reports of declines in IQ from pre- to post-FEP dates back to the 
1950s, when Rappaport and Webb found an average decrease of 33 IQ 
points118; and Lubin et al. observed declines in IQ from premorbid levels 
between 0.17 and 0.3 standard deviations119. Kolb and Wishaw120 used a 
variety of tests, developed at the Montreal Neurological Institute, that were 
sensitive to left or right frontal temporal, or parietal function. A group of 30 
medicated, schizophrenia patients displayed significantly lower performance 
IQs (but no significant difference on the verbal scale), than those of the 
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matched controls; this being suggestive of some deterioration after the onset 
of illness, as verbal intelligence is a good indicator of premorbid functioning.  
 
According to Ang and Tan, FEP patients show a statistically significant 
decline in cognitive performance, as measured by academic tests, up to 4 
years prior to the onset of significant symptoms, especially in the area of 
more „fluid‟ mathematical skills121. In a sample of 70 patients, one study 
found a significant drop, and difference from control subjects, between the 
ages of 13 and 16 years (grades 8 through 11) in performance on the Iowa 
Tests of Basic Skills122. Considerable impairments in sports, and handicrafts, 
were also found in children who develop schizophrenia, and are thought to 
be indicative of subtle motor deficits123. These deficits precede the onset of 
psychosis, and are believed to be a significant predictor of future illness. 
After the FEP, two groups emerge: those that have a decline in cognitive 
ability during the initial 3 to 5 years; and a group demonstrating progressive 
decline and „dementia‟ suggestive of a neurodegenerative process.  
 
This intellectually deteriorated group, accounting for roughly 50% of patients, 
display impairments of attention, memory, executive function, and 
oculomotor speed, in addition to intellectual decline, and display an 
increased frequency of delusions117. A recent study by Devinsky implied 
bifrontal lesions and right hemispheric lesions, with subsequent left 
hemispheric overactivity, in the development of delusions124. 
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Cognitive impairment in First Episode Psychosis 
 
There is ample evidence favoring the association of cognitive impairment 
with acute illness and the first psychotic episode21. These deficits appear to 
be specific cognitive disruptions which either ameliorate with improvement in 
primary clinical symptoms, or follow a more progressive course. IQ 
discrepancies between affected and unaffected twins, favoring the 
unaffected twin by ten IQ points, have been reported125. In a sample of 37 
FEP patients, all with prior exposure to medication, a broad range of 
neuropsychological deficits were reported. Subjects performed 1 to 3 
standard deviations below controls on measures of attention, abstraction, 
memory and learning77. These findings were subsequently confirmed in 
studies by Mohamed et al.126 and Bilder et al.21.  
 
Mesholam-Gately et al. published a meta-analysis of 47 publications (1994-
2008), on neurocognitive impairment in 2204 FEP patients, representing 
findings from 14 different countries. FEP patients showed statistically 
significant impairments in all domains (verbal memory, nonverbal memory, 
processing speed, working memory, attention and vigilance, language, 
visuospatial abilities, generalized cognitive abilities, executive functioning, 
social cognition, and motor skills), with standard Z-scores of 6.48-21.21 
(p<0.001). The meta-analysis revealed that FEP groups performed 
significantly worse than controls, the standard mean difference (SMD) being 
1.2 (verbal memory) to 0.64 (motor skills). Fifteen of the included studies 
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incorporated measures of „general cognitive ability‟ which generated a large 
SMD of -0.91 (FEP group vs. controls)127.  
 
Results of a five year study of 42 FEP patients reported some improvement 
on measures of language and executive functions, but a mild decline in 
verbal memory128.  The majority of test scores of 20 FEP patients, evaluated 
at index hospitalization and at a four year follow up, showed no significant 
change; yet, test results for concentration, speed and overall global 
functioning resulted in some improvement129. However, in a subgroup of 
older patients with a lifetime history of early onset of illness and poor 
functional outcome, prominent cognitive impairments resembling dementia 
have been reported on130.  
 
A qualitative review of 11 full reports which focused on assessment of 
cognition in FEP, and schizophrenia-spectrum disorders at initial 
presentation, and with follow-up periods of up to 5 years, indicated that FEP 
patients at presentation for treatment often exhibited compromised cognitive 
functioning, particularly in the domains of verbal learning and memory, 
psychomotor speed and attention. Furthermore, FEP patients performed 
significantly better than patients with a longer duration of illness. Longitudinal 
studies of FEP reported that cognitive functioning generally remained static, 
with limited change in performance over the first few years of illness131. 
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Cognitive impairment in chronically ill patients 
 
Neurocognitive impairments appear to be an enduring feature of 
schizophrenia. However, results relating to cognitive changes in chronically 
ill patients remain contradictory. The studies of Saykin et al.77, and Stirling et 
al.19 substantiated greater cognitive impairment in chronically ill patients vs. 
FEP patients; while cross-sectional studies by Goldberg et al.132, and Zorilla 
et al.133, found no evidence for increased cognitive impairment in association 
with duration of illness, or increase in age, respectively. Wilson et al. 
confirmed that IQ does not deteriorate en masse, but rather that working 
memory and distractibility seems to be the core neurocognitive disturbance 
present, and underlies the additional cognitive deficits134. In a review of ten 
longitudinal studies into the trajectory of neurocognitive deficits of 834 
patients, it was found that overall measures of IQ and gross cognitive status 
of community-dwelling outpatients with schizophrenia did not show any 
deterioration (with some improvement being possible over a five year 
period). However, there appeared to be a marked decline in cognitive 
functioning (frequently associated with the emergence of orofacial 
dyskinesia), in middle-aged and elderly patients who are institutionalized135.  
 
Limitations of the literature 
 
It is clear that there are numerous incongruities between the various studies. 
Reasons for this include, inter alia: disparities in patient attributes such as 
age, gender, severity and duration of illness, language, ethnicity; 
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comorbidity; and prior substance abuse. While the influence of treatment by 
type and duration of antipsychotics; and differing methods utilized by the 
researchers, such as size of the sample, longitudinal/retrospective studies, 
inclusion vs. exclusion criteria, and measurements employed (for example, 
dissimilar test batteries); are influential and cannot be ignored .  
 
This situation is convoluted by factors that are peripheral to the sample 
group, and testing methods used. These complexities may be caused by 
higher levels of education in members of the control groups, and an overlap 
in sampling when studies are conducted at the same research centers. 
 
In focusing on the limitations of classical neuropsychological testing in 
schizophrenia, Frith commented that classical testing cannot compare 
across samples; and that it is founded in studies of patients with 
circumscribed lesions, whereas the „lesions‟ appear to be more widespread 
in schizophrenia136.  
 
From the above, it is not only commonsense, but also crucial to standardize 
assessments of testing procedures in order to eliminate as many of the 
obstructive variables as possible. A standardized and progressive 
assessment battery will also enable researchers to compare findings across 
the continents. It was with this in mind, that the NIMH-MATRICS initiative 
was launched. 
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The MATRICS Consensus Cognitive Battery (MCCB) 
 
Cognitive deficits are recognized as core features of schizophrenia and are 
strongly related to social and vocational outcome23. Despite evidence for the 
importance of cognitive impairment in schizophrenia, identification of new 
pharmacological treatments to address this problem lags behind treatments 
aimed at the management of positive symptoms. One of the factors delaying 
the development of effective interventions for the cognitive deficits has been 
the lack of agreed domains and tests for evaluating cognition in 
schizophrenia. In an attempt to address this problem, the National Institute of 
Mental Health (NIMH), under the direction of Wayne Fenton and Ellen 
Stover, proposed and funded the development of the “Measurement and 
Treatment Research to Improve Cognition in Schizophrenia” (MATRICS) 
initiative in 200155. The contract was awarded to the University of California, 
Los Angeles, in September, 2002, with Stephen Marder as principal 
investigator and Michael Green as co-principal investigator. The goals of the 
MATRICS initiative are to promote the development of novel compounds to 
enhance cognition in schizophrenia, to catalyze regulatory acceptance of 
cognition in schizophrenia as target for drug development, to focus the 
economic research power of industry on a neglected clinical target, to 
identify promising compounds and to support proof of concept trials23.  
 
Although pharmaceutical companies have used various batteries as 
measures of response to treatment in cognitive impairment, the Federal 
Drug Administration (FDA) was concerned that acceptance of one of these 
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measures may unduly benefit a specific manufacturer. In 2002, the NIMH 
initiated this multi-stakeholder (industry, academia and governmental) 
research process to stimulate development and evaluation of medications 
targeting cognitive deficits associated with schizophrenia, including the 
development of an unbiased, standardized assessment which could assist in 
FDA approval of pharmacological agents137,138.  
 
During 2003/2004 six consensus-oriented meetings were held. Prior to the 
first meeting, a pre-conference telephonic survey was conducted according 
to the RAND Panel Method139. Seventy-four experts were invited to partake 
in the survey, of which 62 experts, together with six members of the 
Neurocognition Committee, took part in the survey. This survey aimed to 
identify cognitive targets and test qualities deemed most important in 
developing a standardized assessment battery. Cognitive targets identified 
were executive functions, attention/vigilance, memory processes and 
problem-solving ability. Essential test qualities identified were test-retest 
reliability, coverage of key individual cognitive constructs and the availability 
of comparable alternate forms. 
 
A subgroup of the Neurocognition Committee evaluated empirical evidence 
for separable cognitive performance factors in schizophrenia. To be 
considered „separable‟, cognitive domains had to have distinct causes or 
neural substrates, or at a minimum be distinguishable at statistical or 
analytical level. These dimensions had to be independent or only weakly 
correlated with each other and replicated across several studies. There had 
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to be evidence for these neurocognitive factors in large normal samples and 
factor analytic studies. Lastly, the factors had to have likely sensitivity to 
intervention attempts. Thirteen factor analytic studies of cognitive 
performance in schizophrenia were identified and examined. Sample sizes 
varied from 34 to 209 participants and some also included patients with 
psychosis or severe mental disorders other than schizophrenia. Eight 
domains were identified, based on review of the literature and input from 
experts: working memory, attention/vigilance, verbal learning and memory, 
visual learning and memory, reasoning and problem solving, speed of 
processing, verbal comprehension and general verbal ability140. 
 
During the initial MATRICS consensus conference, “Identifying Cognitive 
Targets and Establishing Criteria for Test Selection”23, the establishment of a 
reliable, valid and consensus-derived method of assessing cognition, and 
the development of a battery which can be used as a standardized way to 
assess the effects of cognitive-enhancing agents across clinical trials, were 
set as goals. More than 130 scientists, representing academia, government 
and pharmaceutical industry, discussed the findings of the Neurocognition 
Committee and agreed on the inclusion of the above domains in a hybrid 
battery, excluding verbal comprehension (due to resistance to change). 
Furthermore, due to newly developed interest in social cognition, and the 
view that it functions as an intermediary translating cognitive capacity into 
functional outcome (as well as preliminary functional neuroimaging data e.g. 
for facial affect recognition), it was decided to include social cognition as an 
eighth domain.  
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Furthermore, five criteria against which to evaluate tests for inclusion in a 
standardized battery were identified; namely good test-retest reliability, high 
utility as a repeated measure, relationship to functional outcome, practicality 
and tolerability. Good test-retest reliability is critical for detecting changes 
with treatment and translates into statistical power. To be used as a 
repeated measure, there should be no substantial practice effects and if 
practice effects are present, then it should be small enough not to create 
ceiling effects and reduce variability. The availability of alternate forms 
alleviates this potential problem. Other factors to take into consideration are 
potential response to pharmacological agents (thus assessing functional 
outcome), practicality (from the administrator‟s perspective, e.g. ease of set-
up, training, administration and scoring) and tolerability (from the subject‟s 
perspective, e.g. length, difficulty and repetitiveness). Participants in the 
conference nominated 90 cognitive tests that might be used to measure 
performance in the above domains. 
 
During the second consensus conference, “Neuropsychopharmacological 
approaches to modulating cognition in schizophrenia: Approaches to 
identifying promising compounds”141, the most promising neural system 
targets for improving cognition in schizophrenia were identified, as well as 
promising models for use in drug development and identification of current 
most promising available compounds.  A similar process to the first 
conference was followed (pre-conference telephonic survey, expert panel, 
etc.). Putative molecular targets identified include the dopamine receptors in 
the prefrontal cortex (PFC), the serotonin receptors in the PFC and anterior 
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cingulate cortex, the glutamatergic excitatory synapse, the acetylcholine 
nicotinic receptors in the hippocampus, the acetylcholine muscarinic 
receptors, and the brain GABA system142,143.  
 
Prior to the third conference, “RAND Panels for Evaluation of Candidate 
Neurocognitive Tests”, the Neurocognition Committee reviewed all of the 
tests nominated during the first conference according to the five selection 
criteria. Individual tests with high test-retest reliability and validity and with 
duration of less than 15 minutes (to limit total duration to 90 minutes) were 
sought. Thirty-six candidate tests were selected (approximately six per 
domain). An interdisciplinary panel of experts systematically evaluated the 
36 candidate tests according to the RAND/UCLA appropriateness method144. 
The 20 most promising tests were selected for inclusion in the beta version 
of the battery.  
 
The MATRICS Psychometric and Standardization Study (PASS) followed145. 
During phase one,  psychometric properties, practicality and tolerability of 
these tests were directly compared in a 5-site trial. One-hundred-seventy-six 
patients (schizophrenia or schizoaffective disorder, depressed type) were 
assessed at baseline and 167 were assessed 4 weeks later146. These 
patients were clinically with stable Brief Psychiatric Rating Scale (BPRS) 
ratings less than 4147; 86% were using SGAs and 13% FGAs. The mean age 
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of the sample was 44.0 years (SD=11.2), mean educational level was 12.4 
years (SD=2.4) and 75.7% of the sample was male.  
 
Test-retest reliability for most of the tests was good (0.70 or higher). Practice 
effects were small. No significant ceiling effects were present. Out of 343 
test scores, one ceiling and floor score were reached for CPT-IP and 11 floor 
and 8 ceiling scores for NAB Mazes. The MCCB is therefore suitable to 
measure cognitive changes over time. Alternate forms available (HVLT-R, 
BVMT-R and NAB Mazes) were also comparable and may also help to limit 
the magnitude of any potential practice effects. Seven-point Likert scales 
were used to assess practicality and tolerability of each test. From these 
results, committee members cast votes and a final battery of ten tests was 
selected (see table 3.1). 
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Table 3.1 Tests included in the MCCB 
Cognitive 
Domain 
Test Description 
Primary 
score 
Test-retest reliability over 
a four week period  
Pearson 
product-
moment 
correlation 
(r) 
Intraclass 
correlation 
coefficient 
(ICC) 
Speed of 
Processing 
Brief Assessment of 
Cognition in 
Schizophrenia (BACS)
148
: 
Symbol-Coding 
Timed paper-and-pencil 
test in which 
respondent uses a key 
to write digits that 
correspond to 
nonsense symbols 
Total 
number 
correct 
0.85 0.85 
Category Fluency 
(Fluency)
 149
: Animal 
Naming  
Oral test in which 
respondent names as 
many animals as 
possible in 1 minute 
Total 
number of 
animals 
named in 1 
minute 
0.74 0.74 
Trail Making Test 
(TMT)
150
: Part A  
Timed paper-and-pencil 
test in which 
respondent draws a line 
to connect 
consecutively 
numbered circles 
placed irregularly on a 
sheet of paper 
Time in 
seconds to 
completion 
0.77 0.75 
Attention/ 
Vigilance 
Continuous Performance 
Test- Identical Pairs 
(CPT-IP)
151
 
Computer-administered 
measure of sustained 
attention in which 
respondent presses a 
response button to 
consecutive matching 
numbers 
Mean d-
prime value 
across 2-, 
3-, and 4-
digit 
conditions 
0.84 0.84 
Working 
Memory 
(nonverbal) 
Wechsler Memory Scale 
– Third Edition (WMS-
III)
152
: Spatial Span 
Using a board on which 
10 cubes are irregularly 
spaced, respondent 
taps cubes in same (or 
reversed) sequence as 
test administrator 
Sum of raw 
scores on 
forward and 
backward 
conditions 
0.74 0.74 
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(verbal) Letter-Number Span 
(LNS)
153
 
Orally administered test 
in which respondent 
mentally reorders 
strings of number and 
letters and repeats 
them to administrator 
Total 
number 
correct 
0.81 0.78 
Verbal 
learning 
Hopkins Verbal Learning 
Test-Revised (HVLT-R)
154
 
Orally administered test 
in which a list of 12 
words from three 
taxonomic categories is 
presented and the 
respondent is asked to 
recall as many as 
possible after each of 
three learning trials 
Total 
number of 
words 
recalled 
correctly 
over 3 
learning 
trials 
0.69 0.68 
Visual 
Learning 
Brief Visuospatial 
Memory Test-Revised 
(BVMT-R)
155
 
A test that involves 
reproducing six 
geometric figures from 
memory 
Total recall 
score over 
three 
learning 
trials 
0.71 0.71 
Reasoning 
and 
problem 
solving 
Neuropsychological 
Assessment Battery 
(NAB)
156
: Mazes 
Seven timed paper-
and-pencil mazes of 
increasing difficulty that 
measure foresight and 
planning 
Total raw 
score 
0.83 0.83 
Social 
cognition 
Mayer-Salovey-Caruso 
Emotional Intelligence 
Test (MSCEIT™)
157
: 
Managing Emotions 
Paper-and-pencil 
multiple-choice test that 
assesses how people 
manage their emotions 
Branch 
score using 
general 
consensus 
scoring 
0.73 0.73 
Adapted from MCCB Manual
158
.   
 
This final version of the MCCB was unanimously approved by the NIMH 
Mental Health Advisory Council in April 2005, and it was subsequently also 
accepted by the FDA‟s Division of Neuropharmacological Drug Products. 
T(TMT)150he primary use for the MCCB is in clinical trials of potential cognitive-
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enhancing drugs for schizophrenia and related disorders, and to act as 
reference battery in basic studies of cognition in schizophrenia. 
 
The final step in the development of the MCCB was the standardization and 
co-norming of the battery (PASS phase 2). Co-norming of a hybrid test (a 
battery made up from separately developed tests) is essential as normative 
reference samples for the individual tests may vary considerably in size and 
composition. For valid interpretation, collecting normative data on the battery 
as a whole (to determine base rates of test score differences, variance in 
test scores, and covariance amongst tests) is important. Such norms 
facilitate communication of information across studies, combination of test 
scores as composite scores, and construction of cognitive profiles across 
different cognitive domains.  
 
During this part of the study, normative data was collected at five different 
sites, representing different geographical areas in the United States, from 
300 healthy community subjects, recruited according to a scientific sampling 
method. Stratification was done by age, gender and education. Age was 
chosen as the primary stratification measure as age-related effects are fairly 
large on cognitive tests. The genders were represented on a 1:1 basis.  
Summing of T-scores of individual tests and subsequent standardization of 
the sums to T-scores yielded domain scores with a mean of 50 and SD of 
10. The T-scores of the different domains scores obtained by the 300 
individuals in this study were summed to yield a Cognitive Composite Score, 
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and the mean and SD of this sum was then computed. Then, the T-scores 
for this Cognitive Composite Score were computed, with the usual mean of 
50 and SD of 10.  
 
Lower cognitive performance was associated with increasing age and lower 
education. Verbal learning showed no age-related effect. Younger subjects 
performed better than older subjects only on social cognition scores. 
Significant differences between men and women were present. Men 
performed better than women in reasoning and problem solving and working 
memory, while women out-performed men on verbal learning tasks. No 
stratification for ethnicity was done. Seventy-six percent of the subjects were 
white, 18% African American, and 2% Asian. Subsequent to this phase of 
the PASS study, a computerized scoring program was developed, with age 
and gender correction as a default scoring option159. 
 
Further conferences during 2004 included the “Workshop on Clinical Trial 
Design” (a multi-stakeholder conference held to develop guidelines for the 
design of clinical trials of cognitive-enhancing drugs), “FDA-NIMH-MATRICS 
Workshop on Clinical Trial Designs for Neurocognitive Drugs for 
Schizophrenia”160 and “New Approaches to Assessing and Improving 
Cognition in Schizophrenia”161. 
 
In the years since its development, the MCCB has gained wide acceptance 
as the „gold standard‟ for measuring cognitive deficits in patients with 
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schizophrenia and is now used in many centers and studies across the 
world. 
 
Conclusion 
 
There is a clear consensus that cognitive impairment is a core feature of 
schizophrenia. The deficit profile is broad, severe, and is likely to be present 
in the majority (if not all) patients. Cognitive impairments have been 
demonstrated in patients before the onset of other clinical features162,163; with 
first degree relatives without any psychotic features demonstrating similar 
deficits, suggesting that there might be a genetic vulnerability to 
schizophrenia89. Individuals at high risk for the development of psychosis, 
nevertheless, do not demonstrate the levels of cognitive impairment typically 
found within and beyond the FEP.   
 
Cross-sectional studies have confirmed the presence of cognitive symptoms 
throughout the course of schizophrenia irrespective of duration, chronicity 
and compliance with medication, though chronicity tends to be associated 
with a greater magnitude of impairment. Cognitive deficits consequently 
appear to be „fixed‟, pre-existing risk factors, rather than the result of harmful 
medication-related effects, or succession of the illness164. For that reason, 
early intervention may reduce cognitive deficits; thereby preventing, 
lessening the severity, or delaying the onset, of psychosis. Neurocognitive 
impairment has clear clinical relevance, and impacts adversely on a patient‟s 
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day-to-day life in areas such as social interaction, schooling, employment 
prospects, and the desire to live.  
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CHAPTER 4 
TREATMENT OF SCHIZOPHRENIA 
 
Antipsychotic medication has formed the basis for the treatment of 
schizophrenia for the past 60 years1. It is used in acute phase treatment, 
long-term maintenance2, as well as for relapse prevention3. 
 
In the acute phase of a psychotic episode, the specific treatment goals are to 
prevent harm, control disturbed behavior, suppress symptoms, effect a rapid 
return to the best level of functioning, develop an alliance with the patient 
and family, psycho-education, formulation of treatment plans, and the 
establishment of aftercare services4.  
 
A therapeutic effect is usually evident within 1-3 weeks of treatment during 
an acute psychotic episode, with most improvement occurring within 6-8 
weeks of starting treatment5. However, recent evidence for an earlier onset 
of action6 has emerged; with indications that a lack of symptoms reduction 
by one week of treatment may possibly be a precursor to later non-
response7.  
 
The review by Baldessarini et al. of 44 placebo-controlled studies of 
antipsychotics, totaling 3 939 subjects, with an average follow-up period of 
9.8 months, found prolific evidence that conventional agents minimize the 
risk of relapse in positive symptoms of schizophrenia; a 14% rate of 
symptom aggravation on active medication (mean daily dose of 397 
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chlorpromazine equivalents) compared to 55% on placebo; thereby 
illustrating a 3.9-fold sparing of relapse accredited to medication8.  
 
First generation (“typical”) antipsychotics 
 
First generation antipsychotics (FGAs) achieve their antipsychotic effect by 
the highly selective blockade of D2 receptors in the mesolimbic areas
9,10. 
 
The efficacy of FGA medications in reducing psychotic symptoms in acute 
schizophrenia was first documented by Guttmacher in 1964. This landmark 
study found that 60% of patients treated with an FGA for an acute psychotic 
episode had a near complete resolution of acute positive symptoms, over a 
six week trial of treatment, compared to 20% of patients treated with 
placebo9. Reviews of randomised control trials (RCTs) have subsequently 
confirmed the superiority of FGAs compared to placebo8,11. In the treatment 
of psychosis all FGAs are equally effective, with the exception of mepazine 
and promazine. However, there are differences in therapeutic effect with 
regard to dose, potency and side effects of these medications12. 
  
Most of the positive symptoms of schizophrenia are adequately treated with 
FGAs. In a review of five large comparative studies of an antipsychotic vs. 
placebo, Klein and Davis found that patients assigned to an antipsychotic 
experienced a reduction in positive symptoms with a secondary decrease in 
negative symptoms13.  
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Unfortunately, FGAs display side-effects ascribable to dopamine blockade in 
the tubero-infundibular, nigrostriatal and mesocortical pathways, as well as 
from effects on other neurotransmitter systems.  Adverse neurological 
effects include extrapyramidal side-effects (EPSEs) such as dystonic 
reactions (10%)4, parkinsonism (20%)14, and akathisia (24%)15. Tardive 
dyskinesia (TD) was found to be present in 5% of patients with 
schizophrenia prior to initiation of treatment with an antipsychotic, rising to 
20% during treatment16. Neuroleptic malignant syndrome (NMS), a rare life-
threatening disorder, presents in 0.01-0.02% of patients17, and has a 10% 
mortality rate18. Non-neurological side-effects include hyperprolactinaemia, 
reduced seizure threshold, postural hypotension (related to α1-receptors), 
and anticholinergic side-effects (which may impact negatively on cognitive 
functioning)19. 
 
Side-effects depend on drug potency. High potency drugs have a stronger 
affinity for dopamine receptors than low potency drugs. Drugs with higher 
potencies (i.e. haloperidol and fluphenazine), have a higher risk of EPSE, 
moderate risk of sedation, low risk of anticholinergic side-effects, and low 
risk of anti-adrenergic side effects20. Low potency drugs, such as 
chlorpromazine and thioridazine, have a lower risk of EPSE, but are 
associated with more anticholinergic and anti-adrenergic side-effects21.  
 
In recent times, RCTs with FGAs have focused on establishing dosing 
strategies to determine the most effective dose range, i.e. where optimal 
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therapeutic response is obtained, while the appearance of side-effects are 
limited.  
When administered judiciously, FGAs have proven to alleviate comorbid 
depression22-24, whereas increased risk of dysphoria and EPSE are 
synonymous with higher doses14,23. A number of studies suggest that 
moderate doses of FGAs are as effective, if not more so, than higher 
doses25-27. 
 
The World Federation of Societies of Biological Psychiatry (WFSBP) 
recommend the following initial target doses in FEP: chlorpromazine 300-
500mg/d po, fluphenazine 2.4-10mg/d po, flupenthixol 2-10mg/d po, 
haloperidol 1-4mg/d po, perphenazine 6-36mg/d po, pimozide 1-4mg/d po 
and zuclopenthixol 2-10mg/d po28. 
 
FGAs have proven to be effective in preventing psychotic symptoms in long-
term treatment, as well as reducing the risk for relapse29. Forty to sixty 
percent of patients with a FEP, who discontinued treatment, relapsed within 
one year20,30-33 compared to a relapse rate of only 30% in patients continuing 
treatment34.  
 
Second generation (“atypical”) antipsychotics 
 
Second generation antipsychotics (SGAs) were developed to address the 
relative inefficacy of FGAs in the treatment of the cognitive and negative 
symptoms (with ongoing functional impairments) of schizophrenia; and to do 
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so without causing the severe side-effects (e.g. EPSE, and dysphoria) 
associated with their first generation predecessors. 
 
The antecedent SGA, clozapine, was introduced in 1990. Kane et al. 
demonstrated clozapine to be more effective than chlorpromazine in the 
management of treatment resistant schizophrenia, with 30% of the clozapine 
treated patients having a response in positive symptoms, vs. only 4% of 
those treated with chlorpromazine34. However, clozapine carries five black 
box warnings and is associated with risks such as agranulocytosis35,36, 
myocarditis37, seizures36, gastrointestinal hypomotility38, hyperglycemia and 
weight gain39. This led to the development of other drugs with 
pharmacological profiles different from those of the FGAs. These so-called 
SGAs were supposed to be “clozapine-like” in their effects, without the 
severe and potentially life-threatening side-effects of clozapine. A number of 
SGAs were introduced over the last two decades, including risperidone, 
olanzapine, quetiapine, ziprasidone and others20,40.  
 
SGAs interact with a wider variety of neurotransmitter receptor types than do 
FGAs, and differ from one another in receptor interaction, selection, and 
affinity. It is hypothesized that these variables in receptor activity account for 
differences in the efficacy, safety, and tolerability of these drugs, and their 
assumed superiority over typical medications41.   
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The concept of „atypicality‟  
 
Pharmacologic tests employed in animals for predicting the antipsychotic 
effects of drugs in humans investigate the ability of a drug to: 1) block the 
action of dopamine (DA), thereby causing catalepsy, as a predictor of EPSE 
in humans, and 2) the blockade of a conditioned avoidance reaction, as 
predictor of antipsychotic effect in humans42, and 3) the ability to counteract 
d-amphetamine locomotor stimulation and stereotypy in rats43,44. Until 
recently, it was thought that both cataleptic potential and blocking of a 
conditioned avoidance reaction in animals was necessary for predicting 
antipsychotic action in humans. However, data emerged which confirmed the 
ability of drugs such as clozapine and olanzapine, to block conditioned 
avoidance in animal experiments, without causing catalepsy45,46. This led to 
the initial view of „atypicality‟ as a compound with antipsychotic effect, in the 
absence the emergence of EPSE. 
 
Atypicality was further expressed as being highly selective for D2 receptors in 
mesolimbic areas and, in relative terms, free of adverse effects relating to 
increased prolactin levels and motor skill side-effects. However, this 
hypothesis is not entirely accurate as studies have shown that atypicals, 
such as risperidone, administered in higher doses cause side-effects that 
include tardive dyskinesia, hypotension, impotence and 
hyperprolactinaemia19,47. Furthermore, the SGAs were also shown to be 
excitatory at D1 receptors, and inhibitory at receptors D3 and D4
48,49. Despite 
their low striatal binding, clozapine and quetiapine occupy a significant 
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proportion of temporo-limbic D2/D3 receptors
65,66. As illustrated by PET 
studies, these two compounds never achieve more than the 80% occupation 
of striatal D2 receptors needed to cause EPSE
50. 
 
In contrast to the dopaminergic hypothesis of schizophrenia, Carlsson and 
Carlsson proposed an alternative dopamine deficit hypothesis, whereby a 
primary defect in dopaminergic synaptic transmission occurs, causing 
feedback activation, DA receptor upregulation, and therefore increase in 
dopaminergic tone51. Synaptic dopaminergic neurotransmission is 
responsible for tonic dopaminergic action, while extrasynaptic dopaminergic 
transmission is phasic, and associated with the appearance of positive 
symptoms in psychosis52-54. Whereas dopamine transmission in the cerebral 
cortex is predominantly extrasynaptic, the opposite is true for the striatum 
where the D2 receptor-mediated transmission is primarily synaptic
55,56. 
 
Typical antipsychotics (FGAs) block synaptic, as well as extrasynaptic 
dopamine neurotransmission, thereby relieving psychotic symptoms, yet 
through this action, also induces a hypodopaminergic state in the striatum 
(that causes EPSE), as well as in the cortex (causing a worsening of 
negative and cognitive impairments). Conversely, SGAs have their principal 
effect on extrasynaptic dopaminergic neurotransmission with occupancy of 
extrasynaptic DA receptors by SGAs nearly equal to that of FGAs, thereby 
alleviating psychotic symptoms. However, lower occupancy of synaptic 
receptors by SGAs could possibly explain their low association with EPSE 
and other adverse effects50,57.  
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Yet another theory of atypicality, the dopamine-serotonin hypothesis58, is 
that SGAs block serotonin type 2A (5HT2A) receptors simultaneous to D2 
blockade (high 5HT2:D2 receptor blocking ratio). In this scenario serotonin 
and DA levels are balanced, and this assigns “atypicality”. In SGAs, with a 
high affinity for D2 receptors, such as risperidone, 5HT2A antagonism 
appears to protect against EPSE at moderate doses. However, this 
preservation is lost at striatal D2 receptor occupancies exceeding the 80% 
limit59,60. Antagonism of the 5HT2A receptors on the soma of dopaminergic 
neurons, in the ventral tegmental area (VTA), boosts the output of 
dopaminergic receptors, and their projections to the PFC. This has been 
proposed as the model by which SGAs improve cognitive deficits. However, 
this hypothesis has been refuted in studies including those of Kapur et al.61, 
and Trichard et al.62. Antipsychotics such as sulpiride and amisulpride have 
no 5HT2A antagonism activity, yet they are known to improve negative and 
cognitive symptoms of schizophrenia. It therefore seems that serotonergic 
action does not distinguish between typicals and atypicals57,63. 
 
According to Kapur et al., the single most powerful predictor of atypicality is 
the low affinity to, and fast dissociation from the D2 receptor, and not its high 
affinity for any other receptor, including 5HT2A, and D4
61. The physiologically 
functional state of the dopamine receptors is the high-affinity state (D2 
high)64, with a dissociation constant (Ki) of 1.75 nM (nanomoles of dopamine 
per liter of water)57. FGAs have Kis lower than 1.75nM. This means FGAs 
have a higher affinity for, and are more tightly bound to D2 receptors than 
DA. SGAs have Kis higher than 1.75nM, therefore a lower affinity and bind 
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more loosely to D2 than DA
57. In other words, SGAs „hit and run‟; the so-
called „fast-off-D2‟ theory
65. This „fast off‟ action, demonstrated by agents 
such as quetiapine and clozapine,  is a rapid molecular event in which the 
drugs are continually going on and off the D2 receptor
65, thereby allowing 
endogenous dopamine relatively unhindered access to the receptor57.  
 
Most SGAs, even those with higher Kis, can still „out-compete‟ DA
66, thereby 
causing dose-dependent EPSEs59. From the equation C50% = Ki x [1+D/D2 
high]‡ , it can be determined that, to effectively occupy 75% of the D2 
receptors, the concentration of an antipsychotic drug needs to be 
approximately 3 times greater than is required to occupy 50% of receptors, 
and is essentially identical to the therapeutic levels of antipsychotic drugs57. 
This would explain the relatively “lower doses” of FGAs producing EPSE and 
antipsychotic efficacy vs. relatively “high doses” of SGAs. However, 
clozapine, quetiapine and remoxipride have Kis higher than 20nM and come 
off the D2 receptor sufficiently fast to allow DA access to the receptor, 
therefore virtually never causing adverse neurological side-effects65.  
 
The International Early Psychosis Association Writing Group68 estimated 
appropriate initial target doses for most patients as risperidone 2mg/day or 
olanzapine 7.5–10mg/day, to which two thirds of patients achieve a good 
response with regard to reduction in positive symptoms within three weeks of 
the initial dose. The WFSBP furthermore recommends the following initial 
target doses in FEP: amisulpride 100-300mg/d po, aripiprazole 15mg/d po, 
                                                     
‡
 Where C50% is the therapeutic concentration needed to block 50% of DA receptors in the 
presence of DA, D is the DA concentration in the synaptic space, and D2 high is the 
dissociation constant of DA at the high affinity state of the D2 receptor. 
Treatment of Schizophrenia 
 
 
 101 
quetiapine 300-600mg/d po, ziprasidone 40-80mg/d po and zotepine 50-
150mg/d po28. 
 
Second Generation Antipsychotics in the treatment of psychosis  
 
A meta-analysis of nine placebo-controlled trials evaluating the efficacy of 
risperidone, quetiapine and olanzapine, calculated the combined effect size 
across 15 therapeutic dose arms for an a priori categorical response rate, as 
determined by the authors, as 0.46 (SE 0.06) and for the continuous 
outcome measure, the Brief Psychiatric Rating Scale (BPRS) >0.53 (SE 
0.07). These results indicated that SGAs, administered in therapeutic doses, 
are superior to placebo69.  
 
Leucht et al. in a systematic review and meta-analysis of 38 RCTs (N=7323) 
that compared SGAs with placebo, confirmed that SGAs were more 
efficacious than placebo, but the pooled effect size for overall symptom 
reduction was moderate (-0.51). The number needed to treat (NNT) was 6, 
with a 24% placebo response rate, vs. a 41% response rate to SGAs. They 
further reported that aripiprazole, olanzapine, ziprasidone and zotepine 
reduced the relapse risk significantly more than placebo during 6-12 months 
of treatment. The relative risk (RR) for relapse for the SGAs combined was 
0.4l (CI: 0.28 to 0.59), while the risk difference (RD) between the SGAs and 
placebo was 0.20 (CI: -11 to -30), translating to a NNT of 5 (p<0.0001)70. 
This is in agreement with an older review on relapse on maintenance 
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treatment over a period of 9.7 months, documenting substantially lower 
cumulative relapse rate of 16% in the antipsychotic group compared with 
53% in the placebo group71. 
 
In another meta-analysis evaluating the efficacy of SGAs, 78 head-to-head 
comparison studies of SGAs, with 178 relevant arms, and 13 558 
participants, were examined. Olanzapine proved superior to aripiprazole, 
quetiapine, risperidone, and ziprasidone. Risperidone was more efficacious 
than quetiapine and ziprasidone, while clozapine proved superior to 
zotepine, and in doses >400 mg/day, more efficacious than risperidone72.  
 
SGAs differ in a number of properties; such as cost, pharmacology, efficacy, 
and side-effects; and cannot be categorized as a homogeneous class73.  
Therefore, some side-effects are more problematic with the use of some 
SGAs, but not others. Side-effects include, but are not limited to: 
 Metabolic side-effects such as weight gain (especially with clozapine 
and olanzapine)74; dyslipidemia75, and hyperglycaemia76.  
 Dose-dependent EPSE, such as with risperidone77.  
 Hyperprolactinaemia, which is associated with all antipsychotics 
especially risperidone78. 
 Prolongation of the QTc time, as with ziprasidone79; and 
 Sedation, as documented with clozapine and quetiapine80,81. 
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Comparing FGAs and SGAs 
 
The American Psychiatric Association (APA) practice guidelines state “The 
second-generation antipsychotics should be considered as first-line 
medications for patients in the acute phase of schizophrenia, mainly 
because of the decreased risk of extrapyramidal side effects and tardive 
dyskinesia, with the understanding that there continues to be debate over 
the relative advantages, disadvantages, and cost-effectiveness of first- and 
second-generation agents” (pg 590)82.  
 
Meta-analyses have supported the idea that some of the SGAs may have a 
modest advantage in short term efficacy, decreased EPSE liability and 
relapse prevention over one year, in comparison with FGAs83.  
 
In a systematic review and meta-regression analysis of 52 RCTs, including 
12 649 participants, substantial heterogeneity was observed when 
comparing SGAs to FGAs. However, these results were dose-related with 
evidence that the use of SGAs in doses equivalent to haloperidol 12mg/d, 
did not display any benefits above FGAs with regard to efficacy or overall 
tolerability, except for causing less EPSE84.  
 
In a meta-analysis by Davis et al. of 142 controlled studies (124 RCTs 
comparing the efficacy of FGAs to SGAs, N=18272 and 18 studies of SGAs, 
N=2748), the effect sizes for clozapine, amisulpride, risperidone and 
olanzapine were highly statistically significant with; 0.49 (0.32-0.67), 0.29 
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(0.16-0.41), 0.25 (0.18-0.33), and 0.21 (0.14-0.28), respectively. However, 
other SGAs were not significantly more efficacious than FGAs. This finding 
was different from that of Geddes et al.84 and concluded that at least some 
SGAs are more efficacious than FGAs and, therefore, that SGAs are not a 
homogeneous group85. 
 
However, another meta analysis of 31 studies, totaling 2 320 patients, 
comparing SGAs with low-potency FGAs found that; as a group, SGAs were 
moderately more efficacious than low-potency antipsychotics, irrespective of 
the comparator doses used. Low-potency FGAs in doses less than 
600mg/day chlorpromazine equivalents (CPZE) did not induce more EPSE 
than SGAs86.  
 
In their updated treatment recommendations of 2003, the Schizophrenia 
Patient Outcomes Research Team (PORT), concluded that there was no 
evidence to support the use of SGAs above FGAs in the treatment of 
positive and negative symptomatology87. Although SGAs have been shown 
to be superior to FGAs in the treatment of negative symptoms, the 
magnitude of the effect was deemed not to be clinically significant88. SGAs‟ 
reduced liability for EPSE was only clear if doses used were less than 12mg 
haloperidol equivalents, while at these lower doses, efficacy between the 
SGAs and FGAs was similar. Furthermore, in a year-long, double-blind, RCT 
in 309 patients with schizophrenia or schizoaffective disorder, who were ill 
for at least 2 years, olanzapine 5-20mg/d did not demonstrate significant 
advantages compared with haloperidol 5-20mg/d po with regard to 
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compliance, symptoms, extrapyramidal symptoms, or overall quality of life. 
Whereas olanzapine showed benefits in reducing akathisia and improving 
memory, this came at a trade off, with more weight gain and higher cost89. 
 
Most of the trials suggesting superiority for SGAs were short term efficacy 
trials that utilized specifically selected test subjects, and received industry 
sponsorship. It is possible that some of these trials were therefore biased in 
favor of SGAs. Subsequently, deliberation on the efficacy and effectiveness 
of SGAs, as well as costliness and side-effects, led to the inception of two 
NIMH funded trials, namely CATIE (Clinical Antipsychotic Trials of 
Intervention Effectiveness)90 and CUtLASS (Cost Utility of the Latest 
Antipsychotic Drugs in Schizophrenia Study)91. These studies were 
conducted to test the widespread notion of SGAs as being generally superior 
to FGAs92. 
 
CATIE is the most comprehensive RCT ever conducted in chronic 
schizophrenia, spanning 18 months, and including 1460 patients90,93. 
Patients were randomized to either the FGA perphenazine, or one of four 
SGAs (risperidone, olanzapine, quetiapine, or ziprasidone)94. 
 
A 74% all cause discontinuation rate (ACDR) across the spectrum of the 
antipsychotics used was reported; with suboptimal efficacy and intolerability 
largely responsible for 1052 patients discontinuing treatment during phase 1 
of CATIE. Of this number, 444 took part in a double-blind study comparing 
the efficacy of ziprasidone olanzapine, quetiapine, and risperidone 
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(„tolerability pathway‟)94; and 99 participated in an open-label study with 
clozapine, or blinded treatment with clozapine, or quetiapine or risperidone 
(„efficacy pathway‟)92. Results of these two studies showed quetiapine and 
ziprasidone to be less effective than olanzapine and risperidone95; and that 
clozapine is more efficacious than either quetiapine, or risperidone93.  
  
Overall CATIE concluded that all of the drugs were similar in efficacy and 
SGAs did not prove superior to perphenazine with regard to symptomatic 
response96, cognition97, cost96, quality of life98, nor psychosocial functioning. 
Perphenazine was determined to be the least costly option96. However, 
various criticisms of CATIE were raised. Suboptimal dosing of quetiapine, 
ziprasidone, and, possibly, risperidone in comparison to olanzapine may 
have favored the latter99. Leucht et al. furthermore suggested that the 
haloperidol group might have been at a disadvantage100. Participants might 
have received medication on which they had a suboptimal response to in the 
past. This could have biased results against the efficacy of haloperidol and 
also increase dropout rates in this group. In patients only moderately ill, and 
relatively stable on current treatment at baseline, a change in treatment 
could cause destabilization of patients with exacerbation of their 
symptoms101. 
Participants who were discontinued from perphenazine in the first phase of 
CATIE had a relatively poor outcome if they were randomized to risperidone 
in phase 2, possibly due to similarities in receptor binding profiles of the 
drugs. The presence of EPSE or TD was previously found to be associated 
with a more severe and less treatment responsive illness102. Therefore, 
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controlling for TD, where 231 patients with TD were assigned to SGAs and 
not FGAs, may also account for the lack of difference in effectiveness 
between FGA and SGAs in the study103. 
 
CUtLASS, a 12 month open-label trial, compared the effectiveness of SGAs 
to FGAs. In phase 1, a sample of 227 patients with schizophrenia, displaying 
poor response, or experiencing side-effects, to current medication were 
assigned by the treating clinician to receive one of 4 depot or 7 oral FGA 
preparations (n= 118); or to one of 4 SGAs (risperidone, olanzapine, 
quetiapine or amisulpride; n= 109). The trial concluded that no significant 
difference between the FGA and non-clozapine SGA groups was found in 
either symptom improvement or quality of life91,92,94,104. 
   
The second phase of CUtLASS included 136 subjects with poor response to 
2 or more antipsychotic agents. These subjects were randomized to either 
clozapine or one other SGA. Results indicated clozapine to be significantly 
superior in symptom improvement, fewer total adverse side-effects, and a 
definitive trend toward superiority in quality of life105. Criticism of CUtLASS 
included arguments relevant to the heterogeneity amongst both FGAs and 
SGAs that may have lessened the statistical power to distinguish between 
the two groups106; and that administration of depot preparations equated to 
higher patient compliance to treatment and, subsequently, improved 
outcome107. 
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In both CATIE and CUtLASS, the difference of efficacy between FGAs and 
SGAs was found to be minimal, leading Swartz et al. to conclude that FGAs 
are as efficacious, and more cost effective, than SGAs104. Following on this 
Leucht et al. conducted a meta-analysis of 150 double-blind studies          
(N= 21 533), comparing nine SGAs with FGAs for overall efficacy, tolerability 
and outcome. Amisulpride, clozapine, olanzapine, and risperidone displayed 
better overall efficacy than did FGAs, with small to medium effect sizes. 
However, the remaining SGAs did not prove to be more efficacious than 
FGAs. Individual and class differences among the FGAs and SGAs were 
noted in relation to side-effects: SGAs caused fewer extrapyramidal side-
effects than did haloperidol, even at haloperidol doses of less than 7.5mg/d; 
whereas no significant differences were recorded in EPSE between low-
potency FGAs and SGAs. Criticism of this study pointed out that, while it is 
known that mid-potency FGAs are less likely to cause EPSE, haloperidol 
was used as the comparator drug in most of the studies, thereby raising the 
question of potential bias against FGAs73.  
 
It is evident that neither FGAs, nor SGAs, are homogenous classes: 
members of each class differ in mechanism of action, tolerability, efficacy, 
and cost. As such, antipsychotic treatment should be individualized from 
patient to patient. 
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Treatment of First Episode Psychosis 
 
During the past two decades, increasing attention has been given to early 
intervention in the management of FEP.  
The first treatment guidelines specifically differentiating between the 
treatment of FEP patients vs. multiple episode patients, was the 
recommendation by PORT which stated that antipsychotic medications, 
other than clozapine, should be used as first-line treatment for the control of 
positive symptoms in patients experiencing an acute psychotic episode. 
They recommend choice of medication to be made on the grounds of patient 
acceptability, prior individual drug response, individual side-effect profile, and 
long-term treatment planning108. This view is supported by the International 
Early Psychosis Association Writing Group68 and the Expert Consensus 
Guidelines109.  
 
Patients with FEP generally respond better to antipsychotic agents than 
those who have had multiple episodes110. In a study at Zucker Hillside 
Hospital, Robinson et al. treated a sample of 118 FEP patients (mean 
duration of untreated illness 143 weeks, DUP 71 weeks) with a standardized 
treatment algorithm until they responded. The sequence of medications 
received was as follows: fluphenazine, haloperidol, haloperidol plus lithium, 
either molindone or loxapine, and clozapine. By one year 87% of the 
participants have responded, with a median time to response of nine 
weeks111.  However, after five years, only 47.2% of the patients achieved 
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symptom remission, while 25.5% had adequate social functioning for two 
years or more112. Only 13.7% of subjects in this study met full recovery 
criteria113. 
 
The dose of FGA needed to achieve remission in FEP patients is typically 
lower than in chronically ill patients (with regard to positive symptoms). 
Lower doses also have fewer side-effects114,115. The same holds true for 
SGAs such as risperidone35. In the “Practice Guidelines of the Treatment of 
Patients With Schizophrenia”, the APA, recommends that FEP patients 
should receive doses measuring approximately half of that used in 
chronically ill patients4.  
 
A placebo-controlled study by Crow et al. of 120 subjects with FEP has 
shown that when no prophylactic treatment is given, 62% of FEP patients 
relapsed within one year31.  Robinson et al. followed 104 FEP patients over a 
period of five years and concluded that discontinuing antipsychotics increase 
the risk for relapse five fold116. Gitlin et al. found that withdrawing 
antipsychotic treatment led to a relapse rate of almost 78% after one year 
without medication, and 96% after two years30.  
 
In the Comparison of Atypicals in First Episode (CAFE) study, 400 FEP 
patients were randomly assigned to olanzapine (2.5-20mg/d), quetiapine 
(100-800mg/d), or risperidone (0.5-4mg/d) as part of a 52-week, 
randomized, double-blind, flexible-dose, multicenter (United States and 
Canada) study117,118, with an ACDR of 70.25%. In this study, the number of 
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patients who discontinued treatment against medical advice (n= 115) was 
compared to the number of patients that completed the study (n= 119).  
Higher cognitive performance at baseline, being of Black ethnic origin, 
ongoing substance abuse, the presence of ongoing depressive symptoms, 
and poor treatment response, were associated with lower medication 
adherence. Furthermore, metabolic side-effects were investigated as a 
secondary outcome measure. Of the 400 patients recruited, 31% were 
overweight and 18% were obese at baseline, with 4.3% patients meeting 
criteria for metabolic syndrome. Treatment-emergent metabolic syndrome 
was reported in 13.4% of patients after 52 weeks of treatment – this being 
more common in participants who received olanzapine, while risperidone 
caused the least metabolic side-effects of the three SGAs examined.  
 
The most recent large multicenter study, the European First Episode 
Schizophrenia Trial (EUFEST), compared the effectiveness of SGAs with 
that of a low dose of haloperidol, in 498 FEP patients. FEP patients between 
the ages of 18 and 40 years, and with minimal exposure to previous 
antipsychotics, were randomly assigned to one year of open-label treatment 
with either haloperidol (1-4mg/d), amisulpride (200-800mg/d), olanzapine (5-
20mg/d), quetiapine (200-750mg/d), or ziprasidone (40-160mg/d). The 
primary outcome measure was all cause treatment discontinuation, which 
was 41.57% within 12 months. Patients treated with haloperidol had the 
highest discontinuation rate (n= 63; 72%), followed by quetiapine (n= 51; 
53%), ziprasidone (n= 31; 45%), amisulpride (n=32; 40%), and olanzapine 
(n= 30; 33%). Comparisons with haloperidol showed a higher likelihood for 
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≥50% response with amisulpride (hazard ratio [HR] 2.27; 95% CI 1.51-3.42), 
olanzapine (HR 2.07; CI 1.38-3.10), and ziprasidone (HR 1.62; CI 1.02-
2.56); and a better chance for remission on amisulpride (HR 2.49; CI 1.43-
4.35), olanzapine (HR 2.58; CI 1.48-4.48), quetiapine (HR 1.96; CI 1.06-
3.64), and ziprasidone (HR 2.03; CI 1.07-3.87).  Although proportions of 
response and remission were higher for most SGAs as compared to 
haloperidol, symptom reductions were similar (approximately 60%). 
Furthermore, discontinuation rates were not necessarily consistent with 
symptomatic improvement119-121. 
 
Care of patients with FEP has come to be a multimodal, multi-disciplinary 
approach, with psychosocial, as well as pharmacological interventions122. 
The aim of treatment is to reduce the frequency, duration and severity of 
episodes, reduce the overall morbidity and mortality of the disorder, and 
improve psychosocial functioning, and quality of life.  
 
The road forward… 
 
With increased concerns over the safety and efficacy of currently available 
drugs, there is a considerable need for the research and development of 
novel agents. The first to claim recognition as a „third generation 
antipsychotic‟ (TGA) is aripiprazole; developed as a DA stabilizer with partial 
agonist activity at D2 and D3 receptors
123, and capable of modulating 
dopaminergic activity with almost no effect on baseline dopaminergic 
activation, while reducing phasic excessive dopaminergic activity. In 
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addition, aripiprazole is a partial agonist at 5HT1A receptors, which could 
possibly explain the lesser EPSE, and contribute to the alleviation of anxiety, 
negative symptoms, and depression41.  
 
Other recent developments include: asenapine (which has been observed to 
have potential to improve both negative and cognitive symptoms)124; 
bifeprunox (a partial D2 and 5HT1A receptor agonist with a reduced risk of 
metabolic complications)125,126; iloperidone (D2 and 5HT2A receptor 
antagonist)127; nemonapride (a typical antipsychotic similar in structure to 
sulpiride); norclozapine (a D2 partial agonist with muscarinic agonist activity; 
the latter believed to be responsible for the observed positive effects it has 
on cognition)124; and paliperidone (the major metabolite of risperidone, 
having D2, 5HT2A, α1 and α2 receptor antagonist activity, but no anti-
cholinergic activity)41.  
 
The use of antipsychotics in the treatment of positive symptoms of 
schizophrenia has enabled millions of patients to live and function outside 
the confines of institutionalization. However, contemporary research has 
found that functional outcome - social functioning, independent living and 
employment128 - is dictated to more by the presence of negative 
symptoms129, and cognitive impairment130, than by positive symptoms per 
se. Therapeutic strategies for the improvement of cognition will be discussed 
in the following chapter.  
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CHAPTER 5  
TREATMENT OF COGNITION IN SCHIZOPHRENIA 
 
Psychopharmacological treatment remains the cornerstone of remedial 
intervention in the treatment of schizophrenia. Yet, cognitive impairments as 
primary therapeutic targets have yet to be adequately addressed1,2.  
 
At a time when institutionalization of patients was the norm, the discovery of 
the antipsychotic effect of chlorpromazine3, and its apparent control of the 
positive symptoms of schizophrenia, led to functional improvement in 
patients and enabled the movement toward deinstitutionalization. This 
serendipitous discovery4 reinforced the thinking of the day, being that 
improved function and management of the symptoms of schizophrenia were 
more readily accessible than cure5. 
 
The ability of first and second generation antipsychotics to rapidly attain their 
primary effect on the positive symptoms of psychosis has often been noted 
in the literature6. However, claims of the improved efficacy of SGAs on 
negative symptoms, as well as lower risk of EPSE, has secured their pre-
eminence as the medication of choice in the initial treatment of 
schizophrenia7,8; with an apparent lack of consideration for their limited effect 
on negative symptoms and cognitive deficits, and the frequent incidence of 
metabolic side-effects9,10.  
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When first describing “dementia praecox” in the 19th century in his 1896 
“Textbook of Psychiatry”, Emil Kraepelin inferred the central importance of 
cognitive functioning11. A decade later, Eugen Blueler renamed the illness 
“schizophrenia”, and shifted the emphasis from cognitive deficits to the 
positive and negative symptoms of the disease12. In the closing years of the 
20th century the realization that functional deficits significantly contribute to 
the disability of the illness, and that cognitive impairments are a major 
influence on these disabilities, led to a resurgence of interest in the role of 
cognition in schizophrenia13.  
 
With the re-emergence of cognitive deficits as a central feature of, and prime 
contributor to, functional disability in schizophrenia, efforts have been 
increased in the field of research to produce actual treatments for these 
impairments14. An unfortunate reality underlying drug development per se, is 
that it is a protracted and costly exercise; often leading to extended delays in 
the developmental program. For this reason few advances have been 
realized in the treatment of cognition in schizophrenia during the past 
decade15.  
 
Cognitive dysfunction in schizophrenia is linked to neuronal dysfunction16. As 
a result of the MATRICS initiative, and the identification of 3 drug 
mechanisms of specific interest (cholinergic, dopaminergic, and 
glutamatergic), the Treatment Units for Research on Neurocognition and 
Schizophrenia (TURNS) project was initiated to select potential cognitive-
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enhancing agents, and evaluate their potential efficacy in the context of proof 
of concept or clinical efficacy trials2.  
 
At present, three primary strategies for the treatment of cognitive symptoms 
have emerged: treatment with SGAs, augmentation strategies, and 
behavioral interventions, all with variable outcomes17. However, the 
treatment options available for the management of the cognitive deficits of 
schizophrenia have thus far been disappointing, with at best modest results. 
For this reason the pursuit for effective interventions continues18.  
 
DOPAMINERGIC STRATEGIES 
 
Dopamine (DA) was first recorded as a neurotransmitter in 1958 by Carlsson 
and Hillarp19. It is a catecholamine commonly found in numerous animal 
species and it plays an important role in cognition, behaviour, and the 
suppression of prolactin production20,21. DA has been found to interact with 
at least 5 types of DA receptors and their derivatives22,23. These receptors 
are divided into 2 primary groups: the DA type 1 (D1)-like group, consisting of 
types 1 (D1) and 5 (D5) that are similar in drug sensitivity and structure
24,25; 
and, the DA type 2 (D2)-like group, consisting of types 2 (D2), 3 (D3) and 4 
(D4) being similar in structure but with significantly varied drug sensitivities
26. 
It appears that D1 and D4 receptors are responsible for the cognitive-
enhancing effects of dopamine 27,28, while D2 is the target for antipsychotic 
effect29.  
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The „classical‟ DA hypothesis of schizophrenia states that schizophrenia is 
associated with an exaggerated dopaminergic activity in the brain30. This 
followed the work of Connell who described amphetamine-induced 
psychosis, closely resembling schizophrenia that was associated with 
increased levels of dopaminergic activity in the brain31.  
 
Although PCP induced psychosis was stated as evidence for the 
glutamatergic hypothesis of schizophrenia32 it was found that it also induces 
a decrease in basal and stress-related DA levels in the PFC33.   
 
This led to the formulation of the revised dopaminergic hypothesis of 
schizophrenia which posits the “co-existence of a hyperdopaminergic state in 
the mesolimbic pathway along with hypodopaminergia in the mesocortical 
tract”34,35 with positive symptoms due to the former, and cognitive and 
negative symptoms due to the latter. However, recent animal research by 
Kellendonk et al. has rejected the position of frontal hypoactivity, which is 
said to cause striatal dysfunction, being the primary deficit in schizophrenia. 
Instead, an over-expression of striatal D2 receptors, resulting in working 
memory (WM) and behavioral deficits, with an increased DA turnover, and 
activation of D1 receptors in the frontal cortex, is suggested
36.  
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The revised dopaminergic hypothesis was subsequently defined as the 
„alternative‟ DA hypothesis of schizophrenia. This hypothesis proposes that 
the primary disturbance in schizophrenia is failure of synaptic dopaminergic 
transmission, which may result in the cognitive and negative symptoms of 
schizophrenia. This hypodopaminergic state leads to a feedback process 
which stimulates both synaptic (more common in the striatum) and 
extrasynaptic (more common in the temporal cortex) DA transmission. 
However, an increase in extrasynaptic neurotransmission can cause general 
hyperarousal, which may develop into psychosis (positive symptoms)37.  
Results of studies of the D1-like receptors have indicated that this group is 
not clinically significant in the remedial action of antipsychotic drugs38,39. 
However, the presence of high concentrations of D1 receptors in the PFC 
suggest that this family of neurotransmitters is more likely to be involved in 
cognitive processes, such as attention, problem solving and memory40. 
Animal studies involving non-human primates have demonstrated increased 
DA levels in the PFC during the execution of WM tasks41. The converse was 
demonstrated when neurons issuing from the VTA (en route to the PFC) of 
rodents were negated; thereby effecting a considerable decline in 
aggregation of DA levels in the PFC to sub-baseline levels, resulting in 
performances of WM tasks being severely impaired42.   
 
Within the D2-like receptor group, it is only the D2 receptor itself that is 
effectively blocked by antipsychotic agents in relation to their antipsychotic 
potencies43-45. Therefore, every pharmaceutical with antipsychotic activity is 
a D2-like receptor antagonist; hence this action is imperative to moderating 
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psychotic symptoms29. Antipsychotic action (antipsychotic threshold) 
measurement results of radioligand binding, using either single photon 
emission computerized tomography (SPECT), or PET, in the striatum of 
patients administered clinically therapeutic antipsychotic doses, show that 
clinically effective dosages of antipsychotic drugs occupy between 60% and 
80% of D2 receptors; whether FGAs or SGAs
26.  
 
Superiority of atypical antipsychotics over typical compounds has been 
suggested in the literature. However, inconsistencies in findings, and 
relatively minor effect sizes, have hampered attempts to analogise between 
studies. This stems from several issues in methodology, such as small and 
heterogeneous sample groups; diagnostic changes (e.g. use of symptoms 
checklist from older studies, or DSM-III-R45); non-randomization to treatment; 
construct validity; disparity in drug doses; effects of established adjunctive 
medication; non-standardization of, and failure to compensate for practice 
and retest effects on, neurological tasks40.   
 
1. First generation antipsychotics 
 
Blyler and Gold summarized results from narrative reviews published during 
the initial 30 years of antipsychotic availability, starting in the 1950s, as 
follows: “Chronic treatment with conventional agents appears to have limited 
cognitive benefit. More specifically, positive effects have been noted on 
aspects of selective/sustained attention, and mild negative effects have been 
observed on aspects of motor function”40.  
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Following on from these early studies, subsequent clinical observations 
found that FGAs either have no effect on47,48, or cause a dose-related 
worsening of, psychomotor speed49. Although various studies have declared 
some positive effects for FGAs on continued performance tasks50-52, these 
may have been mediated through symptomatic improvement. However, 
studies are also lacking in evidence regarding FGAs lack of influence53, 
possible detrimental effects54, and performance on mazes48. 
 
Clear, cognitive benefits for FGAs continued to elude researchers throughout 
the 1990s. Despite this, contradictory conclusions continued to emerge. In a 
review of 28 published studies between 1990 and 1997, FGAs such a 
haloperidol were found not to be very effective in improving cognitive deficits 
of schizophrenia40. In contrast, Davis et al.55 and Mishara and Goldberg56 
stated that FGAs may benefit cognitive function and negative symptoms. 
 
 Results of trials up until the present may have been biased against FGAs 
and therefore fail to reflect any cognitive benefits FGAs might have. Claims 
that FGAs would have no effect on cognition appear to be unnecessarily 
severe, since studies confirmed the ability of FGAs to alter regional brain 
metabolism57. The lack of benefit and possible detrimental effects of FGAs 
on cognition could be a result of methodological problems inherent to studies 
sponsored by the pharmaceutical industry. Some of these problems may 
include factors such as not taking into consideration  inter-drug differences, 
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and the use of non-equivalent, and relatively high doses of, FGAs when 
compared to SGAs58-61. Results, particularly from older trials done in the 
1990s and the early part of this century should therefore be interpreted with 
caution. 
 
A related issue is the fact that high potency agents, such as haloperidol, 
pose a greater risk of causing EPSE than low-potency agents, such as 
chlorpromazine and thioridazine. Therefore, the use of haloperidol frequently 
requires the adjunctive administration of anticholinergic medications that are 
known to have detrimental effects on cognition62,63.  Theoretically, utilization 
of drugs such as flupenthixol, which resemble SGAs in various ways, should 
result in fewer cognitive “problems”64 (to be discussed in chapter 6).  
 
Furthermore, the approach to neuropsychological assessment has remained 
virtually unchanged over decades. Multiple lines of evidence indicate that 
most of these cognitive measures appraise stable traits in patients and 
control groups, and are therefore likely to reflect individual differences that 
are unrelated to the illness. It is plausible that these instruments, although 
they may possess high test-retest reliability, are not sensitive to the subtle 
state changes that are the object of the investigation, and therefore may 
have failed to detect any beneficial effect of FGAs on cognition40.  
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2. Dopamine Agonists 
 
A number of non-human studies have indicated the importance of these 
receptors in WM. D1 agonists such as D-amphetamine improve WM 
performance27. In contrast, D1 antagonists worsen this function and thereby 
indentify D1 as a target for the rehabilitation of cognitive deficits in 
schizophrenia65,66. It appears that there is also a therapeutic window of D1 
agonism, with low doses of agonists improving WM, though causing 
impairment at higher levels67. Relatively few efficacy studies in schizophrenia 
have been undertaken with agonists such as tolcapone (a selective COMT 
inhibitor and indirect DA agonist in the PFC) used in treating Parkinson‟s 
disease68, atomoxetine  (a noradrenaline reuptake inhibitor and indirect 
acting DA agonist in the PFC) currently registered for use in Attention Deficit 
Hyperactivity disorder69, and dihydrexidine70. These studies produced 
variable results. 
 
3. Dopamine stabilizers 
 
With the discovery of DA autoreceptors, DA stabilization was adopted as the 
new approach to treating schizophrenia. Present day antipsychotics are 
antagonists at the D2 receptor, however their efficacy is somewhat limited 
due to hypodopaminergic-induced side-effects. Though evidence points 
toward increased dopaminergic activity in schizophrenia, it has been 
suggested that the problem may not be one of a continuously elevated 
baseline, but one of instability of release. It was proposed that this could be 
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rectified by stabilizing DA with a drug capable of dynamically occupying 
antagonistic pre- and post-synaptic receptors, whilst concurrently modulating 
their activation to a degree whereby tonic baseline dopaminergic activation 
remains largely unchanged, and phasic excessive dopaminergic activity is 
retarded71.  
 
One such DA stabilizer that was developed, with partial agonism at D2 and 
D3 receptors, is aripiprazole. The first published report on the neurocognitive 
effects of this drug was on the findings of an open-label comparative study of 
aripiprazole and olanzapine by Kern et al. A sample of 255 patients with 
schizophrenia or schizoaffective disorder were randomly treated with 
aripiprazole (30mg/d) or olanzapine (15mg/d), with neurocognitive and 
clinical assessments conducted at baseline, week 8, and week 26. Of the 
initial sample, 169 subjects completed the study. Within this group 38% were 
treated with aripiprazole, and 47% with olanzapine. Neurocognitive data 
were reduced to a 3-factor solution: verbal learning, executive function, and 
general cognitive function. From baseline, the aripiprazole group improved 
significantly in verbal learning; neither group improved significantly in 
executive functioning; and both groups improved in general cognitive 
functioning, with effects remaining relatively stable for the duration. This 
study concluded the neurocognitive effects of aripiprazole to be on a par with 
those of olanzapine72.  
 
 
 
 Treatment of Cognition in Schizophrenia  
 138 
CHOLINERGIC STRATEGIES 
 
Acetylcholine receptors are dispersed throughout the brain, in areas 
including the basal ganglia, neocortex, thalamus, and hippocampus73; these 
being components of different neural circuits involved in the facilitation of 
simple and complex cognitive processes. The nucleus basalis of Meynert 
(nbM), part of the cholinergic group (Ch) 4 neuronal cell bodies, located in 
the substantia innominata of the basal forebrain, has a broad projection to 
the neocortex74, while the septal area has projections to the hippocampal 
region75. The cholinergic supply to the striatum is interneuronal, with 
additional input from Ch1-Ch476.  
 
Contemporary studies suggest that disruptions of the cholinergic system, 
specifically in the mesopontine cholinergic projections to the thalamic, 
cortical, and striatal structures, may be underlying to the cognitive deficits 
seen in patients with schizophrenia2. Disruptions in this connection is 
specifically implicated in deficiencies in a number of neuropsychological 
processes evident in patients with schizophrenia, such as motor dysfunction, 
eye tracking abnormalities, sensory gating impairments, processing speed 
impairments, memory problems, and disruptions in the sleep-wake cycle77.  
 
Although most studies confirm the presence of ample receptors in the limbic 
cortex, neocortex, and subcortical regions, cognitive deficits appear to result 
from disruptions of the cholinergic pathway; similar to those observed in the 
mechanism of Alzheimer‟s disease78,79. Lesion studies have established that 
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scopolamine and atropine-induced memory dysfunction in rats, primates and 
humans, is reversible with the administration of acetylcholinesterase 
inhibitors (AchEI)80-82 such as physostigmine. It follows that cholinergic 
enhancing agents may therefore counteract the cognitive impairments 
present in schizophrenia83.  
 
Detrimental effects of FGAs on cognition have been noted. However, studies 
of schizophrenia patients and healthy individuals84 have shown that 
anticholinergic agents may also have a detrimental effect on learning and 
memory. Research has established that co-administration of anticholinergic 
agents for the treatment of EPSE, produces deficits in the performance of 
memory tasks of schizophrenia patients62,85. It follows that in cases requiring 
this concomitant treatment, a reasonable washout period should be 
observed prior to the start of the patient‟s cognitive assessment. 
 
1. Nicotinic receptors 
 
Nicotinic acetylcholine receptors (nAChR) appear to act as modulators of 
cognitive function, with presynaptic nAChR controlling neurotransmitter 
release, and post-synaptic nAChR in the hippocampus and cortex 
participating in the modulation of cognitive functions by controlling ganglionic 
and fast cholinergic neurotransmission83,86.  
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 α4/ß2-nAChR 
 
The pharmacological attributes of the nAChR implicates it as a possible role-
player in schizophrenia78. Studies show almost 80% of patients with 
schizophrenia to be smokers. Patients have significantly higher urinary 
cotinine levels, reflecting deeper inhalation, and take in 50% more nicotine 
per cigarette than non-affected smokers; a possible attempt at self-
medication87,88. Furthermore, auditory sensory gating, a function moderated 
by nAChR, is impaired in patients with schizophrenia83. Positive 
neurocognitive effects in schizophrenia, attributable to nicotine, are in 
keeping with the connection between deficiencies in attention and impaired 
sensory gating89. The effect of nicotine on attention is mediated via  
α4/ß2-nAChR receptors
90. A single dose of nicotine improves some aspects 
of cognition (response inhibition, working and declarative memory)91, 
however, multiple administrations are of no benefit due to the brisk onset of 
receptor desensitization (tachyphylaxis), and are, therefore, not a treatment 
option92,93. However, in a study by Levin et al., nicotine was administered to 
schizophrenia patients treated with haloperidol, subsequent improvements 
were documented in a number of cognitive domains, such as reaction time, 
memory and attention94.  
 
 α7-nAChR agonists 
 
As the α7-nAChR has been implicated in the pathophysiology of 
schizophrenia through numerous genetic and neurobiological data95, it has 
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subsequently been identified as a target for therapeutic intervention and 
treatment of cognitive deficits in schizophrenia96.  
 
Feuerbach et al. administered JN403, a selective partial α7-nAChR agonist, 
to DBA/2 (Dilute Brown Non-Agouti) mice. The authors found rapid onset of 
efficacy, lasting for 6 hours, with respect to: the restoration of sensory gating; 
amelioration of learning and memory performance deficits, alleviation of 
pain; anxiety, and epileptic seizures97.   
 
In a three-arm, double-blind, crossover trial, Freedman et al.86 examined 31 
non-smoking patients with schizophrenia. In addition to their current 
medication, the subjects received one of two doses of 3-(2, 4-
dimethoxybenzylidene) anabaseine (DMXB-A), or placebo, for periods of 
four weeks. Although no significant differences were documented in 
cognitive performance between DMXB-A and placebo over the three 
treatment arms, there was a significant improvement of negative symptoms 
at the higher DMXB-A dose, and some improvement in attention/vigilance 
and working memory on the Scale for the Assessment of Negative 
Symptoms (SANS) total score88.  
 
2. Muscarinic receptors  
 
Aggregations of muscarinic (M) receptors in the nbM and the basal 
cholinergic system are noted to be reduced in the PFC of patients with 
schizophrenia83.  
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 M1 and M4 agonists 
 
The dense distribution, and post-synaptic location, of M1 receptors in the 
hippocampus and cerebral cortex98 identified M1 as a possible site for 
cognitive-enhancing agents. M4 has a similar distribution as M1, as well as 
aggregations in the substantia nigra and striatum. M1/M4 agonists, such as 
xanomeline99, demonstrated utility in improving constructional praxis, 
orientation, spoken language ability, and word-finding difficulties in 
spontaneous speech in dementia patients100. However, due to the non-
selectivity of the drug, the presence of antimuscarinic side-effects is 
problematic101. Allosteric modulators, such as N-desmethylclozapine, which 
has selective activity as a M1/M4 agonist
102, may enhance cognitive 
functioning.  
 
3. Acetylcholinesterase inhibitors 
  
Evidence for the use of AchEI in the treatment of dementia associated with 
neurodegenerative diseases, is well documented. It may affect 
improvements and delay deterioration of cognition. These effects are well 
documented for guanfacine, donepezil, tacrine, rivastigmine, and 
galantamine103-108.  To date, however, data on AchEI as concomitant therapy 
for cognitive impairments in schizophrenia are lacking; being limited to small 
sample sizes and predominantly open label, uncontrolled studies. 
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In a 12-week, double-blind, placebo-controlled RCT, galantamine, an AchEI 
and allosteric modulator of α4/ß2-nAChR and α7-nAChR, was administered to 
a sample of 42 schizophrenia patients, with a control group of 44 assigned to 
placebo. Results suggested that galantamine may possess selective 
advantages for certain characteristics of psychomotor speed and verbal 
memory, but during the execution of an attention task it disrupts practice 
effect109.  
  
In a 2009, 12 week open-label trial by Chung et al., donepezil was 
administered in a daily dosage of up to 10mg concurrent to an established 
atypical antipsychotic regimen in 28 stable schizophrenia patients. Results 
were: significant improvements in attention, memory, psychomotor speed, 
and mental set-shifting ability, as measured by Schizophrenia Cognition 
Rating Scale (SCoRS), and Computerized Neurocognitive Function Test 
(CNT)110.  
 
In their quantitative systematic review of controlled, crossover, and open 
trials of the effects of AChEI agents on the cognitive domains of attention, 
language, motor and executive functions in subjects with schizophrenia, 
Chouinard et al. included 12 studies (N= 444) of add-on donepezil, 
rivastigmine, or galantamine. The results of this review indicated subtle 
improvements in attention, and a trend toward motor task improvement111. 
There is, however, insufficient data at present to conclude whether AChEI 
are suitable, effective agents in the treatment of cognitive impairments in 
schizophrenia105,112.  
 Treatment of Cognition in Schizophrenia  
 144 
GLUTAMATERGIC STRATEGIES  
 
Dopaminergic dysfunction has taken pre-eminence in the more traditional 
models of schizophrenia. Nonetheless, the last 15 years has seen 
glutamatergic models emerging, as aspects of the disorder relating to 
positive, negative and cognitive symptoms are inadequately accounted for 
by dopaminergic dysfunction alone. This theory originated from study results 
documenting how PCP and ketamine, both NMDA receptor antagonists, 
induced neurobehavioral disruptions and psychoses similar to those seen in 
schizophrenia113.  
 
Glutamate, the most prolific excitatory neurotransmitter in the vertebrate 
nervous system114, is involved in fast synaptic transmission, plasticity and 
higher cognitive functions. Glutamate receptors are divided into 2 groups, 
ionotropic, and metabotropic. The ionotropic receptors are characterized 
pharmacologically by binding of particular agonists: NMDA, kainic acid (KA), 
and α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) 
receptors115.  
 
Believed to be involved in the amplification of the glutamate signal, NMDA 
receptors are a primary molecular apparatus engaged in the control of 
memory function and synaptic plasticity. The NMDA receptor is both voltage-
dependent and ligand gated. When at rest, NMDA channels are blocked by 
extracellular magnesium ions (Mg2+)116. When glutamate binds to AMPA 
receptors, the ion channel opens, thus facilitating the process of sodium 
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(Na+) influx. The ensuing excitatory post-synaptic agitation initiates the 
release of Mg2+ from the NMDA receptors, opening the NMDA ion channels 
that allow for the Na+ and calcium influx which 1) facilitates the NMDA 
channel‟s contribution to the electrical response of the cell, and 2) activates 
the cyclic adenosine monophosphate (cAMP) response element-binding 
(CREB), which effects changes in protein synthesis and therefore permanent 
structural changes117.   
 
Regulatory sites on the NMDA receptor channel complex include a glycine-
binding site that facilitates the increase in frequency of agonist induced 
channel opening, as well as binding sites for MK-801 and PCP, both with 
inhibitory actions. These properties create a potential for a number of 
mechanisms for positive and negative control of NMDA receptor channel 
function40.  
 
Glutamate is involved in long term potentiation (LTP): the sustained increase 
in synaptic strength subsequent to high-frequency stimulation of a chemical 
synapse. It is one of the intrinsic phenomena that enable chemical synapses 
to change their strength (synaptic plasticity)118,119, which is believed to be a 
component involved in the encoding of memory114 in the cornus amonis area 
3 (CA3) region of the hippocampus.   
 
Examination of glutamate in the cerebrospinal fluid (CSF) of patients with 
Huntington's chorea, schizophrenia, and sciatic nerve compression (control 
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group), showed that glutamate levels in Huntington‟s and schizophrenia 
patients were lower by nearly half when compared to  the control group, 
despite similar serum glutamate levels. This was not related to neuroleptic 
treatment120. Lesion studies in rodents, with selective abrogation of cortical 
and hippocampal NMDA receptors in mice, during the early postnatal period, 
caused distinct schizophrenia like cognitive and behavioral symptoms with 
onset after adolescence121. 
 
Pharmacological challenge studies with NMDA antagonists such as 
ketamine122, PCP and MK801123, induce symptoms resembling the positive, 
negative and cognitive symptoms of schizophrenia. From these observations 
followed the NMDA receptor hypofunction hypothesis of schizophrenia, 
which proposes that NMDA receptor blockade reduces activation of 
GABAergic inhibitory neurons, causing a failure of mesolimbic and 
mesocortical regulatory projections, which can cause an excessive 
downstream release of glutamate and acetylcholine124,125.  
 
From the interaction between glutamate and dopamine followed a variant of 
the NMDA hypothesis of schizophrenia in which deficits in the NMDA system 
result in abnormal functioning of the dopaminergic system. In the healthy 
brain, descending glutamatergic projections from the cortical pyramidal 
neurons, via GABA interneurons, results in tonic inhibition of DA release 
from the mesolimbic pathway. However, NMDA receptor hypofunction will 
cause mesolimbic dopaminergic hyperactivity and positive symptoms of 
schizophrenia. Furthermore, glutamatergic hypoactivity in the cortico-
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brainstem neurons, which under normal circumstances projects directly onto, 
and stimulates, mesocortical dopaminergic neurons, causes dopaminergic 
hypoactivity in the mesocortical areas, resulting in cognitive, negative and 
affective symptoms of schizophrenia126.  
 
1. N-methyl-D-aspartate receptor agonists 
 
N-methyl-D-aspartate antagonists impair cognitive functioning in laboratory 
animals as described above. These impairments are reversible with 
administration of NMDA agonists, such as glycine127. Milacemide, a glycine 
prodrug128, as well as d-cycloserine (a partial agonist at the NMDA glycine-
binding site) proved to enhance learning129 in rodents. In a six week study of 
22 treatment resistant in-patients with schizophrenia, Heresco-Levy et al. 
demonstrated significant reduction of 16% (±11%; 95% CI: 10%-21%) 
cognitive deficits with administration of glycine (target dose 0.8g/kg) 
compared to an appearance- and taste-matched placebo on the PANSS 
cognitive factor score130. Unfortunately no specific cognitive measures were 
included in this study.  
 
The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST), 
investigated the use of adjunctive glycine, d-cycloserine (DCS), or placebo, 
for relief of negative and cognitive symptoms of schizophrenia. This 16-week 
double-blind, double-dummy, parallel group, RCT involved 157 in-patients 
and outpatients, who met DSM-IV-TR criteria for schizophrenia or 
schizoaffective disorder, and were deemed to have moderate to severe 
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negative symptoms. The primary outcome measures were the average „rate 
of change‟ on the SANS131 scores, and change in the average cognitive 
domain Z-scores. There were no significant differences in change in the 
SANS total score, cognitive symptoms, or negative symptoms change 
between the groups, with the conclusion that neither glycine, nor DCS are an 
effective therapeutic option for treating negative symptoms, or cognitive 
impairments in schizophrenia132.  
 
Although small increases in NMDA-dependent glutamate transmission 
enhances cognition, too large an increase can lead to neurotoxicity and 
degeneration. Studies with the use of agonists, such as d-serine, glycine and 
DCS, have suggested that these agents are effective in treating some of the 
cognitive and negative symptoms of schizophrenia133, whereas others have 
not134. Study results for the therapeutic benefit of NMDA agonists in the 
treatment of schizophrenia therefore remain inconclusive. 
 
2. α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptor  
 
Development of compounds that stimulate AMPA and KA receptors is 
another glutamatergic approach for cognitive enhancement in schizophrenia. 
The AMPA receptors are considered to modulate fast glutamatergic 
excitatory neurotransmission in the central nervous system (CNS), and the 
expression and maintenance of LTP135,136; therefore vitally important for 
cognitive functions such as learning and memory137,138.  
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Rodent studies have reported ampakines to offer a degree of protection 
against excitotoxic brain damage139, to improve neurological signs in 
Parkinson's disease140, and to increase cell proliferation in the dentate 
gyrus141.  
 
However, AMPA agonists rapidly desensitize after stimulation, and are not 
likely to be useful therapeutically137. In an effort to counteract this 
desensitization, a class of compounds known as kainates (allosteric 
potentiators of AMPA receptor function) is being researched as possible 
treatments in enhancing cognition in schizophrenia142. AMPA receptor-
positive modulators (ampakines) facilitate learning and memory in animal 
models143,144, and in preliminary trials in human subjects145.  
Unfortunately, initial clinical trials for the use of CX516, the first ampakine to 
be studied for cognitive enhancement in stable patients with schizophrenia, 
failed to demonstrate efficacy as add on treatment to clozapine, olanzapine, 
or risperidone. It therefore remains inconclusive whether the modulation of 
AMPA receptors has any therapeutic benefit in the treatment of cognitive 
impairments in schizophrenia145. Research in this area is however ongoing.  
 
3. Metabotropic glutamate receptor agonists 
 
Compounds that act as agonists at metabotropic glutamate receptors 
(mGIuRs) to modulate pre- and post-synaptic gluatamatergic 
neurotransmission for the treatment of cognitive dysfunction in schizophrenia 
are currently in preclinical development. Of the eight subtypes of mGIuRs 
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(mGIuR1-8), assembled into three groups, the main focus of investigation for 
cognitive enhancement in schizophrenia has been on group 1 (mGIuR1 and 
mGIuR5)
146.  
 
mGIuR5 receptor agonism potentiate presynaptic glutamate release and 
post-synaptic NMDA transmission147, thereby enhancing cognition, and has 
been observed to inhibit PCP induced DA release in the PFC of male 
Sprague-Dawley rats148. However, mGIuR5 agonism is likely to induce 
tachyphylaxis, therefore restricting their therapeutic usefulness149. Recently 
developed selective allosteric modulators of mGIuR show promise as 
therapeutic compounds150, and preliminary positive results with an mGIuR2/3 
agonist have been documented in phase II trials151.  
 
4. Glycine reuptake inhibitors 
 
Glycine transporters, GlyT1 and GlyT2, are located on neuronal and glial 
cells in the central nervous system152, and are thought to be responsible for 
the regulation of extracellular glycine concentration. Inhibition of glycine 
transporters increases extracellular glycine concentration, which enhances 
NMDA receptor neurotransmission135, thus exhibiting therapeutic potential 
for treatment in schizophrenia153.  
Rodent studies investigated effects of GlyT1 inhibitors on amphetamine-
induced disrupted latent inhibition (LI) and MK-801-induced abnormally 
persistent LI, as pharmacological, and neurodevelopmental models of 
schizophrenia respectively. Both SSR103800 and SSR504734 reversed 
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amphetamine-induced disrupted LI, and reversed MK-801-induced 
abnormally persistent LI. Furthermore, selective high-affinity glycine 
transporter inhibitors, such as Org-24598, SSR-504734, and N-[3-(4‟-
fluoropheny)-3-(4‟-phenylphenox-y)propyl] sarcosine, have been 
demonstrated to reverse PCP-induced hyperactivity in rats154,155. These 
preclinical data allude to the possibility that GlyT1 inhibition may display 
activity in the positive, negative and cognitive symptoms of schizophrenia153.  
 
Tsai et al. documented that sarcosine (N-methyl glycine), a low-potency 
glycine inhibitor, administered concomitant to current antipsychotic treatment 
of schizophrenia patients, effected a highly significant reduction in negative 
symptoms and a modest but significant reduction in cognitive and positive 
symptoms156.   
 
5. Gamma-amino-butyric acid (GABA) 
 
Post mortem studies of schizophrenia patients have revealed decreased 
ribonucleic acid (RNA) levels for glutamic decarboxylase (GAD), the enzyme 
responsible for the conversion of glutamate to GABA157. Other studies report 
GABAA α2 subunit increases in patients with schizophrenia
158. Chandelier 
cells in the PFC synchronize the activation of pyramidal neurons via GABAA 
receptor subtypes. Some evidence suggests that diminished GABA 
transmission in chandelier cells may be secondary to NMDA receptor 
dysfunction, and may prove to be a „final common pathway‟ of prefrontal 
dysfunction in schizophrenia. It follows that compounds modulating 
 Treatment of Cognition in Schizophrenia  
 152 
GABAnergic neurotransmission, such as the GABAA α2 selective 
benzodiazepines, may prove to be effective in ameliorating cognitive deficits 
in schizophrenia159. Unfortunately, benzodiazepines impair cognitive 
function, working memory, cause sedation and are habit-forming151.  
 
Functional magnetic resonance imaging (fMRI) in patients with 
schizophrenia compared to healthy controls, confirmed the association 
between GABAnergic functioning and cognition. Working memory 
performance on an N-back task was assessed as a target discrimination 
index at several levels of difficulty. Activation of the frontoparietal cortex 
increased with task difficulty, and was positively correlated with deactivation 
of the temporocingulate cortex. After placebo administration, schizophrenic 
patients had abnormally attenuated activation of the frontoparietal cortex and 
deactivation of the temporocingulate cortex. A similar pattern, associated 
with impaired WM, was found when lorasepam was administered to controls, 
while exacerbating it in schizophrenic patients. In contrast, flumazenil (a 
negative allosteric modulator of the GABAA receptor complex) enhanced 
deactivation of the temporocingulate and activation of the anterior cingulate 
cortices, and improved WM performance160. It therefore stands to reason 
that disrupted inhibitory GABAnergic function may be related to cognitive 
impairment, and is therefore treatable by compounds targeting GABA 
neurotransmission.  
 
Alpha51A, a GABAA receptor selective inverse agonist, enhances LTP and 
cognitive performance in rodents. Unfortunately, preclinical toxicity and 
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safety studies determined that alpha5 is unsuitable for prolonged 
administration to humans. However, doses of up to 6mg were well tolerated 
by young and elderly subjects, and it reversed ethanol-induced impairment in 
the cognitive performance of young normal volunteers161.  
 
Baclofen, a GABAB receptor agonists, improved cognitive impairment in mice 
administered subchronic methamphetamine treatment (1mg/kg for 7 days), 
whereas gaboxadol, a GABAA receptor agonist exhibited no significant 
effect, suggesting that GABAB receptors may prove to be a novel target in 
the treatment of patients with schizophrenia162.   
 
SEROTONERGIC STRATEGIES  
 
Serotonin (5HT) is a monoamine neurotransmitter synthesized from 
L-tryptophan163, and has a number of functions, such as regulation of mood, 
sleep, appetite, and cognitive functions including learning and memory164. 
serotonergic nuclei are located in the dorsal raphe nuclei in the brainstem, 
from where axons fan out to encompass nearly every part of the CNS. In so 
doing, they innervate the limbic- and neocortex, as well as parts of the basal 
ganglia165,166.  
 
Bosia et al. genotyped and evaluated the attention and cognitive flexibility, of 
233 patients with schizophrenia. Results indicated that the presence of the 
high-activity long allele (L) of the 5HT transporter was a predictor of better 
executive performance, but impaired attention. Therefore, it would appear 
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that disruptions in 5HT availability may, through complex modulation of the 
various performance components, play a particular role in cognitive 
processes, particularly declarative memory167.  
 
Fourteen 5HT receptors have been identified, of which 5HT1A
168, 5HT2A
169, 
and 5HT6
170
 seem to be playing an important in the role in cognition and 
schizophrenia. The highest density of 5HT1A receptors are found on the 
cortical and hippocampal pyramidal cells171, thus suggesting that these 
receptors play a role in modulating cognitive functions172. Studies into the 
5HT1A partial agonist tandospirone in schizophrenia patients receiving FGAs 
or SGAs, reported modest ability of this drug to improve some cognitive 
domains, such as verbal memory, semantic memory, working memory and 
attention173.  
 
A high concentration of 5HT2A receptors is found in pyramidal neurons 
originating from cortical layer V, where they aggregate with NMDA glutamate 
receptors151, as well as on DA neurons in the VTA, therefore playing a role in 
regulating DA and glutamatergic activity. Studies in animals show that 
antagonism of 5HT2A receptors inhibits DA release in the basal ganglia, and 
improves cognitive deficits172. A double blind, randomized, placebo 
controlled study of primavanserin (ACP-103), a selective 5HT2A receptor 
inverse agonist, in 60 patients with L-3,4-dihydroxyphenylalanine (L-DOPA) 
or PCP-induced psychosis, demonstrated significant improvement in 
psychosis in patients receiving pimavanserin compared to placebo. In this 
study pimavanserin did not separate from placebo with regard to motor 
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impairment, hypotension, sedation, or other side effects. This supports the 
hypothesis that attenuation of PCP-induced psychosis may be achieved 
through selective 5HT2A  receptor antagonism
174.  
 
High concentrations of 5HT6 receptors are located in the olfactory cortex, 
neocortex, limbic striatum, and hippocampus. In addition to their D2 
antagonism and inverse agonistic effects, antipsychotic such as olanzapine 
and clozapine were found to have a high affinity for 5HT6 receptors
172, 
leading to concerted efforts to establish and understand this receptor‟s 
potential as a future therapeutic target175.  
 
NORADRENERGIC STRATEGIES 
 
The central noradrenergic (NA) system originates from the locus ceruleus 
(LC) from where it projects to the PFC, playing an important role in cognitive 
function176,177. In addition, this action is thought to be reciprocated by the 
PFC supplying cortical afferents to the LC178,179. Stein and Wise were the 
first to propose a progressive deterioration of central NA pathways in 
schizophrenia, leading to anhedonia and loss of drive180. However, this has 
not been confirmed, as neuronal activity measurement and post mortem 
studies in schizophrenia patients have produced conflicting results181,182, and 
even increased NA levels in the CSF183-185. It is possible that NA disruptions 
in schizophrenia are not homogenous throughout the CNS, and may explain 
the coexistence of low and high NA states mediating different system 
clusters in schizophrenia. Furthermore, activation of pre-synaptic  
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α2 autoreceptors inhibits the release of NA, while stimulation of post-synaptic 
α2 receptors has an agonist effect
186.   
 
Lesion studies in the NA system in rats demonstrated deficits in sustained 
attention187, shifting attention188, and learning189. Rats administered 
diethyldithiocarbamate (DDC), a DA-β-hydroxylase (DBH) inhibitor that 
depletes NA stores in the brain, exhibit complete retention failure of passive 
avoidance learning190. Similarly, puromycin-induced reduction of NA induces 
amnesia of maze learning in rats191. Deficits in the DDC treated rats were 
reversed with a single intraventricular dose of NA192; as was the puromycin-
induced amnesia when treated with agents that increase NA activity, such as 
tranylcypromime, imipramine, d-amphetamine, and specific NA reuptake 
inhibitors191.  
 
The LC is believed to be activated by the presentation of novel stimuli that 
attenuate the influence of distracting stimuli, therefore focusing attention on 
task-relevant behaviours177, such as new learning, vigilance and 
distractibility193. Lesion studies in the PFC of rodents resulted in disinhibited 
firing of the LC, suggesting that PFC dysfunction may disrupt regulation of 
the LC179. This means that, theoretically, cognitive dysfunction related to LC 
dysregulation may be experienced by schizophrenia patients, in addition to 
the cognitive deficits associated with PFC dysfunction194.  
 
Animal studies have provided ample evidence that memory deficits can be 
ameliorated by β-adrenergic agonists195. In human studies endogenous 
 Treatment of Cognition in Schizophrenia  
 157 
levels of β-adrenergic receptor activation selectively enhanced memory 
associated with emotional arousal196. Unfortunately, β-adrenergic agonists 
have a significant side-effect profile, thus limiting their clinical utility as 
cognitive enhancing agents in humans. NA activity enhancement with 
compounds such as tricyclic antidepressants (imipramine), monoamine 
oxidase inhibitors (tranylcypromine), d-amphetamines, and specific NA 
reuptake inhibitors (reboxetine), is problematic, since these agents can 
cause angina, tachycardia, and other arrhythmias197. 
 
Alpha2-adrenergic receptors are thought to be integral to cognitive 
functioning in humans176,177. Treatment with clonidine198 and guanfacine199, 
both α2-adrenergic agonists, improves cognitive performance in patients with 
schizophrenia, while concomitant administration of risperidone and 
guanfacine significantly improves tasks of attention and WM199. Atypical 
antipsychotics such as clozapine are potent agonists at α2-adrenergic 
receptors200. Concomitant treatment of a FGA with idazoxan, a highly 
selective α2-adrenergic receptor agonist, exhibited a profile of antipsychotic 
activity similar to that of clozapine201.  
 
Alpha2-adrenergic receptor activity may well be important in the development 
of new drugs to improve cognition, balancing α2-adrenergic receptor activity 
to effect antipsychotic and precognitive efficacy, in schizophrenia151.  
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OTHER PHARMACOLOGICAL STRATEGIES 
 
Other potential strategies for pharmacotherapeutic advances in the 
management of cognition in schizophrenia include phosphodiesterase 4D 
allosteric modulators202, recombinant human erythropoietin203,204, histamine 
receptor type 3 antagonists205, and modafanil206, but evidence for therapeutic 
application is still lacking. 
 
NON-PHARMACOLOGICAL STRATEGIES 
 
Although antipsychotics have proven to be effective in reducing positive, and 
to some extent negative symptoms, these medications have only proved to 
be of limited benefit with regard to cognitive symptoms and functional 
outcome. Psychosocial strategies therefore aim to address residual 
symptoms, to improve functional (work and social) outcome, and to reduce 
risk of relapse207.  
 
Remediation and rehabilitation of cognitive deficits involve assisting the 
patient in achieving, and maintaining, a durable level of functionality and 
independence, and providing continued support for indigent areas208. 
Although individual psychodynamic therapy209,210 has not been of benefit, 
family intervention211 and personal therapy212 may have modest benefits. It 
seems that the biggest disadvantage of personal therapy, and family 
intervention, is the patient‟s lack of ability to generalize the skills acquired to 
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real-world settings213. Other psychosocial intervention strategies however do 
have evidence for improving functional outcome214.  
 
Social skills training (SST) is aimed at basic skills training, where complex 
social repertoires are dissected into smaller units, such as eye contact, 
speech modulation, and body language, and taught through repetition and 
modeling215,216. Another strategy is social problem solving skills training, 
which attempts to correct deficits in receptive learning, information 
processing and cognitive processes217. These remedial processes were 
found to improve social functioning, and positive symptoms such as 
hallucinations218. However, limitations regarding the ability to generalize 
these skills, and the durability thereof, have remained. 
 
Researchers realize that cognitive deficits in patients must first be addressed 
in order to meet the need for the improved effectiveness of SST. Cognitive 
remediation (CR) programs, such as neurocognitive enhancement therapy 
(NET), were therefore developed with the aim to address deficits in the 
patient‟s thinking and memory abilities. Cognitive remediation can be 
individual or grouped based interventions, which usually involves task 
practice via repeated drill and/or strategy coaching. Techniques employed 
include instruction, didactic training, monetary reinforcement, verbalization of 
action criteria (the patient „talks‟ him/herself through the task at hand), and 
task simplification. Previous studies have found benefits for CR with regard 
to improvements in attention219, working memory220, verbal memory221, 
social functioning, and symptomatic improvement222 in schizophrenia, with 
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some benefits retained at six months post-treatment223. Wykes et al.224 
estimated that an improvement of at least 50% in different cognitive domains 
is needed for the benefits to generalize to improvement on social functioning. 
It is unclear whether these improvements are ascribable to restorative or 
compensatory mechanisms.  
 
Computer based NET showed some success in improving cognition. 
Dickinson et al.25 randomly assigned 69 schizophrenia patients to 36 
sessions of computer-assisted cognitive remediation or an active control 
condition. Sixty-one patients completed the study. Although significant 
improvements were seen in performance on computer exercises, it did not 
generalize to significant benefits on any neuropsychological or functional 
outcome measure, either immediately after treatment, or at the three month 
follow-up. In another study, 72 patients received vocational training, or 
vocational training and NET, for a period of 12 months. The patients 
receiving combined treatment had a significant better occupational outcome 
with more hours worked, and higher rates of competitive employment226.  
 
Evidence for the efficacy of cognitive behavioral therapy (CBT) in addressing 
positive and negative symptoms of schizophrenia is still contradictory. 
Although effectiveness was established for addressing positive 
symptoms227,228, CBT appears to be less effective in addressing negative 
symptoms229,230, while some studies reported no benefit at all231. Although 
CBT has not been shown to improve functional outcome232, or reduce 
relapse rates233, it did improve medication compliance234. Subsequently, a 
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CBT therapy intervention program for relapse prevention in FEP, has been 
developed by the Early Psychosis Prevention and Intervention Centre 
(EPPIC)235. Other psychosocial strategies employed are psychoeducational 
programmes236, and supported employment programmes237.  
 
A logical next step 
 
Decades of research have established the need for psychopharmacological 
and psychotherapeutic interventions in addressing cognitive deficits in 
schizophrenia. Antipsychotics remain the cornerstone in treatment of this 
disease. However, further research and development of agents more 
efficacious in addressing cognitive symptoms are clearly needed. 
Unfortunately, research and development of novel drugs is a slow and 
expensive process. In the meantime, it would behove researchers and 
clinicians to consider and reconsider agents which are already available, but 
have not been adequately researched.   
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CHAPTER 6  
FLUPENTHIXOL  
 
Flupenthixol, a thioxanthene derivate developed by H. Lundbeck A/S as an 
antipsychotic agent, was first tested in 19651,2. Zapletalek et al.3 can be 
credited for the first therapeutic administration to patients with schizophrenia, 
while Rimestad et al.4 described a three year trial with use of flupenthixol in 
various disorders. Since 1965, various studies, especially in the 
Scandinavian countries, have reported, in addition to the antipsychotic 
efficacy of flupenthixol, evidence for efficacy in the treatment of neuroses, 
reactive depression, psychosomatic disorders and functional organic 
disturbances. Flupenthixol has been commercially available in the UK since 
1962 and in the rest of the world (except the United States) since 1972.   
 
Chemical structure 
 
2-trifluoromethyl-9-(3[4-(2-hydroxyethyl)-1-piperazinyl]propylidene)-
thioxanthene‟s, better known as flupenthixol, chemical structure is 
C23H25F3N2OS, with an average molecular mass of 434.52 g/mol (see figure 
6.1). It is available as a dihydrochloride (for oral use), as well as a decanoate 
(for intramuscular use)5.  
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Figure 6.1: Chemical structure of flupenthixol 
 
Flupenthixol exists as two geometric isomers, the cis(Z) and trans(E) forms. 
Only cis(Z)-flupenthixol is pharmacologically active. Flupenthixol 
hydrochloride is soluble in water and ethanol. Esterification of cis(Z)-
flupenthixol forms a highly lipophilic substance, which, when dissolved in oil, 
can be injected intramuscularly. The ester diffuses slowly from the oil to the 
body-water phase where it is rapidly hydrolyzed to release the active cis(Z)-
flupenthixol5. 
 
 
 
 
 
R 
R = OH (in tablet) 
R = OCO(CH2)8CH3 in depot  
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Pharmacokinetics 
 
Absorption6-9  
 
Absorption of flupenthixol is fairly slow and incomplete. First pass 
metabolism reduces oral bioavailability with 40%. There exists a linear 
relationship between administered dose and serum level, and maximum 
serum levels (Tmax) are reached within 4-5 hours after oral, and 3-7 days 
after intramuscular, administration.  
 
In these early pharmacokinetic studies, relatively high doses of flupenthixol 
were used (5mg/d po or 40mg 2 weekly IMI) 
 
Distribution8-11  
 
Plasma protein binding is more than 99% and the volume of distribution (Vd) 
14.1 ℓ/kg. The highest levels of flupenthixol are found in parenchymatous 
organs such the lungs and liver, with much lower concentrations in the CNS.  
Flupenthixol hydrochloride has a half-life of (t½) of 19-39 hours, reaching 
steady state (css) after 7 days, while flupenthixol decanoate has a t½ of 8-17 
days, with css of 3 months.  
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Metabolism8,12,13 
 
Flupenthixol has no active metabolites. Biotransformation occurs following 3 
routes: sulphoxidation, side chain N-dealkylation and glucoronic acid 
conjugation.              
  
Elimination and excretion6,12,14  
 
Elimination t½ was found to be between 5 and 113 days, with a mean of 35 
days. Systemic clearance (Cls) was calculated as 0.46 ℓ/min in healthy 
volunteers to 0.31 ℓ/min in psychiatric patients, with a mean Cls= 0.29 ℓ/min. 
Metabolites are excreted mainly in feces (63%), with a minor amount 
excreted in urine (17.4%), and in trace amounts present in bile and breast 
milk. Reduced kidney function does not appear to significantly impact 
excretion. 
 
Pharmacodynamics  
 
Flupenthixol acts as an antagonist at various DA (especially D1 and D2), 
5HT2, adrenaline (α1), and histaminergic (H1) receptors. The following in vitro 
receptor binding affinities (Ki nmol/ℓ) have been calculated: D1 binding = 
0.91; D2 binding = 0.35 and 5HT2A binding = 4.2; while in vivo potency (ED50) 
has been established as D1 binding = 0.15, D2 binding = 0.03 and 5HT2A 
binding = 0.04. Due to very low H1 affinity, flupenthixol does not cause 
sedation, and it is devoid of any cholinergic muscarinic and α2 blockade 
effects15. 
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Flupenthixol can be considered an „atypical typical‟, or „partial atypical‟ and 
resembles SGAs in various ways16. The antipsychotic effect of flupenthixol is 
mediated through D2 antagonism, with D1 and D2 affinity more similar to 
clozapine than to fluphenazine (while it has almost only D2 affinity). 
Flupenthixol displays 40-50% 5HT2A receptor occupancy at 10mg/d with 
improved efficacy against negative symptoms and depressed mood17, and 
reduced risk of EPSE, in comparison to phenotiazines. Unlike the 
phenotiazines, flupenthixol also resembles tricyclic antidepressants in some 
aspects; with antidepressant and anxiolytic effects thought to be mediated 
via preferential D2/D3 autoreceptor blockade, resulting in increased post-
synaptic dopaminergic activity when used at lower doses of  
1-1.5mg/d18-21.  
 
Limited data is available with regard to toxicity, although it is thought that 
toxicity is cause by the same mechanisms as those producing clinical 
effects. The median lethal oral dose (LD50) is 300 mg/kg (in mice) and 791 
mg/kg (in rats). 
                   
Indications       
 
Flupenthixol is used to treat both positive and negative symptoms of 
schizophrenia, and has been documented to ameliorate associated 
depressive symptoms18,22-25. 
 
The application of flupenthixol in low dose as an antidepressant was first 
described by Holst26, Sonne27 and Reiter28, and is licensed in the treatment 
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of mild to moderate depression. Flupenthixol was shown to reduce anxiety, 
while depression scores demonstrated it to be29, more efficacious than 
placebo30 and diazepam31; yet as effective as amitriptyline32-35, 
nortriptyline36, fluvoxamine37 and mianserin38. In all of these studies, 
flupenthixol was found to have a quick onset of action with symptomatic 
improvement evident during the first week. Flupenthixol was superior to the 
comparator drugs in reducing general somatic, gastrointestinal and 
autonomic symptoms14,20,24 causing fewer side-effects24, and a lower patient 
drop-out rate. Although efficacy for both oral and intramuscular use have 
been demonstrated, it is advised that the use of flupenthixol decanoate be 
restricted to: short courses of treatment; patients refractory to other 
treatments; and to patients suspected of poor compliance; as depressed 
patients are known to be more susceptible to EPSE, and should rather use 
oral preparations35.  
 
In a number of controlled studies low dose administration of flupenthixol has 
been seen to be effective in treating psychosomatic disorders24,33,39-41, 
especially in the presence of pain, lowered mood, anxiety or asthenia42. It 
demonstrated efficacy in reducing suicidal acts in borderline personality 
disorder43,44; the treatment of mania in bipolar mood disorder45; and reducing 
craving and enhancing abstinence in cocaine dependence46,47. Although 
evidence for enhancing abstinence in alcohol dependence is lacking, a 
potential indication for treating “dual diagnosis” patients (schizophrenia and 
alcohol abuse) exists48. Hashash et al. has demonstrated clinical efficacy in 
the treatment of functional dyspepsia49.  
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Side-effects and contraindications 
 
Flupenthixol is generally well tolerated, with a low incidence of mild adverse 
effects, which tend to disappear after the first few months of treatment. The 
most common side-effects reported are insomnia (5%), drowsiness (3.5%) 
and EPSE (0.8% at doses of 3mg/d or less). According to the product 
monograph5, EPSE are usually minor, and temporary, with onset typically 
occurring within the first few days after depot injection5,50. However, this 
author could find no substantiating evidence in the literature. Other studies 
report the incidence of EPSE to be much more common, and similar to that 
occurring with fluphenazine decanoate51-53.  
 
Flupenthixol is contraindicated in patients with a known hypersensitivity to 
any of the following components, patients with circulatory collapse, central 
nervous system depression, comatose states, blood dyscrasias or 
pheochromocytoma5.  
 
Flupenthixol is relatively contra-indicated in excitable or hyperactive patients, 
especially in low doses (below 6mg/day) as it may exacerbate these 
features. It is also contraindicated in parkinsonism, severe arteriosclerosis, 
senile confusional states and severe renal, hepatic or cardiovascular 
disease. Caution is advised with use in organic brain syndrome, convulsive 
disorders, and advanced hepatic disease. Concomitant use with lithium 
increases the risk of neurotoxicity, while concomitant use with 
metoclopramide and piperazine increases the risk of EPSE54. Although there 
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is no evidence of teratogenicity, it should nevertheless be avoided in early 
pregnancy55.  
 
Administration                
 
The following doses for the use of flupenthixol are advised:     
 
1. For the treatment of depression, and for anxiolytic and activating 
benefits, 1-2mg/d, to a maximum of 3 mg/d per os54.  
 
2. For the treatment of psychosis, especially in apathetic, withdrawn, 
depressed and poorly motivated patients, 3-15mg/d, with a maximum 
of 40mg/d per os; or 20-60mg 2-4weekly, to a maximum of 18mg/d 
(100mg/2weeks) per deep intramuscular injection (IMI)50.  
 
Flupenthixol 3mg/d is generally accepted to be equal to 100mg/d CPZE56. 
Though consensus has been reached for the equivalent doses between 
different depot antipsychotics, discrepancies exist concerning the oral 
equivalent of depot antipsychotics. Atkins et al.57 concluded that flupenthixol 
decanoate 40mg 2 weekly IMI is equal to 100mg/d CPZE. 
  
Flupenthixol in the treatment of schizophrenia 
 
Various studies since the 1960s confirmed the efficacy, and tolerability of 
flupenthixol. Although only one placebo-controlled trial58 could be traced, 
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phase II and phase III clinical trials have proven the efficacy and tolerability 
of flupenthixol. 
 
Johnstone et al.58,59 evaluated 45 patients with acute schizophrenia in a 
double-blind trial in which they received either α-flupenthixol (activity as a DA 
receptor blocker), ß-flupenthixol (inactive), or placebo. Alpha-flupenthixol 
was found to be significantly more effective in treating positive symptoms 
than either of the other two treatments. The authors concluded that DA 
blockade is necessary for antipsychotic effect, and demonstrated that  
α-flupenthixol is active as such. Thirty-eight patients were reassessed at one 
year58 with regard to clinical, social and cognitive functioning. However, 
assessment procedures are vague and no conclusions with regards to 
efficacy or tolerability were made.  
 
In one the most extensive studies, Carney and Sheffield 60 reported on their 
clinical experience with flupenthixol decanoate (FD) during 1970-1974. After 
initial stabilization, patients with schizophrenia received 15mg FD, 20mg one 
week later, 30mg another week later, and then 30-120mg 3 weekly. One-
hundred-and-thirty-four patients were initially included, but the study was 
then extended to include 199 patients, with a mean duration of follow-up of 
21 months. The mean dose of FD required was 31.97-33.46mg every three 
weeks. Twenty-eight percent of patients developed mild parkinsonistic 
features which did not require any intervention, while 10% of patients 
required re-admission due to relapse. There was an annual default rate of 
7%. The authors concluded that FD is efficacious and suitable for outpatient 
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and maintenance therapy. Although they did not compare FD to 
fluphenazine, they did report an observation that patients appeared more 
sociable, active and communicative on FD51,60. 
 
Gottfries and Green52 and Curson et al.61 confirmed the efficacy of FD 
preventing relapse. In a 12 year observational study52 22 of 58 completers 
(of 101 included participants), did not experience relapse. Although relapse 
and admission histories may reflect severity of illness, FD discontinuation 
increased relapse rates to 45% within 13 months61.  
 
In a more recent trial of one year duration, 62 patients with chronic 
schizophrenia were assigned to one of three different maintenance doses of 
FD. Forty-seven patients did not relapse, and completed the study. A 
consistent clinical improvement of 14-18% occurred after 3 to 6 months of 
treatment as measured by the BPRS. Negative symptoms, as measured by 
the SANS, also diminished with 22%. During the course of the trial, 26.4% of 
patients developed mild involuntary movements as measured by the 
Abnormal Involuntary Movement Scale (AIMS) for which 23.5% needed 
anticholinergic treatment62.  
 
Two studies investigated the use of large doses (50-400mg FD 2-3 
weekly)63,64. These high doses utilize the sedative effect of FD, and the 
authors suggest that high doses should be considered for patients with poor 
response in previous or present psychosis, and whose syndrome is 
characterized by extreme psychomotor agitation, anxiety or aggression, or 
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treatment resistance. However, patients experienced four times more 
tremors, and this practice cannot be recommended.  
 
In standard-of-care studies, non-inferiority of FD compared to fluphenazine 
in the treatment of schizophrenia was repeatedly established, with FD 40mg 
2-3 weekly at least as effective as fluphenazine decanoate 25mg 2-3 weekly 
in reducing symptoms, as measured by the BPRS, and Clinical Global 
Impression scale (CGI)29,53,65-68.  
 
In 1975, Johnson and Malik did a double-blind comparison of FD and 
fluphenazine decanoate in 40 consecutively admitted patients with 
Schneiderian first rank symptoms of schizophrenia. All patients had a 7 day 
run-in period during which they received either oral chlorpromazine or other 
short-acting intramuscular preparations, followed by half a dose of FD or 
fluphenazine decanoate, with a full dose one week, and a further two weeks 
later. In addition, patients also received chlorpromazine 50-300mg/d per os 
(blinded). No difference was observed in antipsychotic effect, or the 
presence of EPSE, during the 56 days of the study69.  
 
In a double-blind cross-over design study, 30 patients received one month of 
placebo, followed by 12 weeks of either FD or fluphenazine decanoate, then 
again one month of placebo, and then the alternate depot antipsychotic. 
Twenty-two patients completed the trial, and the two depots proved to be 
equipotent70. 
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Wistedt and Ranta entered 32 relapsed chronic schizophrenic patients into a 
double-blind randomized study. Participants received either FD (mean dose 
31mg) or fluphenazine decanoate (mean dose 27mg) for a period of two 
years. No differences were reported with regard to global effect or effect on 
schizophreniac symptomatology during the first six months. However, after 
one year of treatment, FD showed a trend for better effect on control of 
schizophrenic symptoms53.  
 
Studies also suggested that FD demonstrated added benefit in the treatment 
of depressive symptoms, withdrawal, anxiety and psychomotor retardation 
and recommended that FD should be the treatment of choice in patients with 
a depressed mood, or a history of depression18,29,53,69-71. This held only true 
when FD was used in relatively low doses72, and was disputed by Knights et 
al.73.  
 
Furthermore, FD may have a role in reducing the risk of relapse. In a double-
blind six month withdrawal study of 41 chronic schizophrenic outpatients74, 
FD (20-40mg every 3rd week) or fluphenazine decanoate (12.5-25mg  
3 weekly) were used in comparison to placebo. Drugs were significantly 
more effective than placebo in preventing relapse and readmission to 
hospital, with a relapse rate of 62% in the placebo group, compared to 27% 
in the drug group. 
In further double-blind active-comparator trials, FD was also demonstrated to 
be as efficacious as pipotiazine undecylenate75, penfluridol76, pimozide77 and 
trifluoperazine78.  
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In a Cochrane review of studies conducted between 1966 and 1998, FD 
demonstrated no differences with regard to outcomes such as death, global 
impression, relapse, or discontinuation when compared to other depot 
preparations79. However, the review suggested that that flupenthixol causes 
less movement disorder than other depot preparations (OR 0.23; CI: 0.08-
0.7; NNT 5). This did not hold true for tremor (OR 1.2; CI: 0.3-4) and tardive 
dyskinesia (OR 1.60; CI: 0.4-6). It has to be kept in mind that, a meta-
analysis/ reviews of results can only be as good as the data it is based on.   
 
A few recent studies compared flupenthixol with the SGAs risperidone80,81, 
amisulpride82,83, and olanzapine84,85. Hertling et al. compared the effects of 
oral flupenthixol (mean dose 6.6 [±2.9] mg/day), and risperidone (mean dose 
3.6 [±1.2] mg/day) in a multicenter, double-blind trial of chronic schizophrenic 
patients with mainly negative symptoms. Both groups showed a significant 
improvement regarding subjective quality of life (as measured by the 
EuroQol-Visual Analogue Scale), and positive attitude towards medication 
(assessed by means of the Drug Attitude Inventory-30). The flupenthixol 
group improved significantly more with regard to the „ability to cope with 
stress‟, „feel more relaxed‟, and the „ability to achieve something‟80.  
 
In a six month randomized double-blind study in 144 chronic schizophrenic 
patients, comparing oral flupenthixol 6.23 (±2.86)mg/d with risperidone 3.56 
(±1.20) mg/d, flupenthixol demonstrated non-inferiority with regard to 
effectiveness on negative symptoms (as measured by the PANSS negative 
subscale). The authors reported a trend in favor of flupenthixol concerning 
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the improvement of depressive symptoms, and a trend in favor of risperidone 
concerning the improvement of preexisting parkinsonian symptoms25. 
 
Flupenthixol (mean daily dose 22.6mg) was used as an active comparator in 
a randomized double-blind six week study of 132 patients with acute 
schizophrenia, investigating efficacy and tolerability of amisulpride (mean 
daily dose 956mg)83. Intention-to-treat evaluation demonstrated significant 
improvement under both medications, with 62% of patients in each group 
being responders. However, the mean difference in decrease of symptoms 
(BPRS) was 5.6 points (95% CI: 0.55-10.65) in favor of amisulpride. 
Withdrawal, due to intolerability, favored amisulpride (6%) over flupenthixol 
(18%), with less EPSE in the amisulpride group. Further analysis showed 
that amisulpride was significantly superior to flupenthixol regarding 
depressive features, but not negative symptoms, nor anhedonia-apathy82. 
 
Gattaz et al. compared the efficacy and the safety of olanzapine and 
flupenthixol in a four week double-blind RCT, in twenty-eight in-patients with 
schizophrenia. Sixty-nine percent of the olanzapine and 74% of the 
flupenthixol group were considered responders (a 40% decrease in BPRS). 
No significant group differences were reported with regard to overall efficacy 
(BPRS, Negative Symptoms Rating Scale [NSRS], and CGI scales)84. 
Statistically significant (p<0.01) more EPSE were reported in the flupenthixol 
group, and weight gain in the olanzapine group. A case report by 
Haberfellner also reported remission of TD when switching from flupenthixol 
20mg, to olanzapine 10mg every three weeks. Both agents were 
Flupenthixol 
 
 201 
administered concurrent with an established lithium dosage. At two months 
the olanzapine was increased to 15mg, with complete remission of TD four 
months thereafter85. 
 
Two phase IV, post marketing surveillance trials on the use of flupenthixol in 
schizophrenia were recently published86,87. In the first study, 658 patients 
were treated for approximately ten weeks. Seven-point-eight percent of the 
sample was FEP, while 90.6% had been suffering from schizophrenia for a 
mean duration of 7.7 years. Sixty-six-point-three percent of the participants 
were treated with FD (mean dose equivalent of 9.2 mg/d) while the 
remainder received oral flupenthixol (mean daily dose 6.3 mg/d). 
Concomitant medication was allowed. Clinical efficacy was demonstrated in 
77.8% of patients, with the CGI improving from 5.83 to 3.43 during the 
course of treatment. Tolerability was good with only 4.6% of patients 
experiencing treatment related side-effects. Quality of life (QOL) also 
improved with SWN (Subjective Well-being under Neuroleptic treatment; 
short version) scores improving from 61.2 to 78.586. In a continuation study, 
128 of the initial 658 patients were followed up for a subsequent 18 months. 
At the end of follow-up period, 68% of patients received FD, while 31.3% 
received oral flupenthixol, both at a mean daily dose of 6.7 (± 5.9)mg. The 
efficacy of flupenthixol treatment increased over time, with 89% of 
participants improving significantly over the 18 months. QOL further 
improved to SWN scores of 80.0. Physicians rated efficacy of flupenthixol as 
good, or very good, in 73.3% patients. Tolerability was assessed as good, or 
very good, in 86%. Although the rate of side-effects reported was only 5.5%, 
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22.7% of patients were reported to have needed anti-parkinsonism 
medication at some point during therapy87. The results of this study suggest 
that flupenthixol is a potent and safe antipsychotic for the long-term 
treatment of schizophrenia in routine clinical practice. 
 
Flupenthixol and cognition   
 
Despite flupenthixol being extensively administered for more than 40 years, 
only six studies mentioning the effect thereof on cognition could be 
traced58,88-93.  
 
A 1979 study by Johnstone et al. documented assessment of patients in 
clinical, cognitive and social terms. However the methods are vague, and the 
singular mention of cognitive assessments is the use of “memory for faces 
test”. No results are given, and no conclusions stated58. 
 
In 1985, Rösler et al. described the use of endogenous event-related brain 
potentials (ERP) as a measure of pharmacopsychological effects on 
cognitive functioning. The investigators documented a detrimental effect on 
perceptual and psychomotor functions, as well as memory retrieval after four 
days of treatment with flupenthixol 2mg/d per os91. It has to be noted that the 
aim of this study was to demonstrate the use of ERP as a measurement 
instrument, and not to document cognitive effects of flupenthixol.  
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The Scottish Schizophrenia Research Group88 studied 46 patients with a 
FEP over a period of 12 months in a double-dummy double-blind trial of 
pimozide versus FD. Patients were assessed at baseline, at 3, 6, 9 and 12 
months. Only 57% of patients were retested at one year, with only 44% 
realizing a good outcome in terms of absence of schizophrenic symptoms 
and relapse. Pimozide and FD were equally effective. Repeat psychometric 
assessment at 12 months found modest improvements from baseline on the 
Progressive Matrices94, the Block design sub-test of the Weschler Adult 
Intelligence Scale (WAIS)95 and the Digit Copying test96. No changes were 
documented for performance on the Mill Hill Vocabulary Scale97 and the 
Similarities sub-tests of the WAIS. 
 
Classen and Laux examined sensorimotor and cognitive performance of 
schizophrenic in-patients treated with antipsychotics. They assigned 50 
patients to treatment with either haloperidol (10-30mg/day), flupenthixol (5-
20mg/day) or clozapine (150-200mg/day) for seven days. Patients were 
assessed with the “Motorische Leistungsserie”§, the “Bettendorff 
Reaktiometer”**, a color-word-interference-test (FWIT, Stroop-test), and 
verbal and spatial ability tasks from the “Leistungsprüfsystem”††. There were 
no differences between treatment groups with regard to verbal or spatial 
abilities. Patients treated with clozapine performed better on the cognitive 
parameter “naming colored stripes” compared to patients treated with 
flupenthixol and haloperidol. Interhemispheric processing was reported to be 
less affected by clozapine and flupenthixol than by haloperidol. The authors 
                                                     
§
 Schoppe, KJ; 1974 
**
 Bettendorff, SA; 1974 
††
 Horn, W; 1983 
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concluded that risks in driving a car, or working at highly technical 
machinery, are due to impaired attention, rather than impaired motor 
function93.  
 
In 2007, Dunn and Killcross investigated the reversal potential of different 
substances on acute PCP induced disruption of a conditional discrimination 
task. Rats were taught a conditional discrimination task, wherein 
reinforcement was contingent on an appropriate lever press during a specific 
auditory stimulus. In the first experiment, PCP disrupted task performance at 
1.5mg/kg, attenuated correct lever pressing at 2.5mg/kg, and abolished 
overall responding at 5 mg/kg. In the second experiment, PCP disrupted 
instrumental conditional discrimination performance in a dose dependent 
fashion, with 1.5 and 2.5mg/kg PCP having no disruptive effects on basic 
sensory, motor or motivational processes; while 5mg/kg PCP did disrupt 
these processes. They demonstrated that acute pretreatment with clozapine, 
SCH 23390 and α-flupenthixol (all known to have D1 antagonistic effects) 
could attenuate PCP (1.5mg/kg) disruption of conditional discrimination; 
however, pretreatment with haloperidol (a D2 antagonist) did not attenuate 
task disruption. The authors ascribe this effect to the relative abundance of 
D1 receptors in the prefrontal cortex, whereas D2 receptors are present in 
most cortical areas. They concluded that cognitive deficits in schizophrenia 
can be accounted for by D1 receptor overstimulation
89. 
One other RCT compared the efficacy of flupenthixol and risperidone in a 
sample of 144 patients with stable schizophrenia. Patients were randomized 
to flexible doses of flupenthixol 2-6mg/d po or risperidone 2-6mg/d po. The 
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primary outcome measure was the change in PANSS negative subscale 
score. The authors concluded that flupenthixol was non-inferior to 
risperidone in the treatment of negative symptoms. Furthermore, they also 
report improvement in cognition, as measured by the PANSS cognitive factor 
(consisting of P2, N5, G10, G11 and G13), in both treatment arms. No 
neuropsychological assessments were done. Although the incidence of 
EPSE was reported to be low in both groups, the total number of patients 
receiving biperiden was significantly higher in the flupenthixol group (53.7%) 
vs. the risperidone group (32.6%) (p<0.01)25. 
 
By its very absence, the literature on the efficacy of flupenthixol, in relation to 
aspects of cognitive functioning and functional outcome in schizophrenia, 
attests to an urgent need for more studies into these therapeutically 
important aspects of the illness.  
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CHAPTER 7 
THE USE OF DEPOT ANTIPSYCHOTICS 
 
Schizophrenia is a life-long, chronic disorder, often marked by frequent 
relapses, incomplete inter-episode remission, chronic deterioration, and 
disability. According to Andreasen et al. remission is “a state in which 
patients have experienced an improvement in core signs and symptoms to 
the extent that any remaining symptoms are of such low intensity that they 
no longer interfere significantly with behavior and are below the threshold 
typically utilized in justifying an initial diagnosis of schizophrenia”1. Criteria 
for remission state that patients should be assessed on three dimensions of 
psychopathology: psychoticism (or reality distortion), disorganization, and 
negative symptoms. Simultaneous severity scores of mild, or less, should be 
maintained for a period of six months on all relevant items.  
 
Although prospective and retrospective studies report that a minority (10%) 
of patients has a persistent, unremitting course2,3 only one third of patients 
have a relatively good outcome, with no more than mild symptoms and 
impairment of functioning, while the remainder of patients will experience 
moderate to severe symptoms and functional impairment4.  
 
According to Robinson et al. recovery requires concurrent remission of 
positive and negative symptoms, therefore being relatively free of 
psychopathology, as well as adequate social and vocational functioning in 
the community. In a five year study of 118 patients with FEP, Robinson et al. 
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found that although sustained symptomatic and functional recovery is 
possible, the overall rate of recovery during the early years of the illness is 
low. After five years, 47.2% of their sample achieved symptom remission, 
and 25.5% had adequate social functioning for two years or more. Only 
13.7% of subjects met full recovery criteria for two years or longer5.  
 
Considering the high relapse rates, and the possibility that with each relapse, 
patients are less likely to return to previous levels of functioning6, a major 
focus of attention in FEP should be early, effective intervention and, 
subsequently, the prevention of relapse in order to improve long-term 
outcomes7.  
 
Medication adherence prevent relapse 
 
The ability of antipsychotics to prevent relapse is well documented. As early 
as 19758, a review of 33 studies, summarizing double blind studies in 
outpatients observed for at least six months, documented frequency of 
relapse as 4-35% on treatment, compared to 29-80% on placebo, while May 
et al. also proved antipsychotics to be superior to psychotherapy9. Although 
there are many potential causes for relapse, the strongest predictors appear 
to be poor compliance and medication discontinuation10,11, with a direct 
relation between degree of adherence and level of symptomatology12.  
 
Weiden and Glazer13, studied 131 consecutively admitted patients with 
schizophrenia. Of these, 63 were considered “revolving door” patients, and 
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had an average of 1.3 hospitalizations per year over the three years prior to 
the index admission, and were only out of the hospital for a median period of 
five months before the index admission. Of the 50 patients with complete 
histories about precipitants for the index episode, the most common reason 
for rehospitalization was considered to be non-adherence to medication  
(n= 25; 50%), followed by medication non-response (n= 13; 26%). Monthly 
relapse rates for patients on antipsychotic medication were estimated as 
3.5%, and 11.0% per month, for patients who had defaulted treatment. Over 
a period of two years, noncompliance contributed to 40% of rehospitalization 
costs, while loss of medication efficacy accounted for 60% of the costs14.  
 
In an open treatment withdrawal study of 32 schizophrenic outpatients on 
depot neuroleptics, 81% relapsed within one year, and 93% within two years 
of treatment discontinuation15. In a Cochrane review of 10 RCTs (N= 1042) 
examining the impact of medication withdrawal in patients with 
schizophrenia, stable on chlorpromazine, the relative risk for relapse (RRR) 
was 6.76 (CI: 3.37-13.54) within two months, and a RRR of 1.70 (CI: 1.44-
2.01) after six months, of discontinuation16.  
 
Non-adherence to treatment in schizophrenia is high: by ten days after 
discharge, 25% of patients are non- or partially adherent17. Within the first 12 
months of treatment after a FEP, 26% to 39% of subjects were found to be 
non-adherent, and 20% partially adherent with treatment18-20; this despite 
literature suggesting a one year post-hospital relapse rate in FEP of 41% on 
placebo vs. 0% on antipsychotic medication21. A 1986 review by Young et al. 
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reported a median default rate of 41% (range 10-76%) on oral antipsychotics 
and 25% (range 14-36%) with depot antipsychotics over periods of up to one 
year22. Non-compliance with oral antipsychotics was calculated at 40-60% 
over 4-6weeks, compared to 10-15% over two years with depot 
preparations23. Fenton et al. summarized findings from subsequent 
medication adherence studies in schizophrenia as a median one month to 
two year noncompliance rate of 55% (range 24-88%)24. Sustained delivery of 
a treatment that improves compliance is therefore particularly relevant to 
patients with FEP25.  
 
The development of long-acting depot antipsychotics during the 1960s was 
specifically aimed at addressing the issue of poor compliance and, although 
all findings were not consistent, they have been shown to be superior to 
conventional oral agents in preventing relapse26. In a review of studies that 
compared conventional oral and depot antipsychotic medications, mirror-
image studies, in which patients served as their own controls, provided 
evidence of substantial benefit for depot antipsychotics. Across the studies 
reviewed, the one-year relapse rate for long-acting depot medication was 
27% compared with 42% for patients who received oral medication19.  
 
In a South African study, premature discharge (i.e. early discharge due to 
bed pressure, against clinician‟s opinion), and depot use were the two 
significant predictors of high-frequency vs. low-frequency users of mental 
health in-patient services27. Under-utilization of depot antipsychotics 
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therefore seems to contribute to high-frequency use of mental health 
services. 
 
Perceptions about depot antipsychotics 
 
Despite evidence that depot antipsychotics enhance treatment compliance 
and decrease relapse rates, depot preparations remain less frequently 
prescribed than their oral counterparts28. In many countries fewer than 20% 
of individuals with schizophrenia receive depot antipsychotic medication, 
with rates ranging from 5% in the USA to 20% in the Scandinavian countries. 
Frequently stated reasons are psychiatrists‟, patients‟ and relatives‟ 
objections to depot treatment29. 
 
Psychiatrists remain reluctant to prescribe depot antipsychotics, with less 
than 10% offering depot treatment as an option after a FEP. Some clinicians 
regard the use of depot antipsychotics as stigmatizing, coercive, and 
frequently unacceptable to patients. Although a survey in a sample of 225 
participants, of whom 83 were patients, confirmed that patients do harbor a 
fear with regard to constricted autonomy and painful injections; it was found 
that 67% of the patients did not receive adequate information to be able to 
make an informed decision29. A cross-sectional study by Patel et al. of 202 
out-patients with schizophrenia confirmed that depots were perceived as 
more coercive than oral antipsychotics. However, patients‟ preference was 
associated with current medication formulation: depots were preferred by 
43% (33/76) on depot vs. 6% (8/146) on orals (p<0.001). Patients who had 
The Use of Depot Antipsychotics 
 
 221 
been treated with both tend to favor their current formulation30. A systematic 
review of the literature found that most patients have a positive attitude 
towards the use of depot antipsychotics31.  
 
Depot antipsychotics bypass pharmacokinetic issues with regard to 
absorption and first-pass metabolism32 cause less fluctuation in drug levels33 
and therefore potentially cause fewer dose-related side-effects. Although 
clinicians frequently raise concerns with regard to EPSE, data on the 
incidence of EPSE with depot formulations are controversial, with some 
studies reporting an increased incidence with depot use, while others show 
no difference between oral and depot antipsychotics34. Recent studies 
reported the opposite, with lower rates of EPSE with the use of long-acting 
risperidone when compared to oral risperidone35.  
 
Recommendations 
 
According to Kane et al., any patient for whom long-term antipsychotic 
treatment is indicated should be considered for depot antipsychotics36. 
These drugs have been described as a milestone in the development of 
psychopharmacology and a breakthrough in the treatment of psychosis37. 
Furthermore, depot antipsychotics improve adherence32,38, and promote 
increased clinician contact and ease the detection of non-compliance39; a 
combination that may reduce relapses and hospitalization.  
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However, functional recovery depends on more than merely symptomatic 
stabilization and treatment19. Therefore, antipsychotics should never be used 
in isolation, but should form part of a treatment plan which includes 
psychosocial interventions, such as family psychoeducation, social skills 
training, and cognitive-behavioral therapy. In choosing which drug to 
prescribe, the clinician should consider previous experience, personal 
patient preference, patients‟ history of response (both therapeutic and 
adverse effects), and pharmacokinetic properties. 
 
Depot antipsychotic maintenance therapy should be strongly considered, 
and may be used as the first-option maintenance strategy for persons who 
have difficulty to adhere to oral medication, who experience frequent 
relapses despite being compliant with oral medication; and those who prefer 
the depot regimen40.  
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CHAPTER 8 
PURPOSE OF THIS STUDY 
 
Despite the enormous impact of the illness, schizophrenia remains largely 
under-researched in South Africa. The overall outcome in schizophrenia 
remains poor1, and is typically characterized by prominent impairment in 
social and occupational functioning, frequent relapses, and hospitalization2. 
 
Initial research and treatment of schizophrenia was primarily focused on the 
positive symptoms of the illness. The introduction of antipsychotics enabled 
millions of patients to live and function outside the confines of mental 
institutions. However, contemporary research into this illness has recognized 
other symptom domains of this disorder to be extremely important in 
determining outcome. Among these, cognitive impairment is considered to 
be a major contributing feature3,4 to the overall burden of schizophrenia.  
 
During the past decade there has been an increased interest in the early 
intervention and management of FEP. The primary aim has been to reduce 
overall morbidity and mortality; and the frequency, duration and severity of 
these episodes. Cognition has also become the main focus of detailed 
research to develop specific, targeted treatments5-7. Unfortunately, the 
search for new drugs is a protracted and costly exercise; often hampered by 
extended delays in the developmental process that limit advances in 
treatment. 
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Cognitive functioning can be improved by psychopharmacological 
intervention8. SGAs are thought to be more beneficial in the treatment of 
cognitive impairments, as outlined in various guidelines9,10.  At the same 
time, contradictory study results continue to emerge regarding the efficacy 
and tolerability of FGAs.  
 
A review of 28 studies that were published between 1990 and 1997 found 
that FGAs such as haloperidol have not proven to be very effective in 
improving cognitive deficits of schizophrenia11. However, Davis et al.12, and 
Mishara and Goldberg13, stated that FGAs may benefit cognitive function 
and negative symptoms. A number of possible scenarios exist that may 
explain the reasons for these discrepancies. It remains an issue of debate 
whether SGAs are truly pro-cognitive, or have reduced cognitive liability14, 
compared to FGAs. 
 
To illustrate this conundrum, one may consider the suggestion that the lack 
of efficacy and possible detrimental effects of FGAs on cognition fails to take 
into consideration the considerable inter-drug differences between FGAs. 
For example, haloperidol, a high potency agent, poses a greater risk of 
causing EPSE than low-potency agents such as chlorpromazine, and 
thioridazine. Therefore, the use of haloperidol frequently requires the 
adjunctive administration of anticholinergic medication that is known to have 
detrimental effects on memory15,16. Also of relevance is the fact that drugs 
with less specificity (i.e. prominent D2 and D1 blockage) will have the dual 
action of being an antipsychotic, and demonstrate adverse cognitive effects.  
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In both the CATIE17 and CUtLASS18 studies, the difference in efficacy 
between FGAs and SGAs was found to be minimal, leading Swartz et al. to 
conclude that FGAs are as efficacious, and more cost effective, than SGAs19.  
 
Flupenthixol has been therapeutically administered since 1962, yet only six 
documented studies could be traced that make mention of its effect on 
cognition20-26. It is clear that flupenthixol is not „just another FGA‟, if such a 
thing exists at all. In many ways, it can be considered an „atypical typical‟, or 
„partial atypical‟ as it resembles SGAs in various ways27. The receptor binding 
profile (D1 and D2)  of flupenthixol is more similar to clozapine than to 
fluphenazine, and it also has additional 5HT2A receptor occupancy
28, with 
D2/D3 autoreceptor blockade, resulting in increased post-synaptic 
dopaminergic activity29-32. 
 
With the increased awareness of the importance of sustained drug delivery 
as a cornerstone in the effective long-term management of schizophrenia, 
there is a strong drive for the wider use of depot antipsychotic medications.  
By its very absence, the literature on the efficacy of flupenthixol, in relation to 
aspects of cognitive functioning and functional outcome in schizophrenia, as 
well as an absence of studies comparing flupenthixol with SGAs, attests to 
an urgent need for more studies. Clearly, none of the industry leaders are 
likely to pursue research into the efficacy of drugs that are „off-patent‟; 
therefore it will be up to academic departments to do so.  
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This study formed part of a larger project: a prospective longitudinal study of 
patients with FEP treated according to a standard protocol. The aim of the 
project is to investigate clinical, socio-demographic, biological (including 
structural and functional brain-imaging, genetic and biochemical markers) 
and treatment aspects related to outcome. 
 
The aim of this study was to investigate cognitive deficits in patients with 
FEP, and its response to treatment with a depot formulation of the FGA  
flupenthixol (FD).  
 
The specific objectives of this study were: 
1. To document the specific cognitive deficits associated with FEP in a 
sample of South African patients. 
2. To assess the changes in these cognitive deficits over time. 
3. To investigate the relationships between cognitive deficits and: 
a. Psychopathology (in the following domains: psychosis, 
disorganization, negative, excitement and depression)  
b. Treatment outcome, in response to FD, in terms of:  
i. Symptom reduction 
ii. Achieving remission 
iii. Social and occupational functioning 
iv. Quality of life 
4. To assess the value of cognitive assessments at baseline in 
predicting the outcome of FEP. 
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5. To examine the relationship between subjective and objective 
assessments of cognitive impairment. 
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CHAPTER 9 
METHODOLOGY 
 
This was a prospective, non-randomized, single arm, open-label, longitudinal 
study of participants with FEP; treated with a long-acting antipsychotic, 
according to a fixed protocol, over a period of 12 months.  
 
Subjects 
 
We recruited 60 participants within 18 months. Participants were recruited 
from first admissions to Tygerberg and Stikland hospitals, as well as 
outpatients presenting at community clinics within our catchment area. The 
catchment area covers the metro and rural areas of the North Eastern part of 
Cape Town, the Winelands, and the Cape West Coast. The population of 
this area is approximately 1.5 million people.  
 
Approval to conduct the study was obtained from the Institutional Review 
Board of the University of Stellenbosch (N06/08/148) and registered with the 
Medical Research Council of South Africa (MRC). The study was conducted 
in accordance with Guidelines on Ethics for Medical Research issued by the 
Medical Research Council of South Africa1, the International Conference on 
Harmonisation of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH-GCP) 2 and the World Medical 
Association Declaration of Helsinki3. 
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Patients who presented with FEP were approached by the researcher, dr R 
Schoeman or the co-investigator, dr B Chiliza. Each potential participant was 
adequately informed of the aims and methods of the study, the institutional 
affiliation of the researchers, the anticipated benefits and potential risks of 
the study, and sources of funding. The participants were assured that refusal 
to participate, or the withdrawal of consent, would not affect their current, or 
future, care in any way, shape or form. The subjects' integrity, privacy and 
confidentiality were ensured at all times. After the researchers explained the 
study, ensured that the potential participants had ample time to ask 
questions, and that questions were adequately answered; voluntary, written, 
informed consent was obtained before any study-related procedures were 
undertaken. 
 
In the case of minors, or where a participant was unable to give consent due 
the severity of illness, the investigators obtained assent from the potential 
participant, and written informed consent from the legally authorized 
representative of the participant, according to the Mental Health Care Act4. 
As soon as the participant was able to give consent, written, informed 
consent was obtained. For the purposes of this study the mental condition 
which could potentially render a participant unable to give consent (i.e. 
psychosis), was a necessary characteristic of the research population.  
 
Participants received ongoing treatment after completion of the study. The 
clinical treatment of the participant remained priority, and participants could 
be withdrawn from the study if deemed necessary by the investigator; for 
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example, another treatment was indicated due to the development of 
adverse effects, or non-response.  
 
Inclusion criteria:  
 
1. Male or female in- or outpatients 
2. Aged between 16 and 45 years (extremes included). 
3. DSM-IV-TR5 diagnosis of schizophreniform disorder, schizophrenia or 
schizo-affective disorder. 
4. Participants who had, during their lifetime, been exposed to a 
maximum of four weeks of antipsychotic medication. 
5. An educational level of at least Grade 8. 
 
Exclusion criteria:  
 
1. DSM-IV-TR5 diagnosis of delusional disorder, brief psychotic disorder, 
bipolar mood disorder with psychotic features, major depressive 
disorder with psychotic features, substance induced psychotic 
disorder, psychotic disorder secondary to a general medical condition, 
and psychotic disorder not otherwise specified. 
2. Subjects who had been treated with a long-acting depot antipsychotic. 
3. Significant physical illness. 
4. Mental retardation. 
5. Subjects unable or unwilling to give informed consent. 
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Withdrawal criteria: 
 
1. If the investigator deemed it in the best interest of the participant to be 
withdrawn for any reason, this included the development of side-
effects, or lack of efficacy. 
2. Withdrawal of consent. 
 
Procedures 
 
All potential participants were assessed by one of the two investigators, dr R 
Schoeman or dr B Chiliza; both being qualified psychiatrists. Extensive 
interrater reliability (IRR) training was done on all rating scales used in the 
study, and an IRR coefficient of >80% was achieved on all scales. IRR was 
re-tested every six months. 
 
Cognitive assessments were conducted by Dr Schoeman who completed 
her Masters level in psychology, and is a certified psychometrist. She 
attended a course, and received training in the use, and scoring of the 
MCCB in Boston, USA. IRR training sessions formed part of this course. Dr 
Schoeman acquired substantial experience in the assessments, qualifying 
her to train two suitably qualified research assistants to assist in the 
administration thereof. Regular IRR training sessions were completed, and a 
high level of IRR was maintained.   
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The following information was gathered at baseline by means of a clinical 
psychiatric interview and evaluation. 
 
1. Demographic data and personal history, such as age, gender, ethnicity, 
first language, language of education, educational level, occupational 
history, marital status, and current living conditions. Collateral history was 
obtained, where possible, from participants‟ mothers (or other family 
members, if applicable), particularly regarding obstetric and developmental 
history.  
2. Psychiatric history, including the chief complaint, the history of the current 
illness, specifically also attending to duration of untreated illness (DUI), and 
DUP, and changes in social, interpersonal and occupational functioning. We 
also explored any past psychiatric history, previous and current substance 
use/abuse/dependence, and previous psychiatric illness and treatment. 
3. Medical history, including any presence of head injuries, epilepsy, or other 
significant illnesses, past and current treatment.  
4. Previous and concomitant treatment was recorded as completely as 
possible. 
5. Specific attention was also paid to collecting history with regard to a family 
history of psychiatric illness, and treatment received, as well as a family 
history of medical diseases, such as hypertension or diabetes.  
6. Mental status examination, specifically evaluating the participant‟s 
appearance, orientation, attention and concentration, mood and affect, 
speech, thought processes and behaviour. 
 
Methodology 
 
 241 
Each subject underwent a full physical examination at baseline, including a 
neurological evaluation. Safety and side-effect measures included weight, 
height, waist circumference, glycated haemoglobin (HbA1c), fasting blood-
glucose, fasting lipogram, serum prolactin and an electrocardiogram. These 
assessments were repeated every three months.  
 
At baseline and on each of the visits, participants were asked about 
substance use since the previous visit, and urine metamphetamine and 
cannabis drug screens were performed at baseline and every three months 
thereafter. 
 
The following rating scales and instruments were used to assess all of the 
participants: 
 
1. The Positive and Negative Syndrome Scale for Schizophrenia (PANSS)6. 
The PANSS was used as a primary meaure of psychopathology and 
treatment response. It consists of 30 clinician-rated items with ratings based 
on all information relevant to the week prior to ratings. The information 
derives from both the 30 to 40 minutes semi-structured clinical interview, as 
well as collateral information obtained from, for example, the primary 
caregiver. During the interview attention was being paid interpersonal 
behaviour, cognitive-verbal processes, thought content, physical behaviour, 
and response to structured questioning; thereby permitting direct observation 
of affective, motor, cognitive, perceptual, attentional, integrative and 
interactive functioning of the patient (see table 9.1) 
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Table 9.1: The Positive and Negative Syndrome Scale for Schizophrenia 
 Description Primary score 
Test-retest 
reliability: 
Pearson 
product-
moment 
correlation 
(r) 
Internal 
consistency: 
α coefficients 
Positive Scale  
7 items: P1 delusions, P2 
conceptual disorganization, 
P3 hallucinatory behaviour, 
P4 excitement, P5 
grandiosity, P6 
suspiciousness/persecution 
and P7 hostility. 
Each item has a 7-
point rating (where 1 
indicates the absence 
of a symptom or sign, 
while 7 is the most 
extreme 
presentation). The 
PANSS is scored by 
summation of item 
scores, with total 
scores ranging from 
30 to 210 
0.8 (p<0.001) 0.73 (p<0.001) 
Negative Scale 
7 items: N1 blunted affect, 
N2 emotional withdrawal, 
N3 poor rapport, N4 
passive/apathetic N5 
emotional withdrawal, N6 
lack of spontaneity and 
flow of conversation and 
N7 stereotyped thinking. 
0.68 (p<0.1) 0.83 (p<0.001) 
General 
Psychopathology 
Scale 
16 items: G1 somatic 
concern, G2 anxiety, G3 
guilt feelings, G4 tension, 
G5 mannersims and 
posturing, G6 depression, 
G7 motor retardation, G8 
uncooperativeness, G9 
unusual thought content, 
G10 disorientation, G11 
poor attentionm, G12 lack 
of judgment and insight, 
G13 disturbance of volition, 
G14 poor impulse control, 
G15 preoccupation, G16 
active social avoidance. 
0.68 (p<0.2) 0.79 (p<0.001) 
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2. Clinical Global Impression rating scales (CGI)7 
The CGI was used as a secondary measure to provide a global rating of 
illness severity, improvement and response to treatment. This is a clinician 
rated scale, requiring the clinician to compare the subject to the clinician's 
past experience with patients who have the same diagnosis. The CGI is 
rated on a 7-point scale, with the severity of illness scale (CGI-s) using a 
range of responses from 1 (not ill) 
through 7 (extremely severe), while the change in illness scale (CGI-c) 
scores range from 1 (very much improved) through 7 (very much worse). 
Each component of the CGI is rated separately and the instrument does not 
yield a total score. 
 
3. Calgary Depression Scale for Schizophrenia (CDSS)8 
The CDSS is a nine item structured interview used for assessing the 
presence of depressive symptoms during a two week period. Items 
assessed are: depression, hopelessness, self-depreciation, guilty ideas of 
reference, pathological guilt, morning depression, early awakening, suicide, 
and observed depression.  Each item has a four point distribution, anchored 
by descriptors, with 0 indicating an absence of symptoms, while 3 indicate 
severe symptoms. The possible total score range from 0 to 36, with a score 
of 7 being the cut-off for depression. The intraclass correlation coefficient 
(ICC) was estimated at 0.895, while the Cronbach‟s alpha was 0.799 
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4. Extrapyramidal Symptom Rating Scale (ESRS)10  
The ESRS was used as a side-effect measure and rates the presence of 
parkinsonistic, dystonic, and dyskinetic side-effects. The scale includes a 
subjective questionnaire used by the clinician to ask the patient about the 
presence of symptoms which may not be observable or present during the 
interview. Scores can range from 0 (absent) to 3 (severe) for each of the 12 
items.The individual items are analyzed separately and a subtotal of scores 
is calculated for parkinsonism (items 1 to 7), dystonia (items 8 and 9 ) and 
dyskinesia (items 10 and 11). Item 12 (dizziness when standing up) is rated 
separately. A total score is derived by totaling the sub-scores of these items. 
Hereafter symptoms are assessed following a standard procedure as 
described in the manual11, which forms part of a routine neurological 
assessment.  The presence and severity of parkinsonism is rated by 18 
items evaluating expressive automatic movements, bradykinesia, rigidity, 
gait and posture, tremor, akthisia, sialorrhea, and postural stability. Eighteen 
items evaluate the presence of acute and non-acute/chronic dystonia in the 
limbs, head, jaw/chin, tongue, lips and trunk; and 7 items evaluate the 
presence and severity of dyskinetic movement in the tongue, jaw, bucco-
labial area, trunk, limbs, and face. Four items assess the clinical global 
impression of severity of parkinsonism, dystonia, dyskinesia and akathisia. 
Each item has a seven point distribution, anchored by descriptors, with 0 
indicating an absence of symptoms, while 6 indicate extremely severe 
symptoms. IRR coefficients were determined for each item of the scale and 
ranged from 0.80 to 0.9710. While for the different divisions, IRR ranged from 
0.88 to 0.9712.    
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5. Premorbid Adjustment Scale (PAS)13 
The PAS was used to evaluate the degree of achievement of developmental 
goals at each of several periods of a subject‟s life, prior to the onset of 
schizophrenia. The aspects evaluated include social accessibility-isolation, 
peer relationships, ability to function outside the nuclear family, and capacity 
to form intimate socio-sexual ties. The four life periods assessed are 
Childhood (up to 11 years), Early Adolescence (12-15years), Late 
Adolescence (16-18 years), and Adulthood (19 years and beyond). A 
general section also evaluates the highest level of functioning obtained prior 
to illness onset, as well as the duration and characteristics of onset of illness, 
and information pertaining to level of education. Each item has a seven point 
distribution, anchored by descriptors, with 0 indicating the healthiest 
adjustment, while 6 indicate the least-healthy end of the spectrum of 
functioning. Subscale scores for the specific life periods are calculated by 
summing the item scores and dividing this total by the maximum possible 
score for the items. An overall score is calculated by averaging the subscale 
scores. The ICC for IRR for the subscales were calculated as 0.62 
(Childhood), 0.83 (Adolescence) and 0.91 (Adulthood), while for the overall 
score, the intraclass coefficient was 0.74 (p<0.001).  
 
6. Social and Occupational Functioning Assessment Scale (SOFAS)14 
The SOFAS is rated by a clinician as an indication of an individual‟s level of 
social and occupational functioning on a scale from 0 to 100, where 1-10 
represent the individual with a persistent inability to maintain minimal 
personal hygiene,  being a risk for harm to the self or others, and who needs 
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considerable external support such as nursing care and supervision; while 
91-100 is indicative of excellent functioning. Impaired functioning can be due 
to both mental and/or physical limitations. 
 
7. WHO Quality of Life (WHOQOL-BREF)15   
The WHOQOL-BREF is a self-administered scale, but if the subject does not 
have the ability to complete it independently, he/she may be assisted by the 
interviewer. Twenty-six items are scored from 0 (not at all satisfied) to 5 
(completely satisfied) and items are summed in order to obtain 4 domain 
scores, denoting an individual‟s perception of quality of life with regard to the 
specific domain.  Physical health (consisting of activities of daily living, 
dependence on medicinal substances and medical aids, energy and fatigue, 
mobility, pain and discomfort, sleep and rest, work capacity), Psychological 
health (bodily image and appearance, negative feelings, positive feelings, 
self-esteem, spirituality/religion/personal beliefs, thinking, learning, memory 
and concentration), Social relationships (personal relationships, social 
support, and sexual activity) and Environment (financial resources, freedom, 
physical safety and security, health and social care: accessibility and quality, 
home environment, opportunities for acquiring new information and skills, 
participation in and opportunities for recreation/leisure activites, physical 
environment [pollution/noise/traffic/climate], and transport) are evaluated.  
 
Domain scores are scaled in a positive direction (i.e. higher scores denote 
higher perceived quality of life), with 100 being complete satisfaction. 
8. The Wechsler Adult Intelligence Scale (WAIS): Vocabulary Subscale16  
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The Vocabulary Subscale score of the WAIS (3rd ed) was used as estimation 
of premorbid intelligence. It is a measure of expressive word knowledge, and 
is the subscale with the highest mean proportion of predictable variance for 
validity (r=0.95; p<0.05). For this subtest, the subject has to give oral 
definitions for words presented by the clinician. Thirty-three words are 
presented to the subject. Reponses are scored according to sample 
responses, where a two-point response indicates that the subject has a good 
understanding of the word; a one-point response is not incorrect, but shows 
poverty of content; while a zero-point reponse is an entirely incorrect 
response. The test is discontinued after six consecutive zero-responses. The 
maximum score obtainable is 66. Hereafter, the Z-score is calculated 
according to suitable norms provided in the manual. The test was translated 
and back-translated into Xhosa, enabling us to administer the test in the 
participant‟s first language (Afrikaans, English, or Xhosa).  
 
9. The MATRICS Consensus Cognitive Battery (MCCB)17 
The MCCB was used as primary outcome measure of cognition.  Domains 
assessed were Speed of Processing, Attention/Vigilance, Working Memory, 
Verbal Learning, Visual Learning, Reasoning and problem solving, and 
Social cognition (see table 3.1, p70-71 for details). Testing can usually be 
completed in one session of 60 to 90 minutes. Breaks can be provided as 
needed, and testing can be extended over multiple sessions if the situation 
warrants it. Detailed instructions for administration are provided in the 
manual. All of the ten tests are clinican administered. Nine of the tests are 
pencil-and-paper tests, while the CPT-IP is a computerized test. Participants 
Methodology 
 
 248 
were randomized to alternative versions of the tests included in the battery, 
where available, in order to limit the practice-effect of repetitive testing over 
time.The MSCEIT™ and CPT-IP results are computer generated. The 
MCCB Computer Scoring Program was used to convert the primary raw 
scores obtained on the tests into T-scores and percentile scores. The 
program also provides T-scores and percentiles for the seven cognitive 
domains, as well as a Cognitive Composite T-score and percentile score.  
 
 
10. Subjective Scale to Investigate Cognition in Schizophrenia (SSTICS)18 
The SSTICS, a 21-item self-report measure, which allows a quantitative 
approach to the subjective experience of cognitive deficits in schizophrenia. 
Subjects are asked to rate the frequency of their cognitive difficulties 
according to a four-point Likert-type scale ranging from  0 (“never”) to 4 
(“very often”). The questions formulated focused on participants‟ perceived 
impairments in four cognitive areas: memory, attention, executive functions, 
and praxia. Eleven questions assess working memory and explicit (episodic 
and semantic) memory. Attention is explored by five questions with regard to 
distractibility, alertness, selective attention, divided attention and sustained 
attention. The executive functions are assessed by three questions on 
planning, organization, and flexibility. The last two questions assess 
language and praxia. The scale has a good internal consistency with a 
Cronbach‟s alpha coefficient of 0.858. The Spearman‟s correlation 
coefficient for test-retest reliability at a mean interval of 11 days was 0.82 
(p<0.01). Factor analysis revealed subjective cognitive domains of 
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complaints such as Sustained executive function, Memory of information, 
Consciousness of effort, Daily life, Distractibility, and Alertness. This 
questionnaire was only used after the initial six months of the study, due to 
difficulty translating and applying the instrument in our cultural context.  
 
11. Birchwood Insight Scale (BIS)19 
The BIS is an eight-item self-report measure with possible responses to the 
items being "agree," "unsure," or "disagree" that are scored on a three-point 
Likert-type scale ranging from 0 to 2. Two items evaluate the ability to re-
label experiences as part of one‟s illness, two items assess the individual‟s 
awareness of illness, and 4 items evaluate the individual‟s awareness of the 
need for treatment. Subscale items are summed, and the Need for 
Treatment subscale is divided by 2, yielding a total score for each subscale. 
Total scores may be summed for a BIS total score ranging from 0 to 12, with 
higher scores indicating greater insight. The BIS is widely used in research 
on psychosis and has very good test-retest reliability (0.90; p<0.001), validity 
(Cronbach‟s alpha of 0.75; p<0.001), and sensitivity to change. 
 
The duration of the clinical evaluation and completion of the first 7 rating 
scales was 2.5-3 hours. Participants‟ cognitive assessments were completed 
the following day during a 2-2.5 hour period (instruments 8 to 11). 
Where participants were judged to be too ill to undergo neuropsychological 
testing, these tests were postponed until such participant was considered to 
be adequately stabilized by the investigator and treating team.  
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After baseline evaluation, each subject was seen daily for the first week, for 
monitoring of adverse events, and completion of the PANSS and CGI. 
Hereafter, participants underwent 8 scheduled visits over a 12 month period, 
with order of evaluation and administration of instruments as indicated (see 
table 9.2). Subjects were monitored for side-effects and adverse events 
throughout the study. Some participants were seen more regularly due to 
unforeseen events. Cognitive assessments were done at baseline, four 
weeks, and then at 3, 6, and 12 months. 
 
 
Table 9.2: Study plan 
Visit Baseline  
Week 
0  
Week 
2 
Week 
4 
Week 
6 
Month 
3 
Month 
6 
Month 
9 
Month 
12 
Consent x         
History x         
Physical 
Examination 
x        x 
Vital signs x     x x x x 
Heigth and 
weight 
x        x 
ECG x        x 
Lab tests x     x x x x 
Drug screen x   x x x x x x 
Adverse events 
and concomitant 
medication 
x x x x x x x x x 
PANSS x x x x x x x x x 
CGI x x x x x x x x x 
CDSS x x x x x x x x x 
ESRS x x x x x x x x x 
PAS x         
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SOFAS x      x  x 
WHOQOL x      x  x 
WAIS x        x 
MCCB x   x  x x  x 
SSTICS x   x  x x  x 
BIS x      x  x 
 
 
Treatment 
 
There was a wash-out phase of up to seven days, during which all 
psychotropic medications were discontinued. Treatment with oral flupenthixol 
1-2mg/d was started for one week, prior to the first FD dose (so as to rule 
out hypersensitivity to flupenthixol), and then for a further week if needed, to 
allow FD to take effect. However, due to the development of EPSE in two of 
the first five participants, the protocol was amended so that all participants 
received oral flupenthixol 1mg/d per os for seven days only. Hereafter, FD 
was introduced. The starting dose of FD was 10mg every 2nd week, with 
dose increases allowed, at 6-weekly intervals, in increments of 10mg, to 
30mg per fortnight. These dose increases were determined according to 
clinical response of the participants, as well as tolerability. 
 
Criteria for dose increments:  
 
 At week 6: failure to have an adequate response, as defined by a 
decrease in PANSS total score of 20%, as well as at least minimal 
improvement on the CGI. 
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 At week 12 (3 months): failure to attain remission, as defined by 
PANSS score of 3 or less on items P1, P2, P3, N1, N4, N6, G5 and 
G6, as well as CGI much/ very much improved20. 
 At week 18: at least a 20% reduction in PANSS total score, but CGI 
was not much/very much improved, AND CGI severity mild or less 
 At week 24 (6 months): at least a 20% reduction in PANSS total score 
 
If by 6 months participants did not have at least a 20% reduction in PANSS 
total score, they were discontinued due to non-response and offered 
clozapine. 
  
In cases where additional antipsychotic medication was required due to 
acute exacerbation of symptoms between visits, oral flupenthixol tablets 
1mg/d were given at the discretion of the clinician.  
 
Concomitant medication: 
 
1. Any medication for physical conditions, in use prior to the 
commencement of the trial, was allowed to be continued. Medication for 
other conditions that arose during the course of the trial was permitted at 
the investigator‟s discretion. 
2. Lorazepam was prescribed for additional sedation in doses of up to 
12mg/day during the acute phase of the study; thereafter doses could not 
exceed 4mg/day. 
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3. Orphenadrine and/or biperidine were permitted for the treatment of 
EPSE.  
4. Propranolol could be prescribed for akathisia.  
Participants were not allowed to receive lorazepam, propranolol or 
anticholinergics for a 12 hour period prior to an assessment. The following 
medications were not permitted: other antipsychotics, mood stabilizers, and 
psychostimulants.  
 
Data analysis 
 
All data was recorded in case record forms. Statistical analyses were 
conducted with the assistance of a biostatistician. Statistical analyses were 
conducted using STATISTICA version 921. A 5% significance level (p<0.05) 
was used as the guideline for significant differences. Mixed model repeated 
measures of variance analysis (ANOVAs) were conducted to examine mean 
T- and Z- score changes over time. The mixed models included all patients 
at a specific time point, whether they have completed the study or not. 
Therefore patients are not excluded from the analyses if they did not 
complete the study. Non-parametric Mann-Whitney U and Kruskal-Wallis 
tests were used to compare different groups of patients. To investigate the 
relationships between cognitive domains (obtained from the MCCB, WAIS, 
SSTICS, and BIS) and psychopathological symptoms (obtained from the 
PANSS), Spearman's rank correlation coefficients were computed. No formal 
sample size had been calculated for. Within analyses of specific variables 
(for ANOVA and mixed models) Fisher LSD was used for multiple testing 
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corrections.  No corrections were applied between analyses of different 
variables.   
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CHAPTER 10 
RESULTS:  DEMOGRAPHIC DATA 
 
A total of 60 participants were included in the study. However, two were 
excluded from analyses due to protocol violations.  
 
Age, gender and marital status 
 
The final sample (N=58) consisted of 19 (33%) females and 39 (67%) males, 
with a mean age of 23.26 years (± 5.81) (see figure 10.1).  
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Figure 10.1:  Age distribution of participants 
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Five of the participants (4 females and 1 male) were married, one male was 
divorced, one female widowed and one female was in a de-facto 
relationship.  The remainder of the sample was single.  
 
There was a significant correlation (p<0.01) between age at baseline and 
severity of illness at baseline (mean PANSS1 Total score = 100.5, ± 15.89; 
r=-0.40), age at baseline and premorbid IQ estimation at both baseline 
(mean WAIS2 Vocabulary  Z-score = -2.20, ± 0.91; r=0.46) and at one year 
(mean WAIS Vocabulary Z-score = -1.93, ± 0.96; r=0.50), and baseline age 
and overall cognition (mean MCCB3 Cognitive Composite Score = 20.51, ± 
13.45; r=0.50) at one year. 
 
Male participants were younger than their female counterparts at baseline 
(see figure 10.2).  
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Vertical bars denote 0.95 confidence intervals
Male Female
Gender
21
22
23
24
25
26
27
28
A
g
e
 in
 y
e
a
rs
 
Figure 10.2: Gender and age of inclusion 
 259 
 
Results: Demographic Data 
There were no significant differences between genders with regard to 
severity of illness at baseline and one year, premorbid IQ estimation at 
baseline and one year, or overall cognition (MCCB Cognitive Composite 
Score) at baseline and one year. 
 
Language and ethnicity 
 
The majority of the sample was of Mixed (African-Caucasian) ethnic origin, 
while 22% were of either White (Caucasian) or Black African ethnic origin 
(see figure 10.3). All of the participants were South African, except for one 
female who held Ugandan citizenship. 
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Figure 10.3: Ethnic origin of participants 
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Seventy-nine percent (46/58) of the participants‟ home language was 
Afrikaans, 8.6% (5/58) English, 10.3% (6/58) Xhosa and 1.7% (1/58) French. 
Assessments were completed in patients‟ preferred language with 60.34% 
(35/58) Afrikaans and 39.96% (23/58) English.  
 
There was a significant difference between participants assessed in 
Afrikaans or English at baseline with regard to illness severity (p=0.03) (see 
figure 10.4), which disappeared by one year.  
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Figure 10.4: Language of assessment and difference in mean PANSS Total score at 
baseline 
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Results: Demographic Data 
There was a significant difference between participants assessed in 
Afrikaans or English with regard to premorbid IQ estimation at baseline 
(p=0.03) and one year (p=0.03), favoring Afrikaans speaking participants. 
Although there was no difference between Afrikaans and English groups with 
regard to mean MCCB Cognitive Composite Score at baseline, at one year, 
Afrikaans speaking participants performed significantly better than English 
speaking participants (p=0.04), with mean MCCB Cognitive Composite 
Scores of 25.17 (± 14.67) and 14.94 (± 8.91) respectively (see figure 10.5).   
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Figure 10.5: Language of assessment and difference in mean MCCB Cognitive 
Composite Score at 1 year 
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Results: Demographic Data 
There was a significant difference between Black Africans and those of 
Mixed ethnic origin with regard to premorbid IQ estimation at both baseline 
(p=0.03) and one year (p=0.02) (see table 10.1 and figure 10.6). However, 
these results should be interpreted with caution due to the small number of 
participants in the White and Black African groups. 
 
Table 10.1: WAIS vocabulary Z-score 
 Baseline (SD) One year (SD) * 
 N Mean N Mean  
White 6 -1.08 (± 0.71) 4 -0.77, ± 0.93  
Mixed 45 -2.33 (± 0.89) 34 -2.11, ± 0.86 
Black African 7 -2.13 (± 0.67) 6 -1.86, ± 1.06 
* LOCF 
 
Kruskal-Wallis p=0.02
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Figure 10.6: Ethnicity and WAIS vocabulary mean score at baseline 
p=0.02 
Vertical bars denote 0.95 confidence intervals 
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Results: Demographic Data 
There were no significant differences among ethnic groups and illness 
severity at baseline and one year, or among ethnic groups with regard to 
cognition (MCCB Cognitive Composite Score) at baseline and one year.  
 
Developmental, family and medical history 
 
Although most of the participants were born from normal pregnancies, 
complications were reported in 22% (13/58) of pregnancies (see figure 10.7). 
One participant‟s mother was informed during several antenatal care visits 
that the baby had died in utero, but later gave birth to a healthy baby. One 
mother was on fluphenazine decanoate for the duration of the pregnancy, 
and another mother suffered from multiple sexually transmitted diseases 
(STDs) during pregnancy.   
 
 
Figure 10.7: Pregnancy history 
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Results: Demographic Data 
The majority of participants were born by way of normal vaginal deliveries. 
However, 12% (7/58) births were complicated. There were two emergency 
caesarian sections (1 due to uterine rupture, and 1 due to pre-eclampsia), 
two elective caesarian sections (previous caesarian sections), two forceps 
deliveries, and two babies born with low Apgar scores after prolonged labour 
and induction.  
 
 All participants attained normal developmental milestones. 
  
The family history of mental disorders was known in 55 of the participants, 
though specific detail was not always accessible (see figure 10.8). One 
patient‟s family history included both depression and post traumatic stress 
disorder. Other affected family members included a younger sibling with fetal 
alcohol syndrome, and a cousin who committed suicide. 
 
 
Figure 10.8: Family history of mental illness 
Number of participants (N = 58) 
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Results: Demographic Data 
Most participants were physically healthy at time of inclusion (other than the 
index disorder), and remained so throughout the study. The mean weight of 
the participants was 59.02 (± 11.62) kg, with a mean height of  
166.01 (± 9.49) cm, and a mean BMI of 21.42 (± 4.01). Two participants 
suffered from diabetes mellitus; the one using insulin, and the other oral anti-
hyperglycaemic medication. Both were well controlled on treatment. One 
participant, known with well-controlled asthma, used an inhaler as needed, 
and another participant had well-controlled epilepsy (after meningitis) for 
which he used clonazepam. One female was diagnosed with subclinical 
hypothyroidism and iron deficiency. She withdrew her consent after the 6 
month follow-up visit. One female, age 16, had a BMI of 14 at inclusion. She 
developed akathisia on the FD and was withdrawn from the study after one 
month. One female had positive serum syphilis tests (RPR and TPHA) at 2 
weeks. Neurosyphilis was excluded (CSF tested VDRL negative). She was 
treated with benzatine penicillin 2.4 million units/week IMI for three weeks. A 
21 year old male developed catatonia three days after baseline. He received 
oral flupenthixol 1mg per day for three days, but left the study prior to 
receiving any flupenthixol decanoate.  
 
Substance abuse 
 
Five participants tested positive at baseline (urine drug screening) for 
substances of abuse: four used cannabis, while one participant used both 
cannabis and methaqualone. There was no difference in severity of 
psychosis (mean PANSS Total score), or the presence of positive (mean 
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PANSS P score), negative (mean PANSS N score) and depressive 
symptoms (mean PANSS D4 score) between the group of participants testing 
positive for substances at baseline (users) and those without (non-users). 
There was no difference in overall cognitive functioning (MCCB Cognitive 
Composite Score) between the two groups. The mean PANSS Cognitive 
factor5 (PANSS C) score did not differ between the groups, although insight 
(PANSS G12) differed significantly between the two groups (see table 10.2). 
 
Table 10.2: Baseline substance abuse 
 Users (n=5) Non-users (n=53)  
Item Mean (SD) Mean (SD) Mann-Whitney p 
PANSS Cognitive factor 19.20 (± 3.03) 16.15 (± 3.47) 0.07 
PANSS G12 6.00 (± 0.00) 4.94 (± 1.03) 0.05 
 
 
At 3 months, 16/56 (28.6%) tested positive for substance use (13 for 
cannabis, 7 for methaqualone and 7 for methamphetamines). Seven of these 
participants were polysubstance users. Although there were no significant 
differences between the two groups with regard to symptoms severity (mean 
PANSS Total score) or cognitive symptoms (mean PANSS C score and 
mean MCCB Cognitive Composite Score), the non-users had better insight 
(p=0.05) (see figure 10.9) 
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 Mann-Whitney U p=0.05
Vertical bars denote 0.95 confidence intervals
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Figure 10.9: Group differences in insight at 3 months 
 
At 6 months 26/48 (54.2%) tested positive for substance use (19 for 
cannabis, 12 for methaqualone and 11 for methamphetamines). At 12 
months 21/41 (51.2%) tested positive for substance use (17 for cannabis, 9 
for methaqualone and 13 for methamphetamines). Ten of these participants 
were polysubstance users. There were no significant differences between 
the users and non-users with regard to illness severity, or cognitive 
functioning at both 6 months, and 12 months. 
 
Premorbid adjustment and functioning 
 
Premorbid Adjustment Scale6 (PAS) ratings were completed on 37 
participants (63.79% of the sample) at baseline. Mean scores on the PAS 
scale indicate that during early childhood, participants attained 83% (± 
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11.73) of expected levels of adjustment, during early adolescence 72% (± 
16.46), while by late adolescence only 62% (± 19.93) of what was expected. 
By adulthood, participants reached 55% (± 24.15) of expected levels of 
adjustment. General adjustment, referring to the participants‟ highest level of 
functioning achieved prior to onset of illness, was 42.8% of expected 
achievement (mean 5.72, ± 0.03). This refers to participants‟ adjustment with 
regard to education, employment, independence, social-personal 
adjustment, degree of interest in life, and energy level. There was a 
significant failure to attain optimal levels of functioning, which propagated 
throughout the participant‟s lifetime (see figure 10.10). 
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Figure 10.10: Deficits in premorbid adjustment over lifetime 
 
There was a positive correlation between mean childhood PAS scores and 
positive symptoms (PANSS P; r=0.39; p=0.02), as well as insight (PANSS 
 269 
 
Results: Demographic Data 
G12; r=0.40; p=0.02) at baseline, indicating that worse premorbid adjustment 
during childhood was associated with more severe positive symptoms and 
worse insight at baseline. Childhood PAS scores had an inverse correlation 
with Attention and Vigilance (r=-0.12; p=0.05) at baseline. Adult PAS scores 
also had a positive correlation with positive symptoms at baseline (r=0.49; 
p<0.01) and DUI (r=0.37; p=0.03). General premorbid adjustment had a 
negative correlation with the mean SOFAS5 score at baseline (r=-0.42; 
p=0.01). 
 
Education and employment 
 
The participants had a mean educational level of 9.71 (± 2.13) completed 
years of schooling (see figure 10.11). There was a significant difference in 
educational level attained between female and male participants with mean 
years of schooling in females being 10.63 (± 1.98) vs. 9.26 (± 2.07) in males 
(p=0.03).  
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Figure 10.11: Educational level attained 
 
Furthermore, participants who chose to be assessed in Afrikaans completed 
more years of schooling (p<0.01), even when corrected for age (see figure 
10.12).  
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Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 10.12: Relationship between language of assessment and educational level 
 
There were no significant differences among ethnic groups in the level of 
educational attainment. There were positive correlations between years of 
completed schooling and premorbid IQ estimation at both baseline (r=0.36; 
p<0.01) and at one year (r=0.38; p=0.01), between years of education and 
social cognition at one year (r=0.39; p=0.01), and  between years of 
education and mean MCCB Cognitive Composite Score at one year (r=0.37; 
p=0.02). 
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The majority of the participants (45/58) were unemployed at baseline (see 
figure 10.13)  
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Figure 10.13: Employment status at baseline 
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Results: Demographic Data 
At baseline, the participants had serious impairment in social, occupational 
and school functioning, as indicated by a mean SOFAS7  score of 42.07 (± 
9.81) (see figure 10.14) 
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Figure 10.14: Social and Occupational Functioning at baseline 
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Results: Demographic Data 
Baseline SOFAS had an inverse correlation (r=0.51; p<0.01) with illness 
severity (PANSS Total). Outpatients‟ level of functioning was significantly 
higher than those of in-patients (p=0.05) at baseline (see figure 10.15). 
However, the correlation between level of functioning and length of hospital 
stay was not significant.  
 
 Mann-Whitney U p=0.05
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Figure 10.15: Level of functioning at baseline and admission status at baseline 
 
Although there were no significant correlations between MCCB Cognitive 
Composite Score and educational level,  and between MCCB Cognitive 
Composite Score and premorbid IQ estimation, a significant positive 
correlation between MCCB Cognitive Composite Score and SOFAS at 
baseline was found (r=0.29; p=0.04). 
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Fifty-seven participants completed the WHOQOL-BREF8 at baseline, with 
the assistance of the interviewer. The raw scores were transformed to 
percentages, where higher percentages represent more satisfaction (with 
100% being the ideal). Participants‟ perceptions on the quality of their lives 
are depicted in figure 10.16.  
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Figure 10.16: Participants’ baseline perceptions on Quality of Life 
 
WHOQOL Physical Health and Psychological Health at baseline did not 
correlate significantly with any of the following (p set at 0.05): age, gender, 
language, educational level attained, illness severity (PANSS Total and 
CGI9), DUI and DUP, social and occupational functioning (SOFAS), 
premorbid IQ estimation, neurocognition (MCCB Cognitive Composite 
Score), premorbid level of adjustment (PAS) or depressive symptoms10 
(CDSS). However, there was positive correlation between Reasoning and 
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Problem solving abilities and perceptions of physical health (r=0.31; p=0.02), 
and an inverse relationship between Working Memory and perceptions of 
psychological health (r=-0.29; p=0.03). There was a significant difference 
between Afrikaans and English participants with regard to WHOQOL Social 
Relationships (p=0.02), with Afrikaans participants reporting more 
satisfaction (50.74, ± 24.68) than English participants (35.55, ± 26.11). 
WHOQOL Environment scores correlated inversely with the severity of 
positive symptoms (PANSS P; r=-0.28; p=0.04) and insight (PANSS G12;  
r=-0.29; p=0.03), and demonstrated a positive correlation with social and 
occupational functioning (SOFAS; r=0.29; p=0.03). 
 
Duration of untreated illness, Duration of untreated psychosis and 
Hospitalization  
 
The mean DUI and DUP for the participants are depicted in figures 10.17 
and 10.18 respectively. Twenty-seven of the participants received oral 
antipsychotics prior to enrollment in the study, with a mean treatment 
duration of 11 days  
(± 6.36) at 152 CPZE/day (± 81.23). 
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Figure 10.17: Duration of untreated illness 
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Figure 10.18: Duration of untreated psychosis 
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DUI and DUP did not correlate significantly (p set at 0.05) with age, gender, 
language, level of education, baseline symptoms (PANSS), or cognition 
(MCCB). Of the participants, 23 (39.66%) were in-patients and 35 (60.34%) 
were outpatients at the time of enrollment. Although DUI did not relate to 
admission status, an inverse correlation between DUP and admission status 
was found, with shorter DUP related to in-patient status (r=0.31; p=0.02) 
(see figure 10.19). 
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Figure 10.19: Duration of untreated psychosis and insight 
 
There was no difference with regard to baseline illness severity (PANSS 
Total) and admission status. However, outpatients had better insight than 
inpatients (PANSS G12 scores 4.74, ± 1.02 and 5.43, ± 0.89 respectively; 
p=0.02). The mean duration of hospitalization from baseline was 67.74 (± 
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33.13) days. Duration of hospitalization did not correlate with DUI, DUP or 
illness severity (PANSS Total) at baseline.  
 
Discontinuation data  
 
Seventy-point-seven percent (41/58) of the sample completed the study. The 
mean duration of participation was 274 (± 116.09) days. During the course of 
the study, one patient was discontinued due to a general medical condition 
and one due to ongoing substance abuse. Only one patient was withdrawn 
due to side-effects. Seven participants withdrew their consent, three 
relocated, and four participants were discontinued due to non-response (see 
figure 10.20).  
 
 
Figure 10.20: All cause discontinuation 
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Baseline descriptive statistics for the participants completing the study, and 
for those who discontinued, are displayed in table 10.2. The groups were too 
small to calculate statistical differences between the groups, therefore no 
statistical specifiers such as degrees of freedom and level of significance are 
specified. 
 
Table 10.2: Completers vs non-completers 
 n % Mean PANSS score 
Mean MCCB Cognitive 
Composite Score 
Completers 41 70.69 100.78, ± 15.35 9.86, ± 14.1 
Non-responders 4 6.89 119.25, ± 11.11 -2.00, ± 3.61 
Withdrawn consent 7 12.07 96.75, ± 15.6 9.83, ± 10.74 
Poor tolerance 1 1.72 85 17 
 
Details on treatment, treatment response, and side-effects are discussed in 
chapter 11.
Results: Demographic Data 
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CHAPTER 11 
RESULTS: PSYCHOPATHOLOGY AND TREATMENT     
EFFECTS 
 
Severity of illness at baseline 
 
Patients were markedly ill at baseline, with a mean PANSS1 Total score of 
100.5 (± 15.89), and a CGI2 of severity (CGI-s) score of 5.28 (± 0.64). 
Although differences in PANSS Total scores at baseline did not reach 
statistical significance (p=0.07), there was a trend in the CGI-s suggesting 
that male participants may have been more severely ill (see figure 11.1) 
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Figure 11.1: Gender differences in illness severity at baseline 
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Treatment and response 
 
During the course of the study, the mean dose of FD administered was 
22.48 (± 0.47) mg/month, with a modal dose of 10mg 2 weekly IMI. See 
chapter 9 for details of treatment protocol. 
 
Participants improved significantly over time, with a 53.9% reduction in 
symptoms (PANSS Total) from baseline to one year (see table 11.1). 
 
Table 11.1: Change in psychopathology over time  
  Mean PANSS score 
 N Total  Positive  Negative  General  
Baseline 58 100.50 (± 15.89) 24.98 (± 4.01) 28.00 (± 5.47) 47.52 (± 9.02) 
1 month 56 80.11 (± 15.26) 18.18 (± 4.12) 23.96 (± 5.23) 37.96 (± 8.14) 
3 months 54 57.96 (± 12.68) 12.27 (± 3.62) 18.55 (± 4.89) 27.14 (± 6.01) 
6 months 48 49.63 (± 11.96) 10.06 (± 2.98) 15.54 (± 4.89) 24.02 (± 6.13) 
12 months 41 45.34 (± 11.28) 8.89 (± 2.08) 14.03 (± 4.45) 22.44 (± 6.06) 
 
 
The greatest improvement in PANSS Total scores occurred early, with 
36.96% of the total improvement observed within the first month, 77.12% 
within the first 3 months, and 92.22% within the first 6 months. This reduction 
were a reflection of improvement in positive (PANSS P), negative  
(PANSS N) and general (PANSS G) symptoms. 
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After six months of treatment, no further significant improvement in 
psychopathology scores occurred (see figure 11.2). 
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Figure 11.2: Decrease in psychopathology over time 
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The improvement in psychopathology, as measured by the PANSS, was 
mirrored in other measures of illness, such as the change in CGI scores (see 
figure 11.3). Participants were rated as much improved as early as one 
month (CGI-c 2.64, ± 0.08). 
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Figure 11.3: Decrease in severity of illness over time 
 
Various studies have used factor analytic approaches to identify a PANSS 
Cognitive factor as one of the dimensions of psychopathology1,3-10. We 
calculated the PANSS Cognitive factor (PANSS C) according to Lancon et 
al.11 and Good et al.12. Lancon et al established their cognitive factor in 
schizophrenia as a group (independent of duration of illness, previous 
treatment, etc.) consisting of PANSS items P2 (conceptual disorganization), 
N5 (difficulty in abstract thinking), G10 (disorientation) and G11 (poor 
attention). Good et al. suggested PANSS C to be of specific relevance in 
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FEP, with the factor consisting of items P6 (suspiciousness/ persecution), N5 
(difficulty in abstract thinking), N6 (lack of spontaneity and flow of 
conversation), G2 (anxiety) and G10 (disorientation). In our sample, there 
was a positive correlation between the two estimates of the PANSS C score 
at all time points (see figure 11.4).  
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Figure 11.4: Correlation between PANSS C Lancon and PANSS C Good at baseline 
 
No differences in mean PANSS C were found between genders, or language 
of assessment. The PANSS C had highly significant, inverse correlations 
(p<0.01) with all MCCB13 cognitive domains at baseline (Speed of 
Processing, r=-0.68; Attention and Vigilance, r=-0.49; Working Memory,  
r=-0.63; Verbal Learning, r=-0.49; Visual Learning r=-0.53; Reasoning and 
Problem Solving, r=-0.44; Social Cognition, r=-0.43; Cognitive Composite 
Score, r=-0.72).  
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The PANSS C continued to decline over time (see figure 11.5 and table 
11.2), while also showing a decline in strength of correlation with cognitive 
domains. By one year, PANSS C had no significant correlations with MCCB 
domains of Attention and Vigilance, Visual Learning, and Reasoning and 
Problem solving. 
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Figure 11.5: Change in PANSS C mean score over time 
 
* The letters in the above graph indicate differences in mean scores for the specific cognitive 
factor over time, as well as interactions between the two cognitive factors. 
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Table 11.2: Mean PANSS C scores at different assessments 
 N Good Lancon 
Baseline 58 
19.56, ± 3.12 16.46, ± 3.51 
1 month 56 16.19, ± 3.12 13.89, ± 3.21 
3 months 54 12.19, ± 3.13 10.41, ± 3.22 
6 months 48  10.17, ± 2.55  8.67, ± 2.63 
12 months 41  9.00, ± 2.18 8.18, ± 2.55 
 
 
Mood symptoms 
 
Mood symptoms were evaluated by the PANSS depression factor (PANSS 
D) as described by Kay14, as well as the CDSS15. 
 
The PANSS D consists of the combined scores of G1 (somatic concern), G2 
(anxiety), G3 (guilt), and depression (G6). The mean PANSS D score at 
baseline was 9.17 (± 3.59). This score declined significantly over the first 
three months of the study (see figure 11.6 and table 11.3). 
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Figure 11.6: Change in mean PANSS D score over time 
 
 
Table 11.3: PANSS D scores at different assessments 
 N Mean PANSS D score 
Baseline 58 
9.17, ± 3.59 
1 month 56 
7.62, ± 3.51 
3 months 54 
5.66, ± 2.01 
6 months 48 
5.61, ± 2.21 
12 months 41 
4.86, ± 1.68 
 
 
PANSS D demonstrated a positive correlation with mean CDSS score from 
baseline to 3 months (baseline, r=0.69; 1 month, r=0.38; 3 months, r=0.34; 
p<0.01), but not at 6 months and at one year. PANSS D at baseline showed 
an inverse correlation with age at baseline (r=-0.28; p=0.03), and an inverse 
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correlation with insight (PANSS G12) at baseline (r=-0.37; p<0.01), one 
month (r=-0.38; p<0.01) and six months (r=0.35; p=0.02). At one month, 
there was a positive correlation between PANSS D and MCCB Speed of 
Processing (r=0.32; p=0.02), while at three months, a positive correlation 
between PANSS D and MCCB Social cognition was found (r=0.34; p=0.01). 
 
The mean CDSS score at baseline was 3.22 (± 0.38). The mean CDSS 
score had positive correlations with mean PANSS G scores from baseline to 
six months (baseline r=0.42, p<0.01; 1 month r=0.46, p<0.01; 3 months 
r=0.35, p=0.01; 6 months r=0.40, p<0.01) and mean PANSS Total scores at 
baseline (r=0.27; p=0.04), 1 month (r=0.34; p=0.01) and 6 months (r=0.33; 
p=0.02). One 24 year old male participant presented at baseline with a 
suicide attempt (PANSS Total score of 120). None of the other participants 
displayed any suicidal behavior during the course of the study, even though 
participants did obtain mild ratings on the CDSS suicide item indicating 
frequent thoughts of being better off dead, or occasional thoughts of suicide. 
Although as a group CDSS ratings remained below 7 (cut off for depression) 
for the duration of the study (see figure 11.7), some individuals did obtain 
higher ratings. This necessitated the addition of selective serotonin reuptatke 
inhibitors (SSRIs) in 11 patients. Five of these participants started 
antidepressants at six months. All received fluoxetine or citalopram 20mg/d, 
but in three participants, the dose had to be increased to 40mg/d.  
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Figure 11.7: Change in CDSS mean score over time 
 
The presence of baseline depressive features (CDSS) had inverse 
correlations with quality of life ratings (WHOQOL) of Psychological Health  
(r=-0.35; p=0.05) and Social Relationships (r=-0.50; p<0.01) at one year, 
while the PANSS D at baseline had a significant inverse relationship with 
Social Relationships (r=-0.51; p<0.01) at one year. The presence of 
depressive symptoms (CDSS) at 6 months also demonstrated inverse 
correlations with quality of life ratings of Physical Health (r=-0.40; p<0.03), 
Psychological Health (r=-0.46; p<0.01) and Environment (r=-0.33; p=0.03).  
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Response, remission and relapse data 
 
Of the 41 participants who completed the study, only six (14.6%) did not 
achieve remission (remission criteria16 met for six consecutive months), 
despite an initial good response to treatment. Three participants relapsed 
during the course of the study, as indicated by an increase of 25% in PANSS 
Total score from the previous lowest score obtained. Two of the participants 
relapsed due to substance abuse; one at 6 months (remission criteria met at 
9 months), and one at 12 months. One participant relapsed at 9 months due 
to non-compliance (remission criteria met at 12 months).   
 
Side-effects 
 
Side-effects that did occur were, on the whole, of mild intensity. No serious 
side-effects were reported on for the duration of the study. Participants were 
evaluated for the presence of EPSE with the ESRS17. The prevalence of 
isolated EPSE in the sample (N=58) was as follows: parkinsonism 3.45%, 
dystonia 3.45% and akathisia 5.17%. Dystonia in combination with 
parkinsonism occurred in 3.45%, as did akathisia in combination with 
parkinsonism. EPSE therefore occurred in 18.97% of the sample. However, 
side effects were mild, and temporary, occurring within the first three months 
of initiation of treatment. Dystonic reactions were mild and occurred within 3-
10 days after the initiation, or dose increase of FD. It responded well to a 
single dose of biperidine. Akathisia responded well to the addition of 
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propranolol 20mg tds per os, while parkinsonism responded well to a 
decrease in dose of flupenthixol to previously tolerated levels.  
 
Four participants (6.89%) were withdrawn due to poor response to 
treatment, with an inability to increase the flupenthixol, due to the presence 
of EPSE. Only one subject was withdrawn due to side-effects. This 16 year 
old lady had a DUI of 332 days and DUP of 57 days. She previously abused 
methamphetamine, heroine, cannabis and alcohol, but was abstinent for four 
months prior to the onset of her DUI. She presented with thought disorder 
and prominent decreased tempo of thought, followed by the onset of a 
refusal to eat, insomnia, and crying. She received chlorpromazine 25mg/d 
per os for one day, then 50mg/d per os for five days during the week prior to 
inclusion in the study. She had a baseline PANSS Total score of 85. Her BMI 
was 14 at baseline. She received flupenthixol 1mg/d per os for two days, 
then 2mg/d per os on days 3 to 10. She received FD 10mg IMI on day 8, and 
developed akathisia three days later. Oral flupenthixol was decreased to 
1mg/d per os and lorasepam up to 8mg/d per os added. Both were stopped 
on day 11 and propranolol 40mg tds per os initiated. The akathisia 
disappeared, but mild cogwheel rigidity in her left arm was evident by day 
16. She received a second dose of  FD 10mg IMI on day 19. She was 
withdrawn from the study on day 33 due to persistence of EPSE.  
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Functional outcome and quality of life 
 
The baseline social and occupation functioning, as measured by the mean 
SOFAS18 score, improved significantly from 42.07 (± 9.81) at baseline, to 
63.26 (± 7.59) at 6 months. Only modest gains occurred between six months 
and one year (63.97, ± 6.66) (see figure 11.8).   
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Figure 11.8: Change in SOFAS mean score over time 
 
There was an inverse correlation between mean SOFAS score at baseline 
and mean PANSS Total score (r=-0.51; p <0.01) which persisted at six 
months (r=-0.55; p=0.01), and at one year (r=-0.69; p<0.01). The presence 
of negative symptoms (PANSS N) at baseline had an inverse correlation with 
functioning at six months (r=-0.37; p=0.01), while there were significant 
inverse relationships between functioning at one year and                    
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PANSS N (r=-0.39, p=0.03), PANSS G (r=-0.38; p=0.03) and PANSS Total 
(r=-0.42; p=0.02) scores. Baseline, as well as 6 month cognitive functioning 
(mean MCCB Cognitive Composite Score) correlated with mean SOFAS 
scores at 6 months (r=0.31, p=0.05; and r=0.32, p=0.03 respectively), but at 
baseline and one year, there was no correlation between cognition and 
SOFAS. 
 
Baseline quality of life ratings (WHOQOL-BREF)19 indicated that participants 
were not satisfied with their quality of life (QOL), with the least satisfaction 
expressed with regard to Social Relations and Environment. WHOQOL-
BREF ratings, with changes over time, are tabulated in table 11.4. 
 
Table 11.4: WHOQOL Domain transformed mean domain scores 
 N 
Physical 
Health 
Psychological 
Health 
Social 
Relations 
Environment 
Baseline 57 48.10, ± 14.83 53.39, ± 17.21 44.53, ± 25.94 45.75, ± 19.44 
6 months 48 56.89, ± 13.54 57.54, ± 14.99 59.02, ± 24.37 58.73, ± 16.07 
12 months 32 57.77, ± 15.87 60.59, ± 13.76 62.88, ± 22.65 65.19, ± 15.33 
 
 
We found no gender differences in the perception of QOL at baseline and at 
6 months (p set at 0.05). However, females were significantly less satisfied 
with their environmental circumstances at one year than their male 
counterparts (54.33, ± 11.63 and 69.43, ± 14.67 respectively; p<0.01). 
QOL, with regard to Physical Health, Social Relationships, and Environment, 
did improve over time, with most gains evident during the first 6 months of 
the study. However, there was no significant change over time with regard to 
Results: Psychopathology and Treatment Effects 
296 
 
Psychological Health (see figure 11.9). Non-significant improvements in 
Physical Health, Psychological Health, Social Relations and Environment 
continued during the course of the study.  
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Figure 11.9: Change in WHOQOL-BREF mean scores over time 
 
The severity of positive symptoms (PANSS P) at baseline had significant 
inverse correlations with Physical Health (r=-0.32; p=0.03), Psychological 
Health (r=-0.30, p=0.04) and Social Relationships (r=-0.33; p=0.03), as well 
as with Social Relationships at 6 months (r=-0.30; p<0.05). However, illness 
severity (PANSS Total), as well as cognitive functioning (MCCB Cognitive 
Composite Score) at 6 months failed to demonstrate significant correlations 
with QOL ratings (p set at 0.05). At six months, social and occupational 
functioning (SOFAS) had positive correlations with Physical Health           
(r=-.34; p=0.02), Psychological Health (r=0.44; p<0.01), Social Relationships 
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(r=0.34; p=0.02) and Environment (r=0.41; p<0.01). Baseline premorbid level 
of adjustment (PAS) had a positive correlation with Psychological Health 
(r=0.75; p<0.01), while years of education had a positive correlation with 
Social Relationships (r=0.40; p=0.02). 
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CHAPTER 12  
RESULTS: COGNITIVE DATA 
 
Premorbid intelligence  
 
We used the WAIS1 Vocabulary Subscale score as estimation of premorbid 
intelligence. Our sample did display evidence of impaired premorbid 
intelligence, with a baseline mean Z-score of -2.20 (± 0.91). There was a 
statistically significant difference between baseline and one year Z-scores 
(p≤0.01) (see figure 12.1). 
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Figure 12.1: Difference in WAIS Vocabulary scale Z-score over time 
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There was a significant inverse correlation between the PANSS Cognitive 
factor and WAIS Vocabulary score at baseline (r=-0.51; p<0.01). A highly 
significant, positive correlation was demonstrated between premorbid IQ 
estimation at baseline and overall cognition (MCCB3 Cognitive Composite 
Score) at both baseline (r=0.46, p<0.01) and at one year (r=0.05, p<0.01). 
There was also a highly significant, positive correlation between premorbid 
IQ estimation at one year and overall cognition at one year (r=0.66, p<0.01), 
but not between overall cognition at baseline and premorbid IQ estimation at 
one year. 
 
Neurocognitive results: Baseline and change over time 
 
The MCCB3 was used for objective measurement of neurocognitive 
impairment. Although 58 participants were included in the initial sample, total 
scores could not be computed for all participants due to some assessments 
having missing data. The primary cause for incomplete data was the 
psychopathology of the patients, e.g. distractibility, and persecutory ideation 
toward computerized assessments. Socio-cultural factors, such as computer 
illiteracy (i.e. participants‟ difficulty with maneuvering the mouse during the 
CPT-IP4), were also detrimental to the assimilation of data.   
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The change in the neurocognitive composite score (MCCB Cognitive 
Composite Score) from baseline to one year is reflected in figure 12.2 and 
table 12.1. 
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Figure 12.2: Cognitive Composite T-score mean improvement over time 
 
 
Improvement in the Cognitive Composite Score occurred early, with 54.1% 
of the improvement from baseline to one month, while 81.5% of the 
improvement occurred within the first three months. No significant further 
improvement occurred after six months. 
 
Note that the Cognitive Composite Score may not be a very sensitive index 
of change within an individual cognitive domain, as it represents an average 
level of cognitive performance across cognitive domains that are often only 
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weakly to moderately intercorrelated. Furthermore, the MCCB computer 
scoring program does not provide a domain T-score if any of the individual 
test scores is missing in Speed of Processing and Working Memory. 
Similarly, the program does not calculate an overall composite if any of the 
seven domain T-scores are missing.  
 
The changes in neurocognitive domains from baseline to one year are 
represented in table 12.1, figure 12.3 and figure 12.4. Changes in individual 
measures are presented in table 12.2. 
 
Table 12.1: Change in neurocognitive composite and domain   
scores over time 
 Baseline 12 months F Test 
*
 
N T-score 
mean (SD) 
N T-score 
mean (SD) 
Speed of Processing 57 12.42 (16.41) 40 25.78 (12.67) 22.92 
Attention and Vigilance 52 23.98 (12.05) 40 34.73 (10.98) 30.23 
Working Memory 58 21.10 (15.93) 39 29.92 (13.58) 18.77 
Verbal Learning 58 31.95 (8.18) 40 36.23 (7.65) 7.58 
Visual Learning 58 25.55 (14.26) 40 36.08 (12.37) 12.06 
Reasoning and Problem solving 58 30.41 (8.84) 40 36.90 (8.76) 10.46 
Cognitive Composite 51 9.71 (15.01) 39 20.97 (13.49) 30.68 
* p<0.001     
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Vertical bars denote 0.95 confidence intervals
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Figure 12.3: Speed of processing, Attention and Vigilance, and Working Memory  
T-score means improvement over time 
 
 
Speed of Processing was the most severely impaired domain at baseline  
(T-score mean 12.42, ±16.41). Improvement in Speed of Processing 
occurred early, with 73.9% of total improvement occurring within the first 3 
months of the 12 month period. Individual measures, contributing to Speed 
of Processing, are the Trail Making Test (TMT)5: Part A, Brief Assessment of 
Cognition in Schizophrenia (BACS)6: Symbol-Coding and Category Fluency 
(Fluency)7: Animal Naming. Fifty-one-point-fourteen-percent of improvement 
in the TMT occurred within one month, 66.34% by 3 months, and 92.92% by 
6 months. No significant gains occurred after 6 months (F test 25.33; 
p<0.01). Eighty-one-point-zero-nine-percent of the improvement in BACS 
occurred by 3 months (F test 18.00; p<0.01), after which improvement 
reached a plateau. Fluency improved early, and quickly, with 65.35% of 
improvement within the first month (F test 5.63; p<0.01).  
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A significant improvement was evident in Attention and Vigilance, as 
measured by the Continuous Performance Test- Identical Pairs (CPT-IP)4 . 
Fifty-eight-point-one-percent of the improvement occurred within three 
months from baseline, with no improvement after six months (F test 28.81; 
p<0.01). 
 
Working Memory showed significant improvement up to six months from 
baseline, with 71.3% of gains occurring within the first three months. Tests 
used as measures of Working Memory include the Wechsler Memory Scale 
– 3rd ed. (WMS-III)8 :Spatial Span (non-verbal memory) and Letter-Number 
Span9 (LNS) (verbal memory). Both of these measures showed improvement 
up to the 3 month mark, with 65.5% (F test 12.06; p<0.01) and 64.8% (F test 
11.86; p<0.01) of total improvement respectively occurring within this time 
frame.  
 
Although these three domains all had a decrease in T-scores from 6 months 
to one year, these changes were small and not significant. This may be an 
artefact due to the attrition rate of participants and the resultant decrease in 
sample size over time. 
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Vertical bars denote 0.95 confidence intervals
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Figure 12.4: Reasoning and Problem solving, Verbal Learning, and Visual Learning T 
score means improvement over time 
 
 
A 51.05% improvement in Reasoning and Problem solving, as measured by 
the Neuropsychological Assessment Battery (NAM)10: Mazes, occurred 
within the first month. By the third month, 72.86% of the overall improvement 
was attained, whereas no further significant gain was evident after six 
months (F test 11.85; p<0.01). 
 
Verbal Learning, represented by the Hopkins Verbal Learning Test-Revised 
(HVLT-R)11, was the least affected of all cognitive domains at baseline (T-
score mean 31.95, ± 8.18). Similar early gain was achieved, with 79.96% of 
all improvement occurring within the first three months (F test 7.44; p<0.01).  
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Visual Learning was the only cognitive domain in which continued 
improvement (as measured by the Brief Visuospatial Memory Test-Revised 
[BVMT-R]12) was evident. At 3 months, 67.46% of improvement took place, 
while at 6 months 95.95% of improvement had occured (F test 10.96; 
p<0.01). 
 
Changes in individual measures and domain scores were small, but for the 
most part positive and significant. T-score means indicate that at baseline, 
participants performed 2 to 4 standard deviations below the mean, while at 
endpoint (12 months), participants performed 1.5 to 3 standard deviations 
below the mean.  
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Table 12.2: Neurocognitive T-scores of individual measures 
 Baseline 1 month 3 months 6 months 12 months 
Variable N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
TMT 57 19.74 (18.19) 56 28.32 (13.82) 54 30.74 (12.13) 47 36.04 (14.30) 40 36.83 (12.64) 
BACS 58 15.57 (15.69) 56 21.73 (15.54) 54 25.22 (12.31) 47 27.47 (11.77) 40 25.58 (13.07) 
HVLT-R 58 32.00 (8.12) 56 34.39 (7.16) 54 36.44 (6.99) 47 37.68 (8.51) 40 36.23 (7.65) 
WMS-III 58 27.03 (14.39) 56 31.16 (14.29) 54 34.46 (12.37) 47 38.38 (12.41) 40 33.83 (14.03) 
LNS 58 25.93 (13.42) 56 28.71 (12.74) 54 31.83 (10.59) 47  35.04 (10.49) 39 32.85 (11.65) 
NAB 58 29.89 (9.53) 56  33.82 (8.31) 54 33.83 (7.91) 47 37.29 (10.02) 40 36.80 (8.76) 
BVMT-R 58 25.43 (13.60) 56 30.11 (14.31) 54 32.09 (13.77) 47 36.11 (13.68) 40 35.18 (13.35) 
Fluency 58 31.55 (10.29) 56 35.36 (10.42) 54 35.74 (9.46) 47 37.38 (6.98) 40 36.33 (7.33) 
CPT-IP 52 23.98 (12.05) 52 28.54 (11.01) 52 30.16 (11.40) 47 35.04 (9.79) 40 34.45 (11.09) 
 
Abbreviations: TMT, Trail Making Test: Part A; BACS, Brief Assessment of Cognition in 
Schizophrenia: Symbol-Coding; HVLT-R, Hopkins Verbal Learning Test-Revised; WMS-III, 
Wechsler Memory Scale – 3
rd
 ed.: Spatial Span; LNS, Letter-Number Span; NAB, 
Neuropsychological Assessment Battery: Mazes; BVMT-R, Brief Visuospatial Memory Test-
Revised; Fluency, Category Fluency: Animal Naming; CPT-IP, Continuous Performance 
Test- Identical Pairs. 
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Spearman correlations between MCCB Cognitive Composite Scores and 
PANSS13 symptom factors are listed in table 12.3.  
 
Table 12.3:  Spearman correlations between neurocognitive composite 
scores and clinical ratings 
 Cognitive 
Composite score at 
baseline  
Cognitive 
Composite score at 
12 months  
PANSS score at 
baseline 
Total -0.58 ** -0.21  
Positive -0.27  0.18  
Negative  -0.63 ** -0.36 * 
General -0.46 **  -0.23  
PANSS C -0.65 ** -0.29 
PANSS D 0.04 -0.02 
PANSS G12 -0.48 ** -0.13 
PANSS score at 12 
months 
Total -0.22 -0.53 **  
Positive -0.05 -0.57 **  
Negative  -0.32 -0.53 **  
General -0.26 -0.43 *  
PANSS C -0.30 -0.54 ** 
PANSS D -0.05 -0.12 
PANSS G12 -0.21 -0.58 ** 
* p<0.05    ** p<0.01    
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Symptom severity (PANSS Total) explained 33.64% of the variance in  
cognitive symptoms (MCCB Cognitive Composite Score) at baseline and 
28.09% at 12 months. Negative symptoms explained 39.69% of cognitive 
symptoms at baseline. At 12 months, positive symptoms explained more of 
the variance in cognition than negative symptoms (32.49% vs 28.09% 
respectively).  
 
However, PANSS C14 predicted only 42.25% of the variance in cognitive 
symptoms at baseline, and 29.16% at 12 months. PANSS D15 had no 
significant correlation with overall cognition, or any cognitive domains, at 
either baseline, or at 12 months. Insight (PANSS G12) showed a highly 
significant, inverse correlation with cognitive symptoms (MCCB Cognitive 
Composite Score) at both baseline and at one year. 
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Spearman correlations between neurocognitive domain scores and PANSS 
symptom factors are listed in table 12.4.  
 
 
Table 12.4:  Spearman correlations between cognitive domain scores 
and clinical ratings 
 Domain score at baseline 
SPO AV WM VerL VisL RP 
PANSS score at 
baseline 
Total -0.56 ** -0.43 ** -0.56 ** -0.50 ** -0.37 ** -0.32 * 
Positive -0.24 -0.23 -0.26 -0.29 -0.12 -0.03 
Negative  -0.64 ** -0.48 ** -0.60 ** -0.50 ** -0.44 ** -0.44 ** 
General -0.46 ** -0.37 ** -0.48 ** -0.40 ** -0.30 * -0.28 * 
PANSS C -0.52 ** -0.56 ** -0.53 ** -0.47 ** -0.48 ** -0.36 ** 
PANSS D 0.13 0.05 0.08 0.04 -0.10 0.01 
PANSS G12 -0.43 ** -0.39 ** -0.37 ** -0.36 ** -0.28 * -0.23 
 Domain score at baseline 
SPO AV WM VerL VisL RP 
PANSS score at 
12 months 
Total -0.41 ** -0.14 -0.45 * -0.34 -0.48 ** -0.20 
Positive -0.26 -0.22 -0.47 ** -0.49 ** -0.31 -0.01 
Negative  -0.39 * -0.22 -0.50 ** -0.28 -0.42 * -0.24 
General -0.40 * -0.09 -0.35 * -0.31 -0.46 ** -0.16 
PANSS C -0.59 ** -0.21 -0.46 ** -0.41 * -0.56 ** -0.28 
PANSS D -0.12 -0.13 -0.27 0.07 -0.07 0.19 
PANSS G12 -0.26 -0.28 -0.25 -0.57 ** -0.40 * -0.13 
* p<0.05    ** p<0.01    
 
Abbreviations: SPO, Speed of Processing; AV, Attention and Vigilance; WM, Working 
Memory; VerL, Verbal Learning; VisL, Visual Learning; RP, Reasoning and Problem solving 
Positive symptoms (PANSS P) at baseline showed no significant correlations 
with any of the cognitive domains. However, at one year, positive symptoms 
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had highly significant, inverse correlations with Working Memory and Verbal 
Learning. Negative symptoms (PANSS N) at baseline showed highly 
significant, inverse correlations with all cognitive domains. However, at one 
year, the only significant correlations between negative symptoms and 
cognition were in the domains of Working Memory and Visual Learning. 
General psychopathology scores (PANSS G) demonstrated significant, 
inverse correlations with all cognitive domains at baseline, while at one year, 
the only significant correlations were with Speed of Processing, Working 
Memory and Visual Learning. PANSS C had a highly significant, inverse 
correlation with all cognitive domains at baseline, while at one year PANSS 
C had significant inverse correlations with Speed of Processing, Working 
Memory and Visual Learning. PANSS D had no correlations with cognitive 
domains at baseline, or at 1 year. 
 
Insight (PANSS G12) showed highly significant, inverse correlations with 
each of Speed of Processing, Attention and Vigilance, Working Memory, and 
Verbal Learning at baseline, while at one year insight had a highly significant 
inverse correlation with Verbal Learning. There were significant inverse 
correlations between insight and Visual Learning at both baseline and at one 
year. 
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Social Cognition 
 
Social cognition was evaluated by means of the Mayer-Salovey-Caruso 
Emotional Intelligence Test16 (MSCEITTM).  
 
There was no difference between genders or ethnic groups at either baseline 
or one year. However, there was a significant difference (p=0.02) in Social 
Cognition at baseline between participants assessed in English (26.59, ± 
6.19) or Afrikaans (32.14, ± 8.95) (see figure 12.5). 
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Figure 12.5: Baseline differences between language and Social Cognition 
 
This difference in Social Cognition between English and Afrikaans groups 
persisted at one year (28.29, ± 9.07 and 35.17, ± 13.73 respectively; 
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p=0.04). Age had a statistically significant positive correlation with  the 
Managing Emotions Branch (MEB) at 1 year (r=0.38; p=0.02). 
 
The ability of female participants to regulate the self (Emotion Management 
Task; REMT) was significantly better than that of male participants (83.44, ± 
8.63 and 77.57, ± 6.74 respectively; p=0.01) at baseline (see figure 12.6). 
This gender difference disappeared by 1 year. 
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Figure 12.6: Difference between genders in self-regulation at baseline 
 
 
Although Social Cognition improved from a mean T-score of 30.00 (± 8.39) 
at baseline to 32.25 (± 12.22) at one year, the change was not significant. 
Thirty-four-point-six percent of the improvement occurred within one month, 
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and 51.71% by 3 months. However, improvement over time was significant 
for both MEB and the Social Management Task (RMT) (see table 12.5). 
 
Table 12.5: Change in Social Cognition and individual measures over 
time 
 Baseline 12 months F Test; p 
value N T-score mean (SD) N T-score mean (SD) 
Social Cognition 58 30.00 (8.39) 40 32.25 (12.22) 2.89; 0.02 
MEB 58 76.99 (7.52) 40 79.73 (10.14) 3.05; 0.02 
RMT 58 79.84 (9.37) 40 81.12 (11.50) 2.63; 0.04 
REMT 58 79.49 (7.84) 40 82.19 (9.53) 1.52; 0.19 
 
Abbreviations: MEB, Managing Emotions Branch; RMT, Social Management Task; REMT 
Emotion Management Task 
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Spearman correlations between Social Cognition and PANSS symptom 
factors are listed in table 12.6.  
 
 
Table 12.6:  Spearman Correlations between Social Cognition and clinical 
ratings 
 Social Cognition scores at 
baseline  
Social Cognition scores at 
12 months  
 Total MEB RMT REMT Total MEB RMT REMT 
PANSS 
score at 
baseline 
Total -0.44 ** -0.51 ** -0.15 -0.27 -0.21 -0.24 -0.14 -0.17 
Positive -0.12 -0.18 -0.1 -0.14 -0.08 -0.17 -0.14 -0.17 
Negative  -0.38 ** -0.46 ** -0.39 ** -0.30 * -0.15 -0.14 -0.08 -0.13 
General -0.40 ** -0.46 ** -0.41 ** -0.33 * -0.17 -0.24 -0.13 -0.28 
PANSS 
score at 12 
months 
Total -0.30 -0.29 -0.27 -0.22 -0.39 -0.38 * -0.40 * -0.15 
Positive -0.17 -0.19 -0.08 -0.18 -0.33 -0.43 * * -0.43 * -0.26 
Negative  -0.25 -0.26 -0.27 -0.19 -0.27 -0.29 -0.34 -0.07 
General -0.35 -0.34 -0.29 -0.25 -0.44 * -0.41 * -0.39 * -0.19 
* p<0.05    ** p<0.01 
 
 
At baseline, negative and general symptoms had a highly significant inverse 
correlation with Social Cognition, and specifically with MEB and RMT. 
However, at one year, negative symptoms did not correlate with Social 
Cognition, while positive symptoms had a highly significant, inverse 
correlation with MEB and RMT. Self regulation showed no significant 
correlation with clinical psychopathology at one year. 
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Insight 
Insight was evaluated by the PANSS insight item (G12), as objective 
measure, as well as the Birchwood Insight Scale (BIS)17, as subjective 
measure. 
 
The mean baseline PANSS G12 score was 5.03 (± 1.03) which is indicative 
of moderately severe impairment in insight, where participants show only a 
vague or shallow recognition of illness. There was a significant, inverse 
correlation between PANSS D and PANSS G12 at baseline (r=-0.37; 
p<0.01).  
 
Participants with poor insight were more likely to be hospitalized (see figure 
12.7) 
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Figure 12.7: Difference between hospital admission statuses with regard to insight 
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Although there was a significant, inverse correlation between insight and 
hospital admission status (r=-0.34; p=0.01), the duration of admission did not 
correlate with insight. 
 
There was a significant improvement in insight after acute stabilization 
(p<0.01), with PANSS G12 decreasing from 5.03 (± 1.03) at baseline to 3.05 
(± 0.95) at 12 months (see figure 12.8). 
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Figure 12.8: Improvement in insight over time 
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The participants BIS total scores are depicted in figure 12.9.  
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Figure 12.9: Birchwood Insight Scale scores at baseline 
 
 
Participants‟ mean BIS score was 9.03 (± 3.34), suggesting “good insight”. If 
we examine the number of participants with “good” (>9) versus those with 
“poor” (≤9) insight, 22 (56%) of the participants who completed the scale had 
poor insight, with 17 (44%) considered having good insight. Although there 
was a small improvement in mean BIS score over time to 9.45 (± 2.01) at 
one year, the change was not significant. 
 
There were no significant differences in levels of insight between age 
groups, different levels of education, genders or language groups at 
baseline. However, at one year, females had better insight than males (10.7, 
± 3.40 versus 8.20, ± 2.44; p=0.03).  
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Correlations between BIS scores and PANSS G12 at baseline, 6 months 
and 1 year did not reach a level of significance (p set at 0.05). However, 
PANSS Total and PANSS G scores at baseline had significant positive 
correlations with BIS scores at 12 months (see table 12.7). 
 
Table 12.7:  Spearman correlations between insight and clinical ratings 
 BIS score at 
baseline  
BIS score at 12 
months  
PANSS score at 
baseline 
Total 0.13 0.51** 
Positive 0.07 0.19 
Negative  0.09 0.27 
General 0.17 0.54** 
PANSS C 0.12 -0.02 
PANSS D 0.10 0.33 
PANSS score at 12 
months 
Total -0.21 -0.06 
Positive -0.14 -0.09 
Negative  -0.47 0.03 
General -0.09 -0.10 
PANSS C -0.02 -0.02 
PANSS D -0.16 0.04 
* p<0.05   ** p<0.01 
 
Although correlations between the BIS scores and MCCB Cognitive 
Composite Scores were not significant at any visit (p set at 0.05), PANSS 
G12 scores showed highly significant (p<0.01) inverse correlations with 
MCCB Cognitive Composite Scores at all visits (baseline r=-0.48; 1 month 
r=-0.41; 3 months r=-0.42; 6 months r=-0.52 and 12 months r=-0.58).  
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There were no significant correlations at baseline between insight and 
premorbid adjustment (PAS), social and occupational functioning (SOFAS), 
DUI/DUP, hospital admission status, or estimation of premorbid intelligence 
(WAIS). 
 
Subjective reports of cognitive impairment 
 
The Subjective Scale to Investigate Cognition in Schizophrenia18 (SSTICS) 
was used as quantitative measure to assess participants with regard to the 
cognitive deficits they experienced.  
 
The mean SSTICS Global score at baseline was 35.23 (± 18.19) (N=39), 
where zero would indicate no impairment, while the maximum score that can 
be obtained is 84. Participants assessed in English reported more cognitive 
impairment at baseline (51.67, ± 20.79) than those assessed in Afrikaans 
(27.93, ± 11.00) (see figure 12.10). At one year (N=37), there was no 
difference between the groups. 
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 Mann-Whitney U p<0.01
Vertical bars denote 0.95 confidence intervals
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Figure 12.10: Language differences in cognitive complaints at baseline 
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No significant differences between gender groups were present at baseline. 
However, at one year, male participants reported more subjective 
impairment than female participants (30.21, ± 15.84 versus 17.33, ± 12.89 
respectively; p=0.03) (see figure 12.11). 
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Figure 12.11: Gender differences in cognitive complaints at 12 months 
 
 
Male participants therefore presented with 15.33% more cognitive 
complaints at one year than did female participants. 
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A significant (p<0.01) decrease in complaints of cognitive impairment 
occurred over time, most notably between one and 3 months (see figure 
12.12 and table 12.8). 
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Figure 12.12: Change in cognitive complaints over time 
 
 
As mentioned (p 248) this questionnaire was only used after the initial six 
months of the study, therefore not all participants completed the 
questionnaire at baseline, one and three month assessments. This would 
explain the apparent discrepancy in number of participants completing the 
SSTICS at a given time point  
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Table 12.8: Change in subjective reports of cognitive impairment  
over time 
 Baseline 
(N=39) 
12 months 
(N=37) 
 
F Test; p 
value Variable (maximum score) Mean (SD) Mean (SD) 
Sustained Executive Function (16) 8.00 (3.97) 6.11 (4.15) 4.09; <0.01 
Memory of information (16) 5.46 (3.73) 4.05 (3.19) 3.32; 0.01 
Consciousness of effort (16) 7.77 (3.90) 6.35 (3.54) 2.83; 0.03 
Daily Life (16) 6.10 (4.16) 4.65 (3.18) 2.46; 0.05 
Distractibility (12) 5.05 (3.49) 4.46 (2.66) 3.06; 0.02 
Alertness (4) 1.41 (1.31) 1.08 (1.23) 2.06; 0.09 
Global (84) 35.23 (18.19) 27.08 (16.02) 5.05; <0.01 
 
 
Sustained Executive Function and Consciousness of effort improved up to 
one month, thereafter, no significant decrease in complaints occurred. 
Problems with regard to Memory of information (working memory and explicit 
memory) and Distractibility decreased up to 3 months, with no significant 
change thereafter. Of the individual measures, Alertness and Daily Life did 
not improve significantly over the 12 months of the study. 
 
No correlations were present between subjective cognitive impairment and 
each of the following: insight, QOL, and hospital admission status, DUI/DUP, 
mood symptoms (CDSS and PANSS D), or severity of illness at baseline 
(PANSS and CGI-s). 
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Spearman correlations between subjective cognitive complaints and 
objective neurocognitive measures and clinical ratings are listed in tables 
12.9 to 12.11. 
 
Table 12.9: Spearman correlations between SSTICS individual measures, 
MCCB scores, and PANSS ratings at baseline 
 SEF MEM COE DL DIST ALERT Global 
PANSS P Total -0.20 -0.05 -0.20 -0.03 -0.03 0.02 -0.11 
PANSS N Total 0.04 0.23 0.20 0.14 0.13 -0.01 0.12 
PANSS G Total 0.17 0.20 0.16 0.28 0.16 0.15 0.19 
PANSS Total Score 0.09 0.24 0.15 0.25 0.19 0.11 0.18 
PANSS C factor -0.21 -0.33 -0.42 ** -0.20 -0.21 -0.08 -0.31 
PANSS D factor 0.12 -0.14 0.07 0.18 -0.05 0.06 0.01 
Speed of Processing 0.02 -0.01 0.04 -0.02 0.16 0.15 0.04 
Attention and Vigilance -0.22 -0.23 -0.43 ** -0.32 -0.22 -0.08 -0.32 
Working Memory -0.15 -0.14 -0.21 -0.08 -0.08 -0.10 -0.15 
Verbal Learning -0.14 -0.22 -0.34 * -0.24 -0.13 -0.12 -0.28 
Visual Learning -0.10 -0.19 -0.22 -0.29 -0.11 -0.21 -0.24 
Reasoning and  
Problem Solving 
-0.22 -0.08 -0.26 -0.27 -0.04 -0.08 -0.24 
Social Cognition -0.26 -0.15 -0.43 ** -0.26 -0.11 0.02 -0.25 
Cognitive Composite -0.23 -0.36 * -0.32 -0.24 -0.13 -0.02 -0.32 * 
* p<0.05; ** p<0.01 
 
Abbreviations: SEF, Sustained Executive Function; MEM, Memory of information; COE, 
Consciousness of effort; DL, Daily Life; DIST, Distractibility; ALERT, Alertness 
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We found a highly significant, inverse correlation at baseline (p<0.01) 
between Consciousness of effort and PANSS C ratings, as well as between 
Consciousness of effort and cognitive domains of Attention and Vigilance 
and Social Cognition (see table 12.9). 
 
Table 12.10: Spearman Correlations between SSTICS individual 
measures, MCCB scores, and PANSS ratings at 1 month 
 SEF MEM COE DL DIST ALERT Global 
PANSS P Total 
0.13  -0.07 0.03 0.12 0.10 0.24 0.14 
PANSS N Total 
0.17 0.06 0.11 0.32 * 0.18 0.10 0.21 
PANSS G Total 
0.38 * 0.22 0.35 * 0.25 0.37 * 0.11 0.42 ** 
PANSS Total Score 
0.34 * 0.18 0.25 -0.28 0.31 * 0.15 0.37 * 
PANSS C factor 
0.25 0.12 0.13 0.12 0.33 0.11 0.24 
PANSS D factor 
0.21 0.07 0.17 0.12 0.13 -0.03 0.14 
Speed of Processing 
-0.46 ** -0.43 ** -0.41 ** -0.33 * -0.40 ** -0.56 ** -0.52 ** 
Attention and Vigilance 
-0.28 -0.25 -0.20 -0.21 -0.35 * -0.25 -0.35 * 
Working Memory 
-0.45 ** -0.25 -0.37 * -0.34 * -0.29 -0.55 ** -0.45 ** 
Verbal Learning 
-0.41 ** -0.40 ** -0.27 -0.35 * -0.34 * -0.44 ** -0.45 ** 
Visual Learning 
-0.38 * -0.42 ** -0.31 -0.26 -0.41 ** -0.47 ** -0.46 ** 
Reasoning and  
Problem Solving 
-0.44 ** -0.35 * -0.35 * 0.01 -0.31 * -0.56 ** -0.48 ** 
Social Cognition 
-0.11 0.05 0.21 -0.28 0.11 -0.20 -0.00 
Cognitive Composite 
-0.44 ** -0.36 * -0.27 0.25 -0.32 -0.54 ** -0.46 ** 
* p<0.05; ** p<0.01 
 
Abbreviations: SEF, Sustained Executive Function; MEM, Memory of information; COE, 
Consciousness of effort; DL, Daily Life; DIST, Distractibility; ALERT, Alertness 
 
 
At one month, subjective cognitive complaints correlated inversely with the 
domains of Speed of Processing, Working Memory, Visual Learning and 
Results: Cognitive Data 
 
328 
 
Reasoning and Problem solving. Global PANSS symptoms had a positive 
correlation with Global subjective cognitive impairment. MCCB Cognitive 
Composite Score correlated significantly, and inversely, with Sustained 
Executive Function and Alertness. No correlation between subjective 
impairment in cognition and PANSS C, or with PANSS D, was found (see 
table 12.10). 
 
At three months, PANSS D had a strong positive correlation with Sustained 
Executive Function (r=0.35, p=0.02), while Verbal Learning had a strong, 
inverse correlation with Sustained Executive Function (r=0.33, p=0.02). No 
other correlations between subjective and objective cognitive measures were 
present. PANSS Total scores showed highly significant (p<0.01) inverse 
correlations with Distractibility (r=0.39), Alertness (r=0.46) and Daily Life 
(0.40). 
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At six months, correlations between PANSS G, Speed of Processing, and 
individual measures of the SSTICS remained significant (p<0.01). 
Furthermore PANSS D had significant positive correlations with subjective 
cognitive impairments reported (see table 12.11).  
 
 
Table 12.11: Spearman Correlations between SSTICS individual 
measures, MCCB scores, and PANSS ratings at 6 months 
 SEF MEM COE DL DIST ALERT Global 
PANSS P Total 0.25 0.24 0.31 0.27 0.28 0.11 0.27 
PANSS N Total 0.32 * 0.13 0.22 0.23 0.21 0.13 0.19 
PANSS G Total 0.40 ** 0.34 * 0.39 ** 0.37 * 0.36 * 0.01 0.38 ** 
PANSS Total Score 0.38 ** 0.28 0.36 * 0.35 * 0.33 * 0.10 0.33 * 
PANSS C factor 0.22 0.21 0.20 0.18 0.11 -0.18 0.15 
PANSS D factor 0.33 * 0.30 * 0.43 ** 0.35 * 0.31 * 0.30 * 0.38 ** 
Speed of Processing -0.41 
** 
-0.31 
* 
-0.32 * -0.28 -0.19 0.10 -0.31 * 
Attention and Vigilance -0.28 -0.36 
* 
-0.13 -0.20 -0.17 -0.10 -0.22 
Working Memory -0.31 * -0.23 -0.32 * -0.26 -0.13 0.01 -0.23 
Verbal Learning -0.18 -0.25 -0.11 -0.16 -0.17 -0.00 -0.17 
Visual Learning -0.11 -0.14 -0.01 -0.04 -0.13 -0.07 -0.02 
Reasoning and Problem Solving -0.03 -0.11 -0.06 -0.00 -0.01 -0.09 -0.03 
Social Cognition -0.11 -0.11 -0.16 -0.14 -0.16 -0.06 -0.09 
Cognitive Composite -0.30 * -0.33 
* 
-0.24 -0.24 -0.24 -0.15 -0.26 
* p<0.05; ** p<0.01 
 
Abbreviations: SEF, Sustained Executive Function; MEM, Memory of information; COE, 
Consciousness of effort; DL, Daily Life; DIST, Distractibility; ALERT, Alertness 
 
 
There were significant, positive correlations present between PANSS D and 
Consciousness of effort (r=0.42, p<0.05) and between PANSS D and Daily 
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Life (r=0.42, p<0.05) at 12 months. There were no other significant 
correlations between clinical ratings and subjective cognitive impairment 
present. However, Social Cognition was inversely correlated with Daily Life 
(r=-0.13, p<0.05) and Distractibility (r=-0.22, p<0.01), while MCCB Cognitive 
Composite Score showed an inverse correlation with Memory of information 
(r=-0.24, p<0.05). 
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CHAPTER 13 
DISCUSSION 
 
The aim of this study was to investigate cognitive deficits in patients with first 
episode psychosis (FEP), and the response of these impairments to 
treatment with a depot formulation of the first generation antipsychotic (FGA) 
flupenthixol. 
 
To date, this study is one of the largest FEP studies in South Africa, with the 
largest number of participants completing the one year follow-up period. 
Only three other South African studies, investigating some of the cognitive 
aspects of schizophrenia, could be traced by the author (those of Mattson et 
al.1, Emsley et al.2, and Skuy et al3.)  The author believes this to be the first 
longitudinal study investigating both cognition in FEP, and the response 
thereof, to ultra low doses of an injectable FGA, to be undertaken in South 
Africa. 
   
The literature indicates that differences in population constructs and the 
variables within schizophrenia itself are important factors influencing the 
presentation, treatment response and patient outcome of the illness, that are 
unique to differing global settings4. Continued investigation to provide 
additional comparable data on these aspects of the illness is, therefore, 
important. This study confirmed the findings of similar investigations held 
elsewhere, and presented some findings not previously documented. 
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GENERAL 
Gender and age (refer pp 257-259, 282, 314, 323) 
 
Disparity between the genders in schizophrenia has been reported on and 
attributed to biological and environmental influences5,6. The disparity 
between gender representation in our sample and the 2007 population 
estimate for the Western Cape7 is as follows: 67% male vs. a 51.9% 
provincial representation; and 33% female vs. a 49.9% provincial 
representation. The mean age for the Western Cape population is 27.1 years 
for males, and 28.3 years for females; whereas the mean in our sample was 
22.43 years, and 25.35 years, respectively  
 
Various studies have reported onset of illness to occur between 15 and 30 
years of age, and the literature suggests a trend toward males being 
younger at onset, and more severely ill, than females6,8,9. However, this 
belief is not supported by all reports5,6,8-10. The findings of our study mirrored 
the mean age of onset11,12, however, we were unable to confirm that males 
were more severely ill at baseline than females. 
 
We did not find any significant differences in objective measures of 
neurocognitive functioning between the genders at any stage of the study, 
though females displayed some advantages in social cognitive skills at 
baseline, and males reported more subjective cognitive impairment at one 
year. 
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Ethnicity (refer pp 259-263) 
 
This study was conducted at the Stikland and Tygerberg hospitals. As the 
majority of the patients who present at these locations are of Mixed (African-
Caucasian) ethnic lineage, this study‟s cohort is a representative sample of 
the ethnicity of this catchment area‟s population, although it does not fully 
reflect the ethnic composition of the Western Cape Province. This composite 
differential is demonstrated as follows: the study sample was 78% Mixed 
ethnic origin vs. a 50.2% provincial population; 12% Black African vs. a 
30.1% provincial population; and 10% White vs. an 18.4% provincial 
population13. 
 
Differences in presentation between ethnic groups, as previously reported14, 
were not supported by the results of this study; nor could any significant 
differences be demonstrated in severity of illness and cognition between 
these groups at baseline, or in response to treatment at the end of the one 
year trial period. Although a significant difference in premorbid IQ estimation 
was evident, this may not be of any clinical significance, but may rather 
reflect the presence of demographic and psychopathological differences at 
baseline. Results on ethnic differences should however be interpreted with 
great caution, due to the small number of participants in the White and Black 
African groups. 
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Language (refer pp 259-261, 313) 
 
“Education and ethnicity cannot be discussed without taking language into 
account”15 (pg 251).  
 
The linguistic cross-section of this study‟s sample, compared to that of the 
Western Cape Province, was as follows: Afrikaans 79% vs. a 55.3% 
provincial usage; Xhosa 10.3% vs. a 23.7% provincial usage; and English 
8.6% vs. a 19.3% provincial usage7. 
 
South Africa‟s 11 official languages are reputed to be the highest number of 
languages recognized on a national level in any country in the world. 
However, only two of these languages (Afrikaans and English) are the 
primary mediums through which mainstream education is delivered. For this 
reason, all assessments in this study were conducted in the patients‟ 
preferred language of either Afrikaans or English, being a reflection of their 
language of education.  
 
Participants, who preferred to be assessed in English, were more severely ill 
at baseline than those assessed in Afrikaans. This could be due to selection 
bias, as well as differences in educational level attained. The difference in 
premorbid IQ between language groups appeared to be an effect of 
educational level attained and not of ethnicity, or language per se. Although 
no difference in objective assessment of neurocognitive functioning was 
evident at baseline, participants assessed in English reported more 
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subjective cognitive impairment, than those assessed in Afrikaans. Although 
participants assessed in English displayed more impairment in social 
cognition at both baseline and one year, this may be a reflection of cultural 
differences. It should also be taken into consideration that bilingualism can 
alter normal performance expectations16.   
 
In this study sample, three late-bilingual male participants (i.e. who learned 
their second language after the age of 6 years) “switched” spontaneously 
from their mother tongue (Afrikaans) to their second language (English) 
during the onset of their psychotic episode, subjectively experiencing 
communication to be easier, and thought processes to be more coherent, in 
their second language. This „preserved‟ second language functioning was 
evident in objective clinical assessments. One such case has been 
documented elsewhere by Schoeman et al.17, and Southwood et al.18.  
 
Language disruption in schizophrenia appears to differ between genders. 
Male patients performed significantly worse than healthy male controls on 
domains of phonology (least affected), semantics, and grammar. 
Conversely, language function has been described as relatively preserved in 
female patients when compared to healthy female controls, with phonology 
most affected19.  
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Abuse of illicit substances (refer pp 265-267) 
 
Numerous studies have indicated that individuals with FEP display a 
significantly higher rate of substance abuse than their non-psychotic peers, 
with a median lifetime prevalence estimate of at least 40%20-23. At baseline, 
five of 58 participants in our study (8.6%) tested positive for illicit substances. 
Although this is slightly higher than the prevalence of illicit substance use in 
the general South African population, it is representative of the prevalence 
for the population of the Western Cape24-26.  
 
Figures from North American studies that compared the estimated lifetime 
prevalence for illicit substance use in individuals with schizophrenia,  
reported a range between 47% in the Epidemiologic Catchment Area Study27 
(ECA), and 59% in the USA National Comorbidity Study28 (NCS), compared  
to 16% in the general population. Other studies of the same nature reported 
figures as high as 65% to 80% (four times that of the general population) 
29,30. In the CATIE trials 60% of the sample was found to abuse substances, 
with 37% of the group reported as being current substance users31. Yet, on 
the other side of the Atlantic, studies in the United Kingdom reported 
significantly lower figures that ranged between 7% and 27%32-34.  
 
Substance abuse in our sample increased from 8.6% at study outset to 
51.2% at 12 months. However, this may not be a reflection of the „real use‟ 
by patients. While we used urine drug screening and reports from 
participants and their family members to evaluate substance use, these do 
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not necessarily reflect variations in the degree of substance abuse that may 
occur over time. This is also in contrast to certain studies which have 
indicated that substance abuse by individuals with FEP declined after entry 
into a treatment program23,35,36. Other studies have  reported that at least 
50% of patients continued their substance abuse unabated37.  
 
The most common substance of abuse during the course of this study was 
cannabis (>70%), followed by methaquolone (>40%) and 
methamphetamines (>60%). Although our study sample did not reflect the 
high prevalence of estimated methamphetamine use in the Cape Town 
population38, cannabis use within the sample did correlate with international 
study documentation that this appears to be the most common illicit 
substance of abuse in schizophrenia39  
 
There is some disparity in the literature on differences in clinical 
symptomatology and severity of illness between patients who use illicit 
substances and those who do not21,40,41. Some studies reported differences, 
specifically fewer negative symptoms and more severe positive symptoms in 
substance abusers, whereas others did not find any significant differences 
between these groups. In our particular case, no significant differences were 
found 31,42.  
 
Due to the small number of participants using illicit substances at the outset 
of our study we were unable to comment on the previously reported 
differences in age, mood symptoms, social functioning, compliance, side-
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effects and relapse between so-called dual diagnosis patients, and those 
who were psychotic but did not use illicit substances21,31,43-48.   
 
There are reports in the literature that claim an effect of substance abuse on 
cognitive performance in schizophrenia patients; however this view is not 
universally held. While some studies reported adverse effects on memory 
and attention49, and impaired verbal fluency50, others have reported 
enhancement of attention span51, psychomotor speed52, memory53, verbal 
fluency53, and visual spatial construction54-56. 
 
Our study found no evidence to support differences in cognitive performance 
between the participants who used illicit substances, and those who did not. 
Our results therefore support those of Pencer and Addington50  who, in a two 
year prospective cross-sectional and longitudinal study of FEP (N=266), 
found no significant associations between cognitive functioning and the use 
of different substances of abuse. However, they did note a relationship 
between illicit substance use and the presence of more positive symptoms. 
Not surprisingly though, the participants in our study, without comorbid 
substance did have better insight, which concur with findings by Addington 
and Addington57.  
 
Social circumstances such as unemployment, religious orientation, and 
availability of illicit substances may have contributed to substance use in our 
sample. However, we cannot disregard the possibilities of attempts at self-
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medication58-60, or of a shared biological and genetic vulnerability61,62 existing 
between schizophrenia and substance abuse.  
 
Developmental history and premorbid functioning (refer pp 263-265, 
267-279) 
 
Longitudinal studies have demonstrated that individuals with schizophrenia 
differ from their peers, even in early childhood, in attaining developmental 
milestones10,63, cognitive functioning64,65, educational achievement10,63,66,67, 
neurological and motor development68,69, social competence67,70, and 
psychological disturbances70.  
 
It has been suggested of late that some of the problems evident in social 
functioning do not reflect premorbid symptoms and signs, but may possibly 
be part of the early prodromal period pre-dating psychosis. In the classic 
long-term follow-up study by Ciompi et al.71, 50% of individuals with 
schizophrenia experienced an acute onset of symptoms, whereas 50% of 
individuals had a long prodromal phase. The presence of this long DUI, 
defined as the interval between the onset of the disorder and the 
administration of the first pharmacological treatment, is often reflected in 
poor social and vocational functioning72,73, and is considered a  poor 
prognostic factor in schizophrenia 74.  
 
The average DUI of our study sample was 1.5 years, thus considerably 
shorter than the 5 year average75 reported  in studies elsewhere. This is in 
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agreement with the belief that subjects with mental illness in developing 
countries have better social support structures, therefore being able to be 
„absorbed‟ in society for longer periods than their counterparts in the first 
world76,77, but it can also reflect readily accessible mental health services in 
our area. It must be noted that, in determining the DUI, information was 
obtained from participants and their relatives, and was not harvested from 
specific rating scales. Results may therefore have been influenced by so-
called „recall bias‟. Furthermore subtle changes during the prodromal period 
may not have been noted by these untrained individuals. 
 
Agerbo et al. found that individuals suffering from schizophrenia are more 
likely to be single, less likely to be married and more likely to divorce if they 
do78.  In our study sample 31.58% of the females were involved in (or had 
experienced) long-term relationships, compared to 5.13% of the male 
participants. Findings that females with schizophrenia tend to have better 
social functioning than males5,6,79-81 and experience a milder course of 
illness8,82, can possibly be attributed to the later onset of illness in this 
gender group. This would enable females to develop more social roles prior 
to the onset of illness, and thereby maintain a greater degree of functioning 
throughout.  It is possible that the single status of the male participants in our 
study may simply have been a reflection of their younger age and different 
social role expectations.   
 
Competitive employment rates for individuals with schizophrenia are lower 
than the general population78,83,84. A review by Marwaha and Johnson 
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reported employment rates in the UK between 4% and 27% (mean 13.7%) 
for individuals with schizophrenia85. In Australia, unemployment rates of 
individuals with schizophrenia is ten times higher than that of the general 
population (50.2% vs 5.1% respectively)23,86, with similar rates documented 
in Canada (43%)87 and Singapore (39%)88.  
 
Whereas no significant differences in status of employment between ethnic 
groups were found in this study, the unemployment figure within the sample 
(78%) was four times higher than that for this catchment area89 (20.3%). 
Seventy-eight percent of the participants were unemployed, 12% were 
gainfully employed, while, 9% were learners. These figures differ significantly 
from those of the EPPIC90 study in which 29% of the FEP sample was 
employed, 25% was receiving a form of educational instruction, and 39% 
was unemployed. These differences could be a reflection of the high 
unemployment rate (29.4%) in South Africa, however, it may also be a 
reflection of the “social drift” hypothesis91, and therefore be a reflection of 
current functional status, and not of highest functional status. 
 
Decreased work functioning could also be attributed to poor scholastic or 
social circumstances. The median number of school years completed for this 
sample was 10 years. Seventy-nine percent of the participants conformed to 
the provincial average of 8-12 years of completed schooling. It therefore 
appears that the high unemployment rate in our sample cannot be attributed  
to educational level only. It is noteworthy that there was a positive correlation 
between cognitive functioning, and social and occupational functioning in this 
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sample. We can therefore conclude that factors impacting on cognitive 
function, will also impact on social and vocational functioning. 
 
It is interesting to note that Afrikaans speaking participants reported more 
satisfaction with regard to social relations than those participants who 
preferred to be assessed in English. This may reflect the social isolation 
minority groups experience in our catchment area, and may not necessarily 
be as a consequence of language per se.  Participants with better social and 
occupational functioning also report better quality of life. Those participants 
with more prominent positive symptoms were less satisfied with their 
environment, which, once again, could be a reflection of aspects of their 
illness (such as delusions), and not of „real-life‟ issues.   
 
Duration of untreated psychosis (refer pp 276-279) 
 
The literature has evidenced that FEP patients experience an alarming delay 
between the times of the first psychotic symptom manifestation to initiation of 
treatment4,92-94. This so-called „duration of untreated psychosis‟ (DUP) 
averages 1-2 years, with a median duration of 3-4 months95-98. It has been 
proposed that the DUP has a biological, toxic effect with deterioration of 
brain function. Therefore it is likely that a longer DUP is a poor, but 
modifiable prognostic factor99-101.  
 
Our study found a DUP of 166.69 (± 168.33) days, which is shorter than the 
average duration of DUP reported in both high income and Low and Middle 
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Income (LAMI) countries99,102-105. Several studies have reported 
schizophrenia to have a more benign course, and better prognosis in LAMI 
countries4,106-108. A recent systematic review found a significant difference 
(p<0.01) in DUP between the DUP of LAMI countries (125 weeks) and the 
DUP of high income countries (63 weeks)109. It appears that differences in 
DUP reflect the nature of the psychosis, and not a delay in treatment as 
such, as evidenced by a re-analysis of data from the original Northwick Park 
Study93,104. Furthermore, increased DUP was also found to be related to 
smaller social support networks and a less insidious onset103,105,110. 
 
Our finding of participants with a short DUP being more likely to be 
hospitalized could potentially be attributed to a more acute onset of illness. 
Participants with more disruptive behavior are more difficult to accommodate 
in the informal settlements common to our catchment area, and therefore 
less likely to be tolerated than in more rural areas. Furthermore, social and 
community support is relatively good in our catchment area, and patients of 
Mixed ethnic origin are less marginalized and isolated. However, this social 
tolerance does not hold true for Xhosa speaking patients111. 
 
We did not find any correlation between DUP and gender, DUP and 
psychopathology, DUP and clinical improvement, or DUP and cognitive 
functioning, and therefore could neither support, nor contradict, previous 
results99,100,112,113. 
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Being reliant on consensus agreement, our assessment of DUP may be less 
reliable than studies that employed specific DUP rating scales such as the 
Retrospective Assessment of Onset of Schizophrenia (IRAOS)114.  
 
TREATMENT 
 
Efficacy of treatment (refer pp 279-280, 302-303) 
 
The participants in our study were markedly ill at baseline with PANSS Total 
scores around 100, and CGI115 ratings of >5. As we recruited from both 
acute in-patient units and outpatient services, we consider this sample as 
being representative of all patients with FEP in our catchment area. 
  
The participants in this study were treated with an ultra low dose of 
flupenthixol decanoate (FD). The mean administered dose was 22.48, ± 
0.47mg/month (28.10mg/d CPZE116,117). This very low dose of antipsychotic 
was effective in treating the symptoms of schizophrenia, as measured by 
PANSS Total score reduction, in the majority of the patients. In our study, 
improvement in both psychopathology and cognitive symptoms occurred 
early - within the first month. The majority of improvement occurred within 
the first three months, and leveled out after six months with no significant 
gains thereafter. Our findings support documented research indicating that 
patients with FEP generally respond better to antipsychotic agents than 
those who have had multiple episodes118,119. Evidence for this is the lower 
dose of antipsychotic treatment needed to achieve positive symptoms 
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remission in FEP than in chronic patients120-125, and a higher response and 
remission rate126,127 
 
The effectiveness of the very low dose of FD used in this study in reducing 
positive symptoms, negative symptoms, general psychopathology 
symptoms, and mood symptoms, compares favorably to studies with higher 
doses of flupenthixol128-136, as well as with the effectiveness documented for 
other FGAs and SGAs137-143. This finding should, however, be interpreted 
with caution, as this was a single arm, open-label study, which did not have 
the comparison between different treatments as an objective.  
 
We performed an extensive search of the available literature, and were only 
able to trace one other study (Ruhrmann et al.136) that specifically compared 
the response of cognitive symptoms to treatment with flupenthixol vs. a SGA. 
In this six month randomized double-blind study of 144 chronic 
schizophrenic patients, comparing oral flupenthixol 6.23 (±2.86) mg/d with 
risperidone 3.56 (±1.20) mg/d, flupenthixol demonstrated non-inferiority with 
regard to effectiveness on negative symptoms (PANSS N) and cognitive 
symptoms (PANSS C). Unfortunately, the authors of this study did not 
conduct any neuropsychological assessments to which we could compare 
our findings.   
 
A three year longitudinal, randomized, open-label trial, investigated the 
neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in 
104 patients with FEP. Participants completed clinical and cognitive 
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evaluations at baseline, 6 months, and one year. Although the degree of 
cognitive improvement was small, all three of the treatment arms 
demonstrated significant improvement in cognitive functioning over the one 
year period.  No significant difference with regard to effectiveness between 
the groups was evident144. 
 
The significant improvements in negative and cognitive symptoms during the 
course of our study are notable. This supports findings by  Davis et al.145 and 
Mishara and Goldberg146, that FGAs may benefit cognitive function and 
negative symptoms.  
 
It is possible that the very low dose of flupenthixol used in our study was less 
likely to cause secondary negative symptoms than standard doses of 
FGAs147. It is also possible that FD, is indeed effective in treating core 
negative symptoms148-150.  However, it is worthwhile to again note that 
flupenthixol does resemble some SGAs with regard to receptor profile151,152, 
with improved efficacy against negative symptoms and depressed mood, 
when compared to agents such as fluphenazine.  
 
Seventy-point-seven percent of our sample completed the study. The ACDR 
of 29.31% (17/58) compares favorably with ACDRs noted for low dose 
haloperidol122, long-acting risperidone153, clozapine154,155,  olanzapine154,155, 
and others156-158. The ACDR in our study was lower than those reported in 
international trials such as EUFEST (41.57%)156-158, CATIE (74%)159,160, and 
the CAFE study (70.25%)161,162. The mean time to discontinuation in our 
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sample was 274 (± 116.09) days; being almost double the median time to 
discontinuation of 4.6 months reported in CATIE 156-158.  
 
During the course of our study, only four patients were withdrawn due to 
inadequate response. Thirty-six participants (85.37%) in the completer 
sample of our study achieved remission163, which is higher than remission 
rates recorded elsewhere for FEP treated with long-acting injectable 
risperidone.  In a open-label study of 50 FEP patients, newly diagnosed with 
schizophreniform disorder or schizophrenia, patients were treated with  
injectable, long-acting risperidone 25-50 mg every 2 weeks for two years153. 
Remission was achieved in 64% of the patients.  
 
High relapse rates within the first few years of illness have been noted164. 
However, in our study, only one participant relapsed as a result of non-
compliance. The first few years of illness has also been described as the 
“critical period”165  in determining long-term outcome. It has been proposed 
that suboptimal outcomes with regard to response, remission and relapse 
rates may have as much to do with non-adherence166-168 as with inadequate 
treatment. Since cognitive impairment, a core deficit in FEP, has been linked 
to poor treatment adherence169-171, there are clearly arguments in favour of 
the use of long-acting injectable antipsychotics in the treatment of FEP172,173.  
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Tolerability (refer pp 292-293) 
 
In our study, side-effects, if present, where of mild intensity, with EPSE 
reported in 18.97% of the sample. However, these side-effects were 
temporary and occurred within the first three months after initiation of 
treatment, and responded well to symptomatic treatment or dose reductions. 
Only one patient had to be withdrawn due to the development of akathisia. 
None of the participants developed tardive dyskinesia.  
 
Our experience with flupenthixol supports previous findings which suggest 
that flupenthixol is well tolerated, with a low incidence of mild adverse 
effects174. Contradictory reports with regard to EPSE rates exist, ranging 
from as low as 0.8% with 3mg/d or less175 per os, to as high as 28% with 
doses of around 30mg 3 weekly175 IMI. Post-marketing surveillance 
trials131,132 have reported treatment related side-effects in 4.6% of 658 
patients, 7.8% being FEP, after ten weeks of treatment  with either FD 
(mean dose equivalent of 9.2 mg/d) or oral flupenthixol (mean daily dose 6.3 
mg/d). Flupenthixol appears to compare very favorably to low dose 
haloperidol with regard to the incidence of EPSE176  
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COGNITION 
  
Premorbid intelligence (refer pp 258-262, 300-301) 
 
We used the WAIS-III177 Vocabulary subscale as estimation of premorbid 
intelligence. This subscale has been proven to be relatively resistant to brain 
impairment, and therefore be an indication of crystallised intelligence178, 
although some researchers have criticised this “hold” approach as being 
simplistic and inaccurate179. 
 
Although our study found a Z-score mean of -2.20 (± 0.91) at baseline, we 
cannot conclude that our sample performed worse than the general 
population as there are no data available for population norms in our 
catchment area, nor did we have a control group. However, it should be 
noted that the Z-scores of individual participants followed a normal 
distribution. 
 
Although the WAIS-III was standardized for English-speaking South 
Africans180-182, the norm group in which the scale was standardized does not 
reflect the ethnic distribution of our sample. The impact of language as a 
mediator of cognitive test performance, which can affect test scores 
significantly, should be borne in mind183. Test-takers whose first language is 
not English, may understand the wording and instructions of items, but the 
interpretation and meaning of words can vary significantly across cultures, 
as well as between first and second language speakers of English, which 
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could significantly affect test scores. Although we used the Afrikaans 
translation of this test in assessing the Afrikaans speaking participants, 
criticism has been raised as to the non-equivalence of the translation due to 
outdated words, difference in difficulty level, and different meanings of words 
included184. However, after careful consideration and consultation, this was 
still deemed the most appropriate measure of premorbid intelligence for use 
in our study. The deliberation on this matter raised the concern that it is 
crucial for local norms to be developed. 
 
Lastly, it is also possible that our sample represents a subgroup of 
individuals with schizophrenia who indeed had a lower level of premorbid 
functioning, or had significant deterioration. It would be worthwhile in future 
studies for researchers to stratify the participants according to IQ 
performance 185, and to compare this with records of school performance. 
 
This study found a significant inverse correlation between premorbid IQ 
estimation and the PANSS Cognitive factor at baseline, as well as a highly 
significant positive correlation between premorbid IQ estimation at baseline 
and overall cognition (MCCB Cognitive Composite Score) at both baseline 
and one year. This means that participants with a lower premorbid IQ at 
baseline, presented with more cognitive problems (a higher PANSS C and 
lower MCCB Cognitive Composite Score). It has been suggested that early 
in the course of schizophrenia, general cognitive ability (as measured by IQ) 
is a more sensitive and reliable predictor of functional outcome, up to ten 
years later, than measures of specific cognitive ability186,187.  
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The inverse correlation between age and IQ estimation at baseline, are likely 
to reflect the educational level of participants, and not age per se188. 
Although we found a statistical significant improvement in IQ estimation from 
baseline to one year, this is more likely a reflection of symptomatic 
improvement, as well as practice effects189,190. 
 
Neurocognition (refer pp 303-311, 259-260) 
 
In our study, all cognitive domains were significantly impaired at baseline 
with performance of the sample below the 5th percentile. This supports the 
notion of multiple cognitive domain impairments and therefore a generalized 
cognitive deficit being present in schizophrenia, and, specifically so, in 
FEP191-198. We are in agreement with Keefe‟s proposal to include cognitive 
impairment in the diagnostic criteria for schizophrenia.  
 
Previous studies have reported more specific impairments in verbal learning 
and memory, speed of processing, and attention and vigilance to be present 
in FEP.  
 
In our study, Speed of Processing was confirmed as the cognitive domain 
with the lowest mean T-score at baseline. Impairment in speed of processing 
has been regarded as a central cognitive deficit in schizophrenia199 that 
influences performance in a number of different cognitive domains200-202. 
According to Townsend et al.203, individuals with FEP generally performed in 
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the average range across the majority of tasks, with the exception of 
speeded processing tasks that appear to be more affected.  
 
In our study, individual measures most impaired at baseline was BACS204: 
Symbol-Coding, these findings concur with previous reports  of WAIS177 Digit 
Symbol processing speed performance being significantly worse than 
performance in other domains205. The majority of improvement (>70%) in 
Speed of Processing occurred within the first three months of treatment. This 
improvement in Speed of Processing was larger than for any other cognitive 
domain. Since this domain has been reported to be more sensitive to side 
effects of medication206, it appears that flupenthixol does not have a 
detrimental effect in the doses administered in this study. 
 
Attention and Vigilance has a close association with Speed of Processing. In 
our study, improvement in Attention and Vigilance followed the same trend 
as improvement in Speed of Processing, with >50% of improvement within 
the first three months of treatment, and then leveling out after six months. 
Reviews have found impairment in this domain to be associated with social 
deficits, decreased community functioning and difficulties in skills 
acquisition207,208. Furthermore, poor performance in this domain has also 
been linked to poor treatment adherence209, which increases the risk for 
relapse.  
 
In our sample Working Memory was second to Speed of Processing as the 
domain most significantly affected, at both baseline and at one year, 
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remaining below the 5th percentile. Working memory, a core component of 
cognitive impairment in schizophrenia210,211, has been shown to have strong 
correlations with other cognitive domains211, such as attention, planning and 
memory211, as well as with IQ212. Working memory performance has been 
linked to employment status213 and job tenure214. It has been proposed that 
decreased encoding speed, rather than the ability to maintain information 
over time, underlies working memory dysfunction202. 
 
Improvement in these three domains (Speed of Processing, Attention and 
Vigilance, and Working Memory) was small. These three domains are inter-
related, with significant overlap. Our findings support evidence for the 
impairment in central executive processes subserved by the dorsolateral 
PFC in schizophrenia215. 
 
More than half of the improvement in Reasoning and Problem Solving, 
important in the ability to adapt to rapidly changing environments, occurred 
during the first month of treatment.  
 
In our study, Verbal Learning appeared to be the least affected and most 
stable neurocognitive domain. As we used alternate forms of the HVLT-R216 
it is unlikely that a ceiling effect can explain the limited improvement in verbal 
learning. Furthermore, it is also possible that the apparently limited cognitive 
improvement despite clinical improvement could be due to relative cognitive 
decline. Cognitive decline could also have been present prior to presentation 
and inclusion in our study63,217,218.  
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The only neurocognitive domain in which we found evidence for continuous 
improvement over time was Visual Learning. In our study, contrary to 
previous reports, Visual Memory were more impaired than Verbal Memory at 
baseline197.  
 
Although changes in individual measures and domain scores were small, 
they were, for the most part, positive and significant. T-score means indicate 
that at baseline, participants performed 2 to 4 SDs below the mean, while at 
12 months participants performed 1.5 to 3 SDs below the mean. Our results 
therefore concur with previous reports of relative cognitive stability, and an 
absence of cognitive decline, in the early years of illness219-221.  
 
It is notable that improvement in cognitive functioning occurred early. More 
than 50% of the improvement occurred within the first month of treatment, 
more than 80% of the improvement within the first three months of treatment, 
with no further significant improvement after six months. Although the 
possibility of practice-related improvement has been mentioned as an 
explanation for increased cognitive scores found during early phases of the 
illness190,222, our use of alternate forms of instruments, wherever possible, in 
this study would have limited this effect. 
 
In accordance with previous reports220,223, we found no difference in 
cognitive performance between genders. Yet, this contradicts reports that 
have demonstrated differential degrees of impairment with male participants 
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performing worse than females across all neuropsychological functions, and 
significantly worse on test scores of attention, verbal memory and executive 
functioning224. Gruzelier et al.225 and Lewine et al.8 reported that although 
gender difference is preserved in schizophrenia, and is similar to that in the 
general population, these differences are often masked by clinical 
psychopathology and age effects.  
 
Although we found no correlation between age and cognitive impairment at 
baseline, a positive correlation between age and cognition was evident at 
one year. This would be in keeping with previous findings226 that patients 
affected at a younger age have a worse outcome, and more severe cognitive 
impairment. However, this finding, as well as the finding that participants 
assessed in Afrikaans demonstrated better cognitive performance at one 
year, may reflect the educational attainment of the participants in our 
sample. 
 
The interplay between neurocognitive symptoms and psychopathology (refer 
pp 286-288, 309-312) 
 
Symptom severity (PANSS227 Total) explained 33.64% of the variance in 
cognitive symptoms (MCCB Cognitive Composite Score) at baseline and 
28.09% at 12 months. Traditionally, cognitive symptoms were seen as a 
product of other symptoms clusters of schizophrenia. It is only more recently 
that cognition has become firmly established as an independent domain228. 
Latter day studies have acknowledged that considerable variability in the 
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severity and pattern of cognitive deficits can be present; these partially 
reflect the clinical heterogeneity of the disorder195,196,220,229. 
 
In keeping with studies elsewhere196,230,231 we found no correlation between 
cognitive deficits at baseline and the presence of positive symptoms. At one 
year we found that the presence of positive symptoms had a highly 
significant inverse correlation with cognitive functioning, thus explaining one-
third of the variance in cognitive impairment. This was specifically relevant 
with regard to working memory232-234 and verbal learning235, in support of 
previous studies. 
 
Cross-sectional associations between cognitive impairment and the severity 
of negative symptoms have been documented in the literature236-238. In our 
study, negative symptoms explained 39.69% of cognitive deficits at baseline. 
Highly significant correlations were present between negative symptoms and 
each of the neurocognitive domains at baseline; however, from 6 months 
onwards only Working Memory and Visual Learning had significant 
correlations with the severity of negative symptoms. Although we found no 
correlation between the presence of depressive symptoms and cognitive 
performance at both baseline and at one year, we cannot exclude the 
influence of poor motivation, and the relationship thereof with negative 
symptoms239,240, on cognitive functioning in our sample. 
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We found that general psychopathology correlated with a variety of cognitive 
domains at both baseline and at one year. The proportion of the variance in 
cognition explained by the severity of these symptoms is approximately 20%. 
In summary, we support the notion that cross-sectional correlations between 
neurocognitive impairment and psychopathological symptoms are 
undoubtedly weak, and concur with the proposal that cognition is a 
separable domain and not caused by psychosis.  
 
In our study the PANSS Cognitive factor (PANSS C) was the strongest 
predictor of cognitive functioning at baseline, displaying highly significant 
inverse correlations with all cognitive domains. At one year the influence of 
the PANSS C was surpassed by those of positive symptoms, and PANSS C 
had significant inverse correlations with Speed of Processing, Working 
Memory and Visual Learning. Since both the PANSS C factors we used 
(Lancon et al.241, and Good et al.242) include PANSS P items (P2 and P6 
respectively), it could be argued that an improvement in cognitive functioning 
is due to a decrease in positive symptoms, thereby explaining the decline in 
strength of correlation of PANSS C with cognitive domains over time. 
However, PANSS C factors previously identified reflect characterisitics of 
participants included in the studies, and therefore may not be the ideal 
representation of our sample. 
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Depression and insight (refer pp288-291, 309-312, 317-321) 
 
It was reported by Kay and Lindenmeyer243 that the presence of depressive 
symptoms during the acute psychosis may be a good prognostic factor, 
whereas persistence of depressive features is considered the opposite244. 
 
In our study, the mean PANSS D245 score at baseline was 9.17 (± 3.59) and 
declined significantly over the first three months to 5.66 (± 2.01). Although, 
as a group, the CDSS246 scores remained low, 11/58 (18.97%) of the sample 
developed clinically significant symptoms which necessitated treatment with 
an antidepressant. Previous studies have reported symptoms of depression 
to be common in schizophrenia, with prevalence rates ranging from 7 to 
70%247, with a modal prevalence rate of 25%248.  
 
In our study, depressive symptoms had an inverse correlation with age, 
affecting younger participants more. The presence of depressive symptoms 
did not correlate with overall cognitive functioning. We also did not find any 
correlation between verbal memory performance and depression as reported 
in studies such as that of Brebion et al.249.  
 
The presence of depressive symptoms has the potential to instill a less 
realistic outlook in participants regarding their illness and treatment, thereby 
with the potential to contributing to non-compliance and relapse. On the 
other hand, poor insight can contribute to problems with therapeutic 
engagement and treatment adherence. Even so, only three of the 
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participants relapsed during our study: two due to ongoing substance-abuse, 
and one because of non-compliance.  
 
Objective measure of insight indicated that the participants in our study had 
a moderate to severe impairment in insight, with only a vague or shallow 
recognition of their illness. Subjective reports of insight confirmed that 56% 
of our participants had poor insight; worse than previously reported258. 
In our study, the presence of depressive symptoms had a significant inverse 
correlation with objective measures of insight (PANSS G12). This is in 
agreement with studies reporting that increased awareness of illness 
contribute to depressive symptoms, low self-esteem, and poor quality of life 
250-252 253-256.  
 
As in studies elsewhere259 we found a highly significant inverse correlation 
between objective insight ratings and cognitive composite scores (MCCB 
Cognitive Composite Score) at all visits, with insight contributing to 23.04% 
of the variance in overall cognition at baseline, and 33.64% at 12 months. In 
a meta-analysis  Mintz et al.255, reported a correlation of 0.25 between 
positive symptoms and insight, and 0.23 between negative symptoms and 
insight. From this it can be argued that impaired insight is part of 
psychopathology and cognitive impairment in relatively equal measures. 
However, we found no correlation between subjective measurements of 
insight (Birchwood260 scores) and cognitive functioning in our sample. 
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At baseline there were no significant differences in levels of insight between 
age groups, different levels of education, genders or language groups in our 
sample. However, females displayed better insight at one year than did their 
male counterparts. Concordant with results of a Dublin Study261, participants 
in our sample with poor insight were more likely to require hospitalization.  
 
The moderating effect of stigma has to be borne in mind, where the 
presence of stigma and negative societal views attached to schizophrenia 
can make the diagnosis more distressing and contribute to a worsened 
outcome257,252. An interesting future exercise would be to evaluate 
community perceptions in our catchment area, as well as the perceptions of 
individuals with schizophrenia, specific to stigma and mental health in order 
to correlate this information with measures of depression and insight. 
 
Social cognition (refer pp 313-316) 
 
Social cognition is the ability to perceive, process, and interpret social and 
emotional information in oneself and others, and have the ability to 
implement this in behaviour262. As such, social cognition has emerged as an 
important concept that contributes to functional recovery in  
schizophrenia263-265.  
 
In our study social cognition of participants was clearly impaired with a score  
2 SDs below average of the norms. Although there was an improvement in 
social cognition from baseline to one year, this change was not significant. 
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We found no difference between genders and ethnic groups with regard to 
social cognition. However, participants assessed in Afrikaans performed 
better than participants assessed in English. The performance of the Xhosa-
speaking participants who preferred to be assessed in English may have 
been adversely affected due to poor understanding of nuances and 
subtleties in the case vignettes in the MSCEIT™ 266, a test that was 
developed in the USA and possibly not culturally relevant for the use in all 
South African sub-populations. 
 
Negative symptoms had a highly significant inverse correlation with social 
cognition, while the PANSS Cognitive factor did not correlate with social 
cognition. Furthermore, the presence of depressive symptoms in our sample 
also had an inverse correlation with social cognition. This could cause 
participants to be less realistic, and more pessimistic, about their illness, 
treatment, and social circumstances, thereby also explaining the inverse 
correlation with quality of life ratings. However, we could not determine a 
causal relationship between depression and social cognition. 
 
Older participants were better at managing their emotions after one year. 
This may be a reflection of illness severity as there was a significant inverse 
correlation between symptoms severity and the ability to manage emotions 
at this time point – with a highly significant inverse correlation between 
positive symptoms and the ability to manage emotions. 
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At baseline, the ability of female participants to regulate the „self‟ was 
significantly better than that of the male participants. However, this gender 
difference disappeared by one year and may be a reflection of the younger 
age of the male participants. Nevertheless, previous studies have found both 
affected and non-affected females to have an advantage over males with 
regard to processing emotional prosody and semantics 267. These findings 
may contribute to females with schizophrenia being less compromised than 
males with regard to social functioning.  
 
Although social cognition did not improve significantly over time, the opposite 
was true of our participants‟ ability to manage their emotions and social 
interactions. This may, in part, be explained by changes in psychopathology. 
At baseline, negative and general symptoms had a highly significant inverse 
correlation with social cognition, and specifically with managing emotions 
and social management tasks. At one year, positive symptoms had a highly 
significant inverse correlation with managing emotions and social 
management tasks. It appears that general symptoms contributed more to 
the variance in social cognition than negative and positive symptoms. At 
baseline 14.4% and 16% of the variance in social cognition was explained by 
negative and general symptoms respectively, whereas only general 
symptoms had a significant correlation at one year with social cognition 
accounting for 19.36% of this variance. 
 
In a one year prospective study of 94 clinically stable outpatients with 
schizophrenia, Kee et al.268 examined cross-sectional and longitudinal 
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relationships between perception of emotion and aspects of social 
relationships, work functioning and independent living. They found emotion 
processing to be a key determinant of work functioning for these individuals, 
independent of the presence of psychopathological symptoms. It has to be 
noted that only a single social cognitive measure was addressed in our study 
and it does not address the range of social cognitive deficits in 
schizophrenia.  Furthermore, a performance-based assessment such as the 
MSCEIT™ assesses whether or not individuals are capable of performing 
certain behaviors in specific situations269, and is not a reflection of broader-
based domains of functional outcome such as vocational functioning270-272. 
 
The relationship between subjective and objective assessments of 
cognitive impairment (refer pp 322-331) 
 
The first reference in the literature to individuals with schizophrenia‟s 
subjective experience of cognitive disturbances was a review of 
autobiographical accounts by Freedman in 1974273. He paved the way for 
what would become known as “basic symptoms”274, so called for their 
representation of the basis of productive psychotic symptomatology. In other 
words, these are symptoms which individuals may report and are able to 
cope with, adapt to, and compensate for, prior to manifesting in objective 
noticeable symptoms and behavior.  
 
The literature on self-reported cognitive deficits compared to objectively 
measured neurocognitive deficits in individuals with schizophrenia is 
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extremely limited. The SSTICS275 was recently developed as a quantitative 
approach to measure the subjective experience of cognitive deficits in 
schizophrenia, and remains a work in progress. We translated and back-
translated the instrument to Afrikaans, and believe this to be the first time 
such a quantitative approach has been used in any FEP sample, and also 
the first time that subjective complaints of cognitive difficulties have been 
compared to objective neurocognitive assessments in South Africa.   
 
We found a 9.70% decrease in cognitive problems reported during the 
course of the study. Participants assessed in English reported more 
cognitive problems at baseline. This may either be a reflection of the amount 
of language dysfunction they experienced, or of their severity of illness 
compared to the participants assessed in Afrikaans. The domains in which 
the most impairment was reported were Sustained Executive Functioning 
and Consciousness of effort. Both these domains improved early, following 
the same course of improvement as psychopathology. Contrary to the 
baseline findings of previous reports276, we found no correlation between 
subjective reports of cognitive impairment and symptom severity, the 
presence of positive symptoms, or the presence of negative symptoms.  
 
We did find a highly significant, inverse correlation between Consciousness 
of effort and PANSS C ratings, as well as between Consciousness of effort 
and cognitive domains of Attention and Vigilance and Social Cognition. From 
this, we can deduce that the participants may have had more difficulty in 
paying attention to information, concentrating on it, and integrating and 
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applying this information as needed. These impairments would also 
adversely affect their focus in a social environment and the ability to make 
social judgments, therefore impeding their ability to accurately report on 
aspects of QOL. It appears that the presence of psychopathology, objective 
neurocognitive impairments, and social stressors, played a larger role in how 
the participants perceived their QOL, than did participants‟ subjective reports 
of cognitive impairments. This is evident from the fact that we did not find a 
significant correlation between subjective complaints of cognitive 
impairments and QOL. It also appeared that a more insidious, versus a more 
acute, onset of illness did not play a role in subjective awareness of cognitive 
deficits. 
 
Although there were no significant differences between gender groups at 
baseline in cognitive deficits as reported by the participants, male 
participants presented with 15.33% more cognitive complaints at one year 
than females. There is no immediate explanation for this, as we would have 
expected females to be more aware of their deficits, based on reports in the 
literature, and our own findings of greater ability for emotional regulation in 
females. 
 
Furthermore, participants did not report any improvement in their alertness 
and ability to function in daily life during the course of the study. It would 
therefore appear that participants in our sample did not experience cognitive 
problems as being of practical importance. This might be a reflection of 
social circumstances of, and the lack of formal cognitive demands on the 
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participants. However, participants who returned to attend their tertiary 
education, as well as the three participants who „switched‟ languages, did 
indeed report an influence of cognitive deficits on their day-to-day life. 
Individual experience may therefore not be adequately reflected by the 
statistical findings.  
 
Although many other significant correlations were present between domains 
of subjectively reported cognitive complaints and objectively assessed 
neurocognitive domains, our sample size was such that we decided on a 
conservative approach in interpretation thereof. Despite this, it should be 
noted that Speed of Processing and Sustained Executive Function and 
Alertness were the two domains that had a highly significant positive 
correlation up to 6 months with social cognition, while Distractibility had an 
inverse relation with social cognition at one year.  
 
Research in prodromal patients has produced conflicting results, with some 
studies reporting subjective and objective cognitive deficits to be 
unrelated277,278, while others279,280 have found neuropsychological deficits, 
either self-perceived or objectively measured, to be able to contribute to 
prediction of transition to psychosis. In a longitudinal study of 96 individuals 
with DSM-III-R diagnoses of personality disorders, Klosterkotter et al. was 
able to correctly predict the development of schizophrenia in 77% of the 
participants who developed schizophrenia over an eight year period281. 
These predictions were based on an earlier presence or absence of self-
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experienced disturbances of thought, speech, memory, perception and 
action.  
 
We were only able to find two other studies that specifically compared 
subjective complaints with objective cognitive performance. In a study by 
Proteau et al., attentional problems were reported to be associated with 
poorer visual memory and planning performance as measured by the 
CANTAB282, while more executive dysfunction was related to poorer visual 
memory scores283. In the study by Medalia and Lim284, clinicians‟ and 
patients‟ ratings of attention, nonverbal memory and verbal memory were 
compared with objective neuropsychological assessment in 185 outpatients 
with schizophrenia. When corrected for chance findings, the agreement 
between classifications with regard to functioning in aspects of memory and 
attention, as assessed by clients, and as assessed by clinicians, vs. 
objective evaluations thereof, were poor. There was no significant correlation 
between clinicians‟ and patients‟ ratings on attention and memory, with 
agreement between clinicians and patients in only 57% of ratings of impaired 
attention and 55% of ratings of impaired memory. It is evident that the 
cognitive nature of these subjective complaints does not necessarily 
correspond with objective performances.  
 
 
As insight is crucial to the awareness of cognitive deficits, it is important to 
recognize that what forms the basis of the SSTICS (i.e. awareness of 
cognitive limitations), may also be the biggest limitation of the instrument 
since, when an individual does not have insight, he/she will not report any 
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deficits. However, we found no correlation between the presence and 
severity of subjective cognitive complaints and insight. It is possible that 
insight may be modular, and therefore  patients with poor insight into their 
symptoms may still have a degree of insight into their cognitive 
impairment285.  
 
We believe that further avenues requiring investigation are: 
1) Reports of increased subjective cognitive complaints in the presence of  
    EPSE that include akathisia, and parkinsonism277,286,287,288; 
2) Treatment of subjective cognitive complaints289,290; and  
3) The relationship with functional outcome291. 
 
Functional outcome and quality of life (refer pp273-276, 294-297) 
 
Reviews of the literature have indicated consistent and highly significant 
relationships between cognition and functional outcome in 
schizophrenia208,292-294. Cognitive impairment is associated with both poor 
premorbid, and current, social functioning, with neuropsychological deficits 
accounting for 5-25 % of the variance in social and vocational outcome after 
FEP220,295.  
 
The social and occupational functioning of our sample improved significantly 
from baseline to 6 months, after which improvement leveled out. Severity of 
illness demonstrated an inverse relationship with functioning for the duration 
of the study. More specifically, negative symptoms seemed to impact 
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considerably on the functioning of participants and support results of studies 
elsewhere192,292.  
 
Contrary to previous reports that documented evidence for processing 
speed214,296,297, attention and vigilance292,293, working memory298, verbal 
memory207,299, 292,300, and visual memory202,293 to be predictors of functional 
outcome, we found no correlation between cognition, and social and 
occupational functioning. However, other studies also negated the 
relationship between cognition and functional outcome53,301-303.  
 
In our study, this lack of correlation between cognition, and social and 
occupational functioning may be a reflection of social circumstances. Many 
participants were receiving disability grants from the local government due to 
being diagnosed with a mental health disorder, and therefore lessened 
expectations by family members for the individual to find gainful 
employment. Furthermore, this may merely be a reflection of the high 
unemployment rate in the general population and not of the influence of 
cognition per se. 
 
The SOFAS304  is a clinician rated assessment used as an objective 
measure of social and occupational functioning.  It is therefore largely free of 
individual confounding factors such as lack of insight305,306, but may not take 
into account the many environmental factors, such as the presence of social 
support, and educational and vocational opportunities, that may facilitate or 
impede the patient's capacity307 to perform a particular activity. Furthermore, 
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intervening factors, such as social cognition, may moderate neurocognition‟s 
impact on functional outcome308,309. Therefore, the best way to accurately 
assess functional outcome would be through direct observation in naturalistic 
settings. For research purposes, a combination of performance-based, 
proxy-measures, and objective ratings, would have to suffice269.  
In recent years, greater attention has been given to QOL in FEP, and studies 
have reported on the influence of various psychopathological domains, and 
cognitive dysfunction, on QOL301,310. 
 
Participants in our study expressed dissatisfaction with regard to their QOL, 
especially in areas of their social relationships, and their environment. We 
found significant positive correlations between premorbid functioning and the 
psychological health of participants, which may be indicative of their duration 
of illness. Social relationships of participants had significant positive 
correlation with age which may be a reflection of social cognitive skills and 
not necessarily the quality of relationships as a whole.  
 
Although at baseline and at 6 months no gender differences were found with 
regard to QOL, females were less satisfied with their environment at one 
year than their male counterparts. This may reflect social factors in the 
community, such as limited opportunities, increased care-taking 
responsibilities for females (often in the absence of adequate support), and 
the psychological strain of being ill and dealing with stigma.  
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QOL with regard to Physical Health, Social Relationships, and Environment, 
did improve over time. A majority of these gains were evident within the first 
six months of this study. The severity of positive symptoms seemed to be the 
most important role player with regard to satisfaction in physical and 
psychological health at baseline, and at 6 months in social relationships. 
This may be a reflection of the impact of disruptive symptoms and psychosis 
per se (e.g. paranoid delusions) on relationships with others, as well as poor 
insight with regard to the illness as such. We noted no improvement over 
time with regard to participants‟ satisfaction with their psychological health. 
These findings should, however be interpreted with care, considering the 
impact of poor insight on the usefulness of self-report instruments311 such as 
the WHOQOL-BREF312. 
 
We found a significant positive correlation between Reasoning and Problem 
solving and participants‟ perceptions of their physical health; and between 
Working Memory and their perceptions regarding their psychological health. 
However, literature has reported cognitive dysfunction to have a greater 
influence on objective QOL than subjective QOL313, and it is therefore 
possible that we would have found more neurocognitive domains with 
significant correlations with QOL were we to use objective measures of QOL 
instead of subjective QOL reports. 
 
Although social and occupational functioning had a significant positive 
correlation with QOL at 6 months, this did not hold true for overall cognitive 
functioning, or severity of illness. This may be an indication that the 
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presence of social stressors such as the ability/inability to function in the 
environment, be gainfully employed, or returning to studies, is more 
important than the presence of residual or mild psychotic symptoms, or 
objective measures of cognitive impairment. 
 
STRENGTHS AND LIMITATIONS 
 
This study is the first FEP study in South Africa, specifically investigating 
cognitive changes over time. Furthermore, it is, according to our knowledge, 
the first study investigating the effect of ultra low dose flupenthixol decanoate 
on treatment outcome, both clinical and cognitive, in FEP. We consider 
ensured drug delivery as one of the strengths of this study. We included 
participants with very limited prior antipsychotic exposure, making this a 
fairly homogenous cohort. The use of a „gold standard‟ cognitive battery, the 
MCCB, enabled us to compare our results with those of studies conducted 
elsewhere in the world.  
 
Although we took the best of care in planning, and executing this study, 
limitations are an inherent part of all research projects. This study is no 
exception. The following are the main shortcomings of this study: 
 
1. Although our sample size is rather large, with a fairly low attrition rate, 
when compared to other FEP studies, the power of the study would have 
been enhanced, did we recruit larger numbers. This would have also 
enabled us to do more sub-analyses with regard to predictors of outcome. 
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2. This study was a single arm, open-label, unblinded study. The addition of 
a comparator group, receiving either placebo, or else an active comparator 
(preferably a SGA), would have strengthened our findings. 
3. The duration of the study was sufficient for the evaluation of cognitive and 
clinical parameters with regard to treatment outcome. However, it is possible 
that subtle changes, which may influence outcome, will occur over extended 
periods of time, and that therefore, increasing the duration of the study would 
have produced additional findings of interest.  
4. It is possible that the inclusion of participants with substance use/abuse in 
our sample may have influenced our results. However, substance abuse is 
highly prevalent in our population. As previously noted, patients with FEP 
have significantly higher rates of substance abuse than their non-psychotic 
peers, and excluding all patients with substance use or abuse would have 
biased our sample. However, we did take care not to include patients with 
substance induced psychoses, or substance dependence; and throughout 
the study we were diligent in obtaining as much accurate information as was 
possible regarding both past and current substance use/ abuse by 
participants. Evidence with regard to the effect of substances on cognitive 
performance is also contradictory. It is possible that substance abuse could 
contribute to cognitive deficits in an etiologically independent way.  
5. We excluded participants with significant medical illness. However, we did 
not control for “subtle” problems such as disordered water homeostasis and 
nutritional deficiencies. The apparent association between disordered water 
homeostasis and cognitive impairment in schizophrenia2, should be 
interpreted with caution. In their study, the authors compared 16 
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schizophrenic patients with severely deranged water homeostasis to 16 
matched schizophrenic controls. Although patients with disordered water 
homeostasis obtained statistically significant poorer scores on the Wechsler 
Memory Scale Visual Reproduction and Trial Marking Test part A than the 
controls, the small sample size, the inclusion of patients ranging from 0 to 10 
years of education, inclusion of patients ranging from 23 to 67 years, and the 
inclusion of patients ranging in duration of illness between 2 and 44 years, 
decreases the power of this study and could lead to a type II error.  
Furthermore, in our study, after initial inclusion, two patients with underlying 
medical conditions were withdrawn: one with hypothyroidism and iron 
deficiency; the other because of the presence of akathisia, with a BMI of 14 
– a condition often associated with nutritional deficiency, thus presenting the 
potential for increased sensitivity to the development of EPSE. These 
“subtle” medical problems could adversely affect cognitive performance. 
6. The use of a self-report measure as a principal measure to assess quality 
of life, may not be a reflection of „real-world‟ functioning.  
7. A number of grey areas exist in the South African context that is inherently 
problematic to study assessments. These include cross-cultural influences 
and bias, and a general lack of well-standardized, culturally-relevant tests314. 
Therefore, the specific ethnic compilation of our sample may have yielded 
results which cannot be generalized to participants in other regions of the 
world. However, in a study by Harvey et al., to determine the viability of 
cross-national cognitive assessments in schizophrenia, a sample of 301 FEP 
patients was assessed in six different languages, across ten different 
countries. Results of this study demonstrated that differences between 
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countries were greater than differences between languages; that 
performance differences across English and other languages were only 
evident for tests of executive functions, vigilance, and psychomotor speed; 
that educational attainment had a significant influence on performance; and 
that executive functioning differences were non-significant. The authors 
concluded that the translation of tests of memory and verbal skills can lead 
to consistent results across translated versions of the tests, thereby 
supporting the validity of cross-national neuropsychological assessments315. 
Despite this, the need to develop appropriate South African translations and 
norms for many of the assessments should be addressed urgently. 
Furthermore, although the tests we used were translated and back-
translated, some of the items were deemed not culturally sensitive. With this 
said, however, it can be argued that the use of any tests customized to suit 
South African norms would produce only „localized‟ results that would be 
unable to stand up in the international arena.  
  
Despite the limitations, we believe that this study makes a significant 
contribution to the literature on FEP, cognition, and treatment with assured 
delivery of a FGA.
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CHAPTER 14 
CONCLUSION 
 
“Madness is, contrary to the opinion of some unthinking persons, as 
manageable as many other distempers, which are equally dreadful and 
obstinate, and yet are not looked upon as incurable;….such unhappy objects 
ought by no means to be abandoned, much less shut up in loathsome 
prisons as criminals or nuisances to the society” (p93).  
 
A living proof of this „old‟ statement would be John Forbes Nash Jr., the 
famous American mathematician and economist. Born 13 June 1928, Nash 
suffered his first psychotic breakdown at the age of 31. In spite of being 
diagnosed with paranoid schizophrenia, and repeated psychiatric 
hospitalizations between 1959 and 1970, Nash persevered with his studies, 
and emerged as a Nobel Laureate in 1994 for his early work on the game 
theory. 
 
Recent decades have seen rapid development in technology that have 
helped shift the opinion of mental illnesses being „all in the mind‟, to „all in the 
brain‟. Furthermore, contemporary treatments for serious mental illnesses 
are highly effective; with 70% to 90% of patients having a significant 
reduction in symptoms, providing the potential for improved long-term 
functional outcome. 
                                                     
 Battie W. A Treatise on Madness. London, UK; 1758 
 Nasar S. A Beautiful Mind. London, UK: Faber and Faber; 2002 
 
 
 
 
However, despite the recognition of cognitive symptoms as a core concept of 
schizophrenia, and the progress made in the field of neuroscience, neither 
the final word, nor even the “middle of the sentence”, has been spoken on 
the optimal management of these symptoms.  
 
Impairment in cognitive functioning is not only an objective measurable 
entity, but also a distressing subjective experience, and it is clear that 
addressing cognition as part of the management of schizophrenia is 
important in terms of quality of life. Furthermore, since cognitive impairment 
has been proven to adversely affect compliance with treatment, thus 
increasing the risk for non-adherence and resultant relapses, it is of the 
utmost importance to develop and use strategies to counter these problems. 
 
More than 20 years of research has established the need for 
psychopharmacological and psychotherapeutic interventions in addressing 
cognitive deficits in schizophrenia. Presently, antipsychotics remain the 
cornerstone in treatment of this disorder.  
 
In this longitudinal study of FEP in South Africa, we documented the specific 
cognitive deficits experienced by the participants, and described the changes 
in response to treatment over a 12 month period. We have demonstrated 
that cognitive deficits are an independent domain, despite their close link to 
negative symptoms, as well as the impact of positive symptoms on cognition 
after the acute illness phase. Whereas mood symptoms were observed to 
affect insight, our sample did not demonstrate any direct relationship 
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between the presence of depressive symptoms and cognitive dysfunction. 
These findings re-confirm the existence of cognition as an independent 
domain, and focus of treatment, in schizophrenia. We have also addressed 
subjective versus objective experiences of cognitive impairment, as well as 
social cognition, functional outcome, and quality of life. We have established 
premorbid intelligence, or, more accurately, baseline intelligence, as one of 
the stronger predictors of 12 month outcome. We believe that our study has 
contributed to research into FEP, and advanced the development of 
culturally sensitive instruments of assessments and norms for evaluation of 
cognitive functioning in FEP.  
 
As research and development of novel drugs is a slow and expensive 
process researchers and clinicians would be well-advised to consider and 
reconsider „on-the-shelf‟ antipsychotic agents that have not been adequately 
researched. In this study, we „dusted off‟ an „old‟, FGA, flupenthixol 
decanoate, and used it in a novel application: at a very low dose, in a FEP 
sample. We found indications (albeit qualified) that the clinical and cognitive 
response to treatment was comparable to studies of SGAs, and that 
treatment was well tolerated – perhaps better so than has been documented 
in studies of haloperidol. Furthermore, the retention rate in our study, 
compared to FEP studies with oral preparations, confirmed the advantage in 
assured drug delivery in the management of FEP. 
 
We trust that this study has contributed towards a more positive outlook on 
the long-term outcome of FEP. We have demonstrated that it is within our 
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grasp to provide effective, tolerable treatment to individuals suffering from 
the disease; not only in terms of suppression of positive symptoms, but also 
in the rehabilitation of cognitive abilities, so that individuals with 
schizophrenia may realize their full potential, and become Laureates in their 
own lives. 
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